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CHEMOTHERAPY RESPONSE AND THE ROLE OF THE WWOX 
TUMOUR SUPPRESSOR 
 
ABSTRACT 
 
Paclitaxel is a widely used chemotherapy drug for the treatment of multiple cancers. 
Paclitaxel works by inhibiting the disassembly of microtubules. Besides the role of paclitaxel 
in mitotic arrest, many studies suggest that paclitaxel could initiate apoptosis by activating 
ER-stress pathways. Cisplatin, another chemotherapy drug is also used for the treatment of 
solid tumours. It works by forming adducts with the structure of DNA leading to cell cycle 
arrest, DNA damage and apoptosis. These two chemotherapy drugs have different 
mechanisms of killing tumour cells, but they are often combined to give greater effect. 
WWOX is a tumour suppressor in many cancers. It has been shown that WWOX promotes 
apoptosis and suppresses in vivo tumorigenesis, but its function remains unclear.  Here in 
my study I hypothesize that ER-stress is an important part of paclitaxel response in cancer 
cells, and the WWOX tumour suppressor is important in mediating paclitaxel induced ER-
stress response. I also hypothesize that WWOX is important in mediating the apoptotic 
response to cisplatin. My results show that paclitaxel could not induce ER stress in multiple 
cancer cells lines, and WWOX did not affect the cytotoxic action of paclitaxel. I show some 
evidence that ER-stress may influence survival in ovarian cancer patients, but this is 
independent of the effect of WWOX expression. I show that WWOX is not important for 
cisplatin response since cisplatin suppresses the expression of WWOX. This effect may 
relate to its location at a common fragile site since cisplatin also down-regulates another 
fragile site-associated gene FHIT. However, I also show the apparent involvement of NF-kB2 
and PAR2 transcription factors in the down regulation of WWOX. These findings increase 
our understanding of the unintended effects of chemotherapy treatments. 
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Chapter 1 Introduction 
1.1 FRA16D and WWOX 
Common fragile sites (CFS) are large regions of genomic instability which are present in all 
individuals. These instable regions are distributed throughout the genome (Arlt et al., 2003; 
Smith et al., 1998). The second most frequently expressed common fragile site in human 
genome is FRA16D [16q23.2] (Sutherland and Richards, 1995). Many types of cancer show 
deletion of this genomic region (Hansen et al., 1998; Balsara et al., 2001). Paige et al., 
(2000) first cloned this chromosomal region FRA16D and reported that there is a 700-kb 
physical map of a region of 16q23.2 which is homozygously deleted in multiple cancers and 
spans the CFS FRA16D. Characterization of FRA16D and its involvement in multiple 
myelomas was reported by Krumel et al., (2000). They showed FRA16D exhibited 
breakages within a region of 2.0 Mbs. It was also demonstrated 16q23.2 region spanned five 
multiple myeloma translocation breakpoints. The genomic region 16q23.3-24.1 (1.0Mb) was 
named as WWOX by Badnarek et al., (2000).  The structure of WWOX shows it has an open 
reading frame 1245 bp long and encodes a 414-amino acid protein. WWOX consist of   two 
N-terminal WW domains (first domain consists of 17-49 amino acids and second domain has 
58-90 amino acids), a C terminal short chain dehydrogenase reductase (SDR) domain and a 
nuclear localization sequence (NLS) between two WW domains (figure 1.1). Of the two N-
terminal WW domains, the first domain is required for classical WW-PPXY interaction. The 
SDR domain associated proteins are needed for oxidation or reduction of lipids hormones, 
sugars and alcohols (Chang et al., 2007).  
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Figure 1.1: Domains and phosphorylation of human WWOX (WW domain containing oxidoreductase) 
protein. WW, WW-domains; NLS, nuclear localisation signal; SDR, short chain dehydrogenase 
domain; Y, tyrosine residues at amino acid positions 33 and 287 (Li et al., 2014) 
 
1.1.1 WWOX and spliced variants 
Human WWOX mRNA has at least eight transcripts (figure 1.2) (Chang et al., 2003) but 
currently it is unknown if all these 8 transcripts can be translated into proteins. The presence 
of wild type WWOX 46-kDa protein is well known (Badnarek et al., 2000). There are 9 exons 
in human WWOX gene which encode a full length WWOX.  The other seven transcripts are 
formed by alternate splicing indicating the isoforms of WWOX protein. The N terminal WW 
domain is encoded by exons 1-4, whereas SDR domain is encoded by exons 4-8. Tyr33 
(y33) and Tyr287 (Y287) are the two known phosphorylation sites. For hormones or 
substrate binding there is a conserved catalytic NSYK motif (N232, S281, Y293 and K297) 
on SDR domain. Within the second WW domain between amino acid 65-68, there is a 
conserved caspase-recognition motif QETD (Chang et al., 2001). 
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Figure 1.2: Human WWOX (WW domain containing oxidoreductase) gene and its sliced variants. WW 
domains are shown in gold and the highly conserved short chain dehydrogenase (SDR)/alcohol 
dehydrogenase domains are shown in blue colour. A nuclear localization sequence (NLS) between 
two WW domains. Tyr33 (y33) and Tyr287 (Y287) are the two known phosphorylation sites. For 
hormones or substrate binding there is a conserved catalytic NSYK motif (N232, S281, Y293 and 
K297) on SDR domain.v1 wild type WWOX gene (46kDa), v2 (41kDa) shows partial deletion of exon 
9 and a different c terminus (orange), v3 (35kDa) deletion of exon 5-8, v4 (26kDa) deletion of exon 6-
8, v5 (24kDa) exon 5-9 deletion, v6 (22kDa) has an alternative exon 6, v7 (4kDa) exon 2-9 deletion, 
v8 (59kDa) TG-deletion at exon 9 (red star) (Chang et al., 2007).  
1.1.2 Subcellular and tissue distribution of WWOX 
Some studies suggest WWOX is localized in mitochondria while other suggests it is localized 
in other parts of the cell. The ectopic expression of murine Wwox has been observed in 
mitochondria by tagging it with EGFP (green fluorescence protein). Monkey kidney 
fibroblasts (COS7) and lung cells (H1299) were tagged with ECFP (cyan fluorescence 
protein) has shown localization of Wwox in mitochondria. Rat liver cells also showed the 
presence of endogenous Wwox in purified mitochondria (Chang, 2002; Chang et al., 2001).  
In a study of normal human breast cells (MCF-10F) by Badnarek et al., (2001), WWOX 
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expression was observed in Golgi apparatus. The reason for the different subcellular 
localisation in these studies is unclear, but may be related to differences in cell lines, 
species, transfection method, or fusion proteins used. In another study by Watanabe et al., 
(2003) WWOX was observed in non-cancerous epithelial cells, mammary gland cells, 
prostate epithelium and follicular cells. Mammary gland cells showed localization of WWOX 
in nucleus, whereas epithelium cells showed WWOX is localized in cytoplasm. The switching 
of WWOX between nucleus and cytoplasm was observed in human fibroblast KMS-6 where 
in less confluence cells WWOX was observed in mitochondria and when cell reached full 
confluence, WWOX was observed in nucleus.  
Chang et al., (2005) observed the effects of hormones on the translocation of WWOX in 
COS7 fibroblasts and MCF7 breast cells. COS7 cells showed nuclear translocation of 
WWOX due to estrogen or androgen, whereas MCF7 cells showed WWOX in peri-nuclear 
area and did not responded to androgen or estrogen induced translocation of WWOX. In the 
same study, similar observation was observed during breast cancer progression where no 
change in nuclear localization of WWOX was observed at hypertrophic and cancerous 
stages. However, prostate cancer showed 1.5-fold increase in nuclear translocation of 
WWOX at hypertrophic and cancerous stages (Chang et al., 2005).  
Chen and colleagues while studying the role of WWOX in light-induced retinal degradation of 
normal mature rat cells reported the presence of a large number of Wwox positive 
immunogold particles near nuclear membrane and rough endoplasmic reticulum, whereas 
little or no Wwox was detected in Golgi apparatus or mitochondria of normal cells. Dead 
photoreceptors by apoptosis showed Tyr33 phosphorylated Wwox (p-wox1) was detected in 
large numbers of immunogold particles in damaged mitochondria and condensed nuclei of 
degenerating photoreceptors which shows activation of wox1 and its translocation to these 
organelles. Little or no Wwox was detected in Golgi apparatus of dead cells (Chen et al., 
2005).  
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Immunohistochemical (IHC) analysis show WWOX protein is ubiquitously expressed in 
human tissues but high levels are expressed in epithelial cells and exocrine and endocrine 
organs such as testis, mammary and prostate glands. Strong expression of WWOX has also 
been observed in neuronal bodies and cerebellum. A summary of WWOX positive organs 
and cells is shown table 1.1. Organs negative for WWOX protein expression are shown in 
table 1.2. Figure 1.3 shows the detection of WWOX by western blotting. Variation in WWOX 
expression levels can clearly be observed.  
 
 
Figure 1.3: Western blot analysis of WWOX protein in human tissues. Full length WWOX protein is 
46kDa. Actin shows equal loading (Nunez et al., 2006). 
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Table 1.1: Summary of organs showing the distribution of WWOX positive staining according to tissue 
and cell type (Nunez et al., 2006) 
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Table 1.2: Summary of organs negative for WWOX protein expression (Nunez et al., 2006) 
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1.1.3 WWOX: Tyr33 phosphorylation, death signalling and tumour suppression 
Tumour suppressor and pro-apoptotic function of WWOX has been shown by in vivo or in 
vitro analysis. Over expression of WWOX induces apoptosis by cytotoxic action of TNF 
(Chang et al., 2001). WWOX undergoes phosphorylation at Tyr33 under stress response or 
apoptotic stimuli, forming a complex with JNK and p53. WWOX-p53 complex synergistically 
induces apoptosis by translocation to mitochondria and nuclei. However, JNK may be 
involved in inhibition of WWOX-induced apoptosis (Chang et al., 2003; Chang, 2002). 
Expression of WWOX was supressed by antisense RNA and protected apoptotic cell death 
from TNF, staurosphire, UV light and ectopic p53 in vitro (Chang et al., 2005). Breast cancer 
cells MDA-MB-435 and T47D showed inhibition of growth in soft agar by ectopic WWOX 
expression. WWOX expression strongly inhibited tumorigenicity of MDA-MB-435 in nude 
mice. Deletions of exon 5-8 or 6-8 of WWOX transcripts were observed in various 
carcinomas but not in normal tissues (Badnarek et al., 2001). In vivo tumorigenesis by loss 
of WWOX was demonstrated by Mahanjan et al., (2005). Activation of tyrosine kinase Ack1 
in prostate cancer cells (LNCap) showed minimal growth in vitro but increased tumorigenesis 
in nude mice which was partially due to negative regulation of WWOX (Mahanjan et al., 
2005).  Transfection of stable Wwox in L929 cells enhanced the cytotoxicity of TNF (Chang 
et al., 2001). Overexpression of both domains i.e., WW and SDR induces cell death which 
confirms both are functional (Change et al., 2001; Chang et al., 2003). The enhanced 
apoptosis due to overexpression of WWOX is partially due to upregulation of p53 (pro-
apoptotic) and down regulation of anti-apoptotic Bcl2 and Bcl-xL in mouse fibroblast L929 
(Change et al., 2001; Chang et al., 2003). Overexpression of transfected WWOX in prostate 
cancer cells (DU145) reduced colony growth and overexpression of WWOX by adenoviral 
suppressed cell growth by inducing caspase dependent apoptosis. Ectopic Ad-WWOX 
expression suppressed tumorigenicity in vivo (Qin et al., 2006). Contrary to this, the study of 
Chang et al., (2001) showed that overexpression of Wwox induced cell death in mouse 
NIH/3T3 fibroblasts which was not blocked by caspase and serine protease inhibitors. This 
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shows the role of caspase in WWOX mediated apoptosis is elusive as shown by another 
study of Fabbri et al., (2005) where re-expression of WWOX by adenovirus in WWOX 
negative lung cancer cells (A549, H460 and H1299) activated caspase-3 and PARP 
cleavage but not in WWOX positive U2020 cells. These studies suggest WWOX may or may 
not be involved in activation of apoptotic caspases.  
Gourley et al., (2009) showed that targeted deletion of Wwox in mice increased 
tumorigenesis and stable transfection WWOX into human ovarian cancer PEO1 cells lacking 
WWOX expression abolished in vivo tumorigenicity, although no correlation was observed 
with in vitro growth. It was further showed that WWOX expression reduced membranous 
integrin α3 protein bit not integrin α3mRNA. This study postulated WWOX acts as ovarian 
cancer tumour suppressor by modulating the interaction between tumour cells and 
extracellular matrix and by inducing apoptosis in detached cells. 
1.1.4 WWOX binding proteins 
Both domains of the WWOX (WW and SDR) are involved in binding with other proteins. 
Proteins bind to WW domain of WWOX via PPxY motif. WW domain of WWOX binds to p73 
(a p53 homolog) by PPPPY motif (Aqeilan et al., 2004a).  In another study by the same 
group Aqeilan et al., (2004b) other WWOX interacting proteins were investigated. Activating 
protein-2Ɣ (AP-2Ɣ) has high binding affinity with the WW domain of WWOX. AP-2Ɣ family 
members are important transcription factors in breast carcinogenesis (Williamson et al., 
1996). The genomic locus 20q13.2 contains AP-2Ɣ and show frequent amplification in breast 
carcinoma. The findings of Aqeilan et al., (2004b) showed that oncogenic activity of AP-2Ɣ 
was inhibited by WWOX protein by sequestering it in the cytoplasm. Verb-a erythroblastic 
leukaemia viral oncogene homolog 4 (ERBB4) is a transcription factor which also binds to 
first WW domain of WWOX (Aqeilan et al., 2005). Ezrin (a signal transducer at the cell 
membrane) (Jin et al., 2006) and small integral membrane protein of the lysosome/ late 
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endosome (SIMPLE) are binding protein which interact with first WW domain of WWOX 
(Ludes et al., 2004). 
The recognition of proline rich motif in all above-mentioned proteins is enhanced by the 
Tyr33 phosphorylation in WWOX/Wwox, whereas any change in the phosphorylation of 
Tyr33 can inhibit the binding of these proteins with first WW domain (Aqeilan et al., 2004a; 
Aqeilan et al., 2004b; Aqeilan et al., 2005). Transcription of p73 and AP-2Ɣ is blocked due to 
their restricted nuclear localization by ectopic WWOX (Aqeilan et al., 2004a; Aqeilan et al., 
2004b). There is a competition between WWOX and YAP (WW domain-containing Yes-
associated protein) for binding with ERBB4 which influence the transcriptional activity of 
ERBB4 (Aqeilan et al., 2005). Currently the involvement of phosphorylation of Tyr33 in 
binding of WWOX with PPxY motifs in ezrin and SIMPLE is not known (Jin et al., 2006; 
Ludes et al., 2004).  
Although there is no identification of any PPxY motif in JNK, P53 and MDM2 (mouse double 
mutant 2), yet their interaction with Tyr33 phosphorylated WW domain has been observed 
and also if there is any alteration in phosphorylation of Tyr33 it inhibits the bindings of these 
proteins with WW domain. The binding of p53 with Tyr33 phosphorylated WWOX takes 
place by Ser46-Pro47 and an adjacent N-terminal proline rich region (amino acid 66-100). 
Without Ser46 and Try33 phosphorylation, p53 does not interact and bind with WWOX. 
However, no binding of ectopic WWOX with ectopic p53 was observed by Arelin et al., 
(2004, possibly because cells used in experiments were not under stress stimulus (Chang et 
al., 2005; Aqeilan et al., 2004; Chang et al., 2005; Chang et al., 2001). In a study by Sze et 
al., (2004) mapping analysis showed that SDR domain of Wwox binds to Tau and preventing 
Tau hyperphosphorylation. However, no information is available about the protein motifs 
which may have been involved in this Tau interaction with SDR domain.  
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 1.1.5 Murine models of WWOX 
Mouse models of tumour suppressors are useful to investigate the biomedical aspects of 
cancer genetics. Tumour suppression function of any gene can be proved by formation of 
neoplasias in knockout mouse models. Although many studies suggest the role of WWOX as 
tumour suppressor gene, but mouse knockout models can provide an insight of its 
pathological functions (Pekarsky et al., 2002). 
Previously it has been shown by Aqeilan et al., (2007) that targeted deletion of Wwox gene 
increase spontaneously and chemically induced tumorigenesis. The same group also 
investigated the in vivo functions of WWOX for phenotypical abnormalities in Wwox-deficient 
(Wwox-/-) mice. These knockout mice are significantly smaller in size, show slow growth, 
suffer from metabolic skeleton disorder and have a life span of 2-3 weeks. These mice show 
a delay in bone formation. The Wwox null (KO) pups looked almost identical to Wwox 
heterozygous (HET) pups and wild type (WT) pups at birth stage. However, after 3 days of 
birth Wwox null pups were easily recognized from HET or WT pups due to their smaller size. 
Apart from size, the weight of the organs was less as compared to WT mice after 14 days of 
birth. However, the brain, adrenal and pituitary gland of KO mice were heavier then WT.  
Histological examination showed no lesions were found on organs but confirmed atrophy. 
Further analysis of serum chemistry showed prominent hypoglycaemia, hypocalcaemia, 
hypocholesterolaemia, hypoproteinaemia. Expression of mRNA from kidney, brain, spleen, 
femur and pituitary by Affymetrix microarray showed varied expression of chromatin and cell 
cycle related proteins in KO mice compared with WT. KO mice are smaller in size, so 
metabolic bone disorder in these mice was also observed. Radiographic images of femur 
bone after 3 weeks of birth showed less density of bone in KO mouse compared with WR or 
HET. However skeletal pattern at birth showed no difference within all three types of mice. 
Effect of Wwox on delayed bone growth was also observed in these mice. RUNX2 is a bone 
marker. The results showed Wwox supressed expression of RUNX2 in osteoblasts. Breast 
cancers cells MDA-MB-242 lacking endogenous WWOX, were re-expressed with WWOX 
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and showed inhibition of RUNX2 and its target genes linked with metastasis. The findings of 
this study suggest Wwox is important for post-natal survival and bone metastasis (Aqeilan et 
al., 2008). The findings of current study were in agreement with Ludes et al., (2009) who 
reported Wwox null mice showed hypoglycaemia and hypocalcaemia. Bone metabolic 
disorders were also observed in KO mouse. In addition, to this impaired haematopoiesis, 
leukopenia and splenic atrophy was also observed in KO mice. However, spontaneous 
neoplasias were not observed. This study provided an insight about functioning of Wwox in 
mice.  
In another study by Aqeilan et al., (2008), effect of Wwox deletion on steroidogenesis in mice 
was examined. Testicular abnormalities were observed in Wwox null mice. Effect of Wwox 
deletion during spermatogenesis and follicles development could not be observed because 
Wwox null pups died at juvenile age. Further the effect of Wwox on follicle stimulating 
hormone and luteinizing hormone was observed. The results showed significant down 
regulation of follicle stimulating hormone in Wwox null mice compared to WT. However, the 
effect on luteinizing hormone was not much, suggesting Wwox may affect functioning of 
gonads.  
Ludes and colleagues (2007) also used a mouse model to study the role of Wwox gene 
expression in tumorigenesis. Homozygous gene-trap mice (Wwoxgt/gt) was used but it 
showed low levels were still detectable in some tissues, so these mice were considered 
Wwox hypomorphs. Deletion of Wwox proves very lethal at postnatal stage but these 
hypomorph mice were more viable. The results showed higher incidence of B-cell 
lymphomas and testicular atrophy in Wwox hypomorphs which suggest Wwox is a tumour 
suppressor gene (Ludes et al., 2007).   
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1.2 Ovarian Cancer 
1.2.1 Epidemiology 
Ovaries are part of the female reproductive system and ovarian cancer arises in the cells in 
and around ovary. It is the most lethal gynaecological cancer.  Ovarian cancer can affect 
younger women but usually women over 50 years of age are diagnosed with this cancer. 
Each year in UK 7400 women are diagnosed with ovarian cancer and 53% of diagnoses 
cases are in women aged 65 or over.  This is the 6th most common cancer in women in UK. 
The 5-year survival rate has improved in last few years and the current 5-year survival rate is 
50% in UK. The 10-year survival rate is 35%. The data of 2014 show there were 4128 
deaths due to ovarian cancer in UK (Cancer Research, UK). The increase in survival rate 
has been suggested due to hormonal contraceptive use, pregnancy, lactation and 
decreasing postmenopausal hormone use (Mosher and Jones, 2010; Collaborative Group 
on Epidemiological Studies of Ovarian Cancer, 2008).  
1.2.2 Molecular pathology of ovarian cancers 
1.2.2.1 Hereditary ovarian carcinomas 
Women with family history of ovarian and breast cancer are at risk of developing the 
disease. About 10-15% ovarian cancer cases are due to genetic factors (Christie and 
Oehler, 2006). Women with the BRCA1 mutation have a risk of 40-50% of epithelial ovarian 
cancer and 20-30% with mutation of BRCA2. DNA repair mismatch gene such as MLH1 and 
MSH2 are linked with hereditary non-polyposis colon cancer (HNPCC) syndrome and are 
believed to be responsible for 10% cases of serous ovarian cancer due to inheritance of 
genes from family (Aarnio et al., 1999).  Polymorphism in glutathione S transferase M1 
(GSTM1) has also been linked with endometrioid or clear cell ovarian carcinomas. Some 
other polymorphisms such as steroid-5- alpha reductase, alpha polypeptide 2 and 
progesterone receptor genes are also thought to be responsible for increasing the risk of 
ovarian cancer (Beesley et al., 2007; Pearce et al., 2008). 
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1.2.2.2 Sporadic ovarian cancer 
Ovarian carcinomas which are not due to hereditary reasons are thought to be sporadic in 
nature and 85% of ovarian cancer cases belong to this category (Christie and Oehler, 2006). 
Many oncogenes such as KRAS, BRAF, PIK3CA AND CTNNB1 show mutations in various 
ovarian carcinomas. Mucinous carcinomas show 50% and low grade serous carcinomas 
show 35% KRAS mutations. Low grade serous carcinomas show 30% BRAF mutation. 
Surprisingly, both KRAS and BRAF mutations do not appear together in the same tumours 
and also do not appear in high grade serous ovarian carcinomas (Gemignan et al., 2003; 
Singer et al., 2003).   
About 30% of endometrioid ovarian carcinoma shows beta catenin (CTNNB1) and Wnt 
mutations (Palacios J, Gamallo, 1998). About 20% of clear cell and endometrioid show 
mutations in phosphatidylinositol 3-kinase PI3K gene (PIK3CA) and it’s not common in 
serous carcinomas (Campbell et al., 2004). 15% endometrioid ovarian carcinomas show 
mutation of PTEN gene and the presence of this tumour suppressor gene is not common is 
other types of ovarian carcinomas (Obata et al., 1998). Mutation of p53 gene has been found 
in 96% of high grade serous ovarian carcinomas (Quartuccio et al., 2014) while clear cell 
carcinomas show 8% of mutation of p53. Presence of p53 mutation has been seen in the 
inclusion cysts and in the patients with positive BRCA mutation (Lee et al., 2007; Medeiros 
et al., 2006) Microsatellite instability (MSI) affects mismatch match repair (MMR) pathway 
due to genetic or epigenetic factors and it appears in 12% of ovarian carcinomas (Pal et al., 
2008). 10-50% of ovarian carcinomas also shows promoter hyper methylation of MLH1 gene 
(Gras et al., 2001).   
1.2.2.3 Borderline epithelial ovarian cancer 
Border line tumours (BOT also known as epithelial ovarian cancer of LMP, are primary 
ovarian lesions with characteristics showing malignancy but different to epithelial high grade 
ovarian cancers. They show no stromal invasion, good prognosis and have a five years’ 
survival rate of more than 80% (Cadron et al., 2007; Barakat et al., 1995). The procedure of 
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staging BOT is like invasive ovarian cancer. Patients with border lines tumours can have 
pregnancy by undergoing organ preserving surgery if contralateral ovary or ovary remnant is 
tumour free. However, there is a risk of reoccurrence if organs are preserved but it does not 
affect overall survival.  Removal of lymph nodes is not required if they look normal on 
palpation. Adjuvant chemotherapy for BOT so far is not beneficial (du Bois Ad et al., 2009; 
Sutton et al., 1991). 
1.2.3 Traditional theories about origin of ovarian cancer 
It is very important to understand the biology of a tumour for its diagnosis and treatment. It 
can only be achieved if the site and originating tissues of the malignant tumour are known. 
Historically it used to be thought that high grade serous ovarian carcinoma arose from 
ovarian surface epithelium and epithelial inclusion glands. Because of the lack of knowledge 
about a precursor in the ovary or peritoneum, it was thought that the pathogenesis of ovarian 
carcinoma was de novo (Vang et al., 2013). Traditionally three inter related theories have 
been proposed to explain the start of epithelial ovarian cancer. According to incessant 
ovulation hypothesis, repetitive postovulatory repair can cause cell proliferation and 
wounding at the ovarian epithelium which can result in genomic abnormalities such as 
formation of cysts which enhances the risk of carcinogenesis.  The second hypothesis 
‘gonadotropin theory’ suggests that during ovulation increased release of gonadotropin 
hormone by pituitary gland and constantly high concentration after menopause can affect 
ovarian epithelium cells causing abnormalities and increasing the risk of carcinogenesis. 
According to the third theory, inflammation and alteration of redox potential during ovulation 
and ovarian epithelium repair can pose a risk of epithelial ovarian cancer (Rodriguez et al., 
2002).  
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1.2.4 The dualistic model of epithelial ovarian carcinogenesis  
There are two types of ovarian carcinomas based on their clinical and molecular pathology. 
This model of dividing tumours into type I and type II is called the two pathway concept or 
the dualistic model of epithelial ovarian carcinogenesis. This model tried to resolve the 
complicated molecular genetic pathways responsible for the pathogenesis of primary ovarian 
carcinomas and to link these pathways with the histopathologic classification (Shih and 
Kurman, 2004).  Table 1.3 show some major characteristics of type I and type II ovarian 
carcinomas. 
Table 1.3: Characteristics of Type I and Type II ovarian carcinomas (Koshiyama et al., 2017) 
 
 
1.2.4.1 Type I ovarian tumours 
Ovarian tumours belonging to Type I are mostly slow growing indolent neoplasms. These 
are the tumours in which precursor lesions in the ovaries have been clearly explained 
(Koshiyama et al., 2014). Figure 1.3B shows the major clinicopathologic and molecular 
differences between type 1 and type II tumours.   
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Figure 1.3B 
A representation of dualistic model of ovarian carcinogenesis: Ovarian carcinoma belonging to 
type I arise from endometriosis, fallopian tube, germ cell and transitional cell. Ovarian carcinoma 
belonging to type II originate from fallopian tube. In type I endometrioid carcinoma, clear cell 
carcinoma and low grade serous carcinoma are the most types, whereas mucinous carcinoma and 
Bernner tumours are rare. Ovarian carcinoma belonging to type II are high grade serous carcinoma, 
carcinosarcoma and undifferentiated carcinoma (Shih and Kurman, 2016).    
1.2.4.1.1 Endometrioid Carcinoma and Clear Cell Carcinoma 
Endometrioid carcinomas are mostly very well differentiated but sometimes they can be 
moderately or poorly differentiated. It is considered that the poorly differentiated carcinoma is 
due to de-differentiation from low grade carcinomas. Clear cell carcinoma are not graded as 
compared to other type I tumours but generally they are considered as high grade tumours, 
contrary to other type I tumours. Sometimes components of both endometroid and clear cell 
carcinoma can be found together in ovarian tumours (Shih and Kurman, 2016).  
Clinical, histopathological and genetic evidence suggest that endometriosis could be the 
precursor lesions responsible for the origin of endometrioid and clear cell ovarian carcinoma 
(Vaughan et al., 2011). Both Endometrioid (40%) and clear cell ovarian carcinoma (60%-
90%) have association with endometrial cysts (Veras et al., 2009). Also, both the tumour and 
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neighbouring endometrioid epithelium show mutation in the genes encoding AT-rich 
interaction domain 1A (ARID1A) and phosphatidylinositol 3-kinase catalytic subunit 
(PI3KCA) (Wiegand et al., 2010 & Yamamoto et al., 2011). Endometrial tissue arising 
from cavum uteri form ectopic neoplasia, affecting 10-15% of reproductive age women. 
Retrograde menstruation (a process in which menstrual blood containing endometrial 
cells flows back into fallopian tubes and into the pelvic cavity instead of out of the body) is 
thought to be responsible for ectopic neoplasia (Hull et al., 2008). Fallopian tubes are the 
main linking connection between all these parts and this makes them very relevant during 
this process. Epidemiological analyses support the fact that the ligation of fallopian tube 
greatly reduces the risk for the development of endometrioid and clear cell ovarian cancer 
(Sieh et al., 2013). Also, ligation of fallopian tube restricts the retrograde transport of 
exfoliated endometrial cells, preventing them from implanting into ovarian or peritoneal 
surface, hence providing protection from these subtypes of ovarian cancer. However, 
ligation of fallopian tube does not provide enough protection against frequent serous 
ovarian carcinoma because cells from fimbriated end of fallopian tube can still penetrate 
ovaries or peritoneum (Dietl, 2014).  
Ovarian clear cell carcinomas (OCCC) are not very common in Europe and only (4%) of 
ovarian carcinomas cases belong to this type (Gram et al., 2012). OCCC have been 
classified as type I but they can be considered as intermediate tumours (Yamaguchi et al., 
2010). Studies of OCCC have revealed that many genes affected in OCCC are stress 
related genes and their upregulation is due to epigenetic mechanism. This suggests that 
OCCC is induced by stressful conditions in endometriotic cyst (Matsumura et al., 2010). 
1.2.4.1.2 Mucinous Carcinoma 
There are different theories regarding the origin of ovarian mucinous carcinomas. According 
to one theory a subset of mucinous carcinomas may develop along with ovarian teratomas 
but mucinous carcinomas themselves do not show any teratomatous elements (Czriker et 
al., 1954; Woodruff et al., 1960). Another theory suggests mucinous carcinomas originate 
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from endometriosis, Brenner tumours and metaplasia of surface epithelial inclusions 
(Horiuchi et al., 2003; Woodruff et al., 1960)., although some other findings suggest that their 
involvement is rare except for Mullerian endocervical mucinous or mixed border line tumours 
(Rutgers and Scully, 1988; Lin and Olivia, 2013).  Mandai et al., (1998) have shown 
morphological transition from cystadenoma to mucinous borderline tumours (MBT) to 
intraepithelial carcinoma and invasive carcinoma. Cystadenomas, MBT and mucinous 
carcinoma also show an increased frequency of KRAS mutations at codons 12 and 13. 
These observations support the hypothesis of ‘mucinous adenoma-carcinoma sequence and 
supporting the argument that mucinous cystadenomas and MBTs develop into mucinous 
carcinomas in an orderly manner (Ichikawa et al., 1994; Mok et al., 1993). 
1.2.4.1.3 Low grade serous Carcinoma 
These tumours are very rare but genetically stable and show less genetic mutations. They 
develop in an indolent manner from their precursors. Comparison of DNA content and 
alterations in the copy numbers closely relate low grade serous carcinoma with serous 
border line tumours (Pradhan et al., 2009; Kuo et al., 2009). Mutations of p53 are also not 
very common in low grade serous carcinomas (Singer et al., 2005). According to one theory 
the transformation of Mullerian metaplasia into ovarian epithelial give rise to low grade 
ovarian serous carcinomas (Lauchlan et al., 1972; Dubeau et al., 2008).  The other theory 
suggests low grade serous carcinomas originate from embryological remains of proximal 
Mullerian ducts which are present in ovarian hilm. However, some recent theories suggest 
that ovarian low grade serous carcinomas and their implants, ovarian epithelial inclusion 
glands and endosalpingiosis may originate from fallopian tube (Vang et al., 2013). According 
to this recent theory the pathogenesis of invasive low grade serous carcinoma originates 
with serous cystadenoma/adenofibroma, which develops in slow stepwise sequence into 
atypical proliferative serous tumour (typical serous borderline tumour), non-invasive 
micropapillary (low grade) serous carcinoma (micropapillary serous border line tumour) and 
then invasive low grade serous carcinoma (Vang et al., 2013). 
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1.2.4.2 Type II ovarian tumours 
These tumours are clinically aggressive in nature and they originate from tubal or ovarian 
surface epithelium.  
1.2.4.2.1 High grade serous carcinomas 
The ovarian carcinomas belonging to this category are very aggressive and show worst 
prognosis. It is thought that high grade serous carcinoma originates from fallopian tube 
(Vang et al., 2013). During the last few years advances in the histological analyses have 
shown that the candidate precursors are at the fimbriated ends of the fallopian tubes called 
as serous tubal intraepithelial carcinoma (STIC) (Vang et al., 2013). Molecular genetics and 
morphology show that STIC resembles serous ovarian cancer and it has been detected in 
>60% of BRCA-unrelated serous ovarian carcinomas. Based on this evidence STIC are now 
regarded as the earliest histological lesions in the pathogenesis of the most common ovarian 
cancer subtype (Dietl, 2014). It has been proposed that STIC implants onto the ovary which 
result in the development of invasive high grade serous carcinoma prompting tumour growth 
(Vang et al., 2013).   
 About 68% of ovarian cancer cases belong to this category and mostly they are diagnosed 
at advanced stage. Mutations of p53 have been observed in 96% of these cancers with a 
high Ki67 proliferation index (50%-75%) (Koshiyama et al., 1995; Salani et al., 2008; 
Quartuccio et al., 2014). In high grade serous carcinomas gene instability due to 
chromosomal arrangements is common and they also have mutations of BRAC1 and 
BRAC2 in 90% hereditary cases (Christie and Oehler, 2006).  According to microarray 
analysis data set from The Cancer Genome Atlas (TCGA) project, high grade ovarian 
carcinomas can be divided into four categories based on their gene expression such as; 
mesenchymal, immunoreactive, proliferative and differentiated (Cancer Genome Atlas 
Research Network, 2011; Verhaak et al., 2013). A study by Murakami et al., (2016) show 
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that carcinomas belonging to subtype immunoreactive show best progression free survival 
and overall survival, while mesenchymal subtype show worst overall survival.  
1.2.5 Stages of Ovarian cancer 
The stage of ovarian cancer gives an idea how far it has grown and spread. There are four 
stages of ovarian cancer also known as FIGO system named after its author –the 
international Federation of Gynaecological Oncologists (Cancer Research, UK).  
1.2.5.1 Stage 1 
Ovarian cancer at stage I means it is limited only in the ovaries. Stage I is further divided into 
three sub-stages; 
Stage 1a- Cancer is only inside 1 ovary 
Stage 1b- Cancer completely inside both ovaries 
Stage 1c- Apart from cancer in one or both ovaries, there is some cancer on the surface of 
the ovary. Presence of cancer cells in the fluid removed from abdomen during surgery. 
 
Figure 1.4: Stage I of ovarian cancer. The figure shows cancer is limited to ovaries 
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1.2.5.2 Stage II 
In stage 2, cancer spreads outside the ovary or ovaries and also in the area of hip bones 
(the pelvis). Cancer cells can also be present in abdomen. Stage II cancer is also divided 
into three sub-stages; 
Stage 2a- the spread of cancer into fallopian tube or the womb 
Stage 2b- the spread of cancer into bladder or rectum 
Stage 2c- the spread of cancer into other tissues of pelvis and also into the fluid inside 
abdomen 
 
Figure 1.5: Stage II of ovarian cancer. The figure shows spread of cancer outside ovaries into the 
area of pelvis. 
 
1.2.5.3 Stage III 
In stage III cancer spread outside pelvis into the abdominal cavity. Cancer also spreads into 
lymph nodes, upper abdomen, and groin or behind the womb. Stage III cancer is also 
divided into three sub-stages; 
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Stage 3a- presence of cancer cells in tissues lining the abdomen 
Stage 3b- growth of cancer up to 2cm or smaller in size within the lining of abdomen 
Stage 3c- growth of cancer larger then 2cm and spread of cancer in lymph nodes in the 
upper abdomen, groin or behind the womb. 
 
Figure 1.6: Stage III of ovarian cancer. The figure shows spread of cancer into the abdominal cavity. 
1.2.5.4 Stage IV 
In stage IV cancer spreads from ovaries to other body organs at some distance away such 
as liver or lungs. Stage IV cancer is also divided into 2 sub-stages; 
Stage 4a- the cancer spreads into the fluid which builds up in the lining of lungs called 
pleura. 
Stage 4b- the cancer spreads inside of liver or spleen, lymph nodes in the groin, outside 
abdomen or other organs such as lungs.  
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Figure 1.7: Stage IV of ovarian cancer. The figure shows spread of cancer to other body organs. 
1.2.6 Screening of ovarian cancer 
Early detection of cancer can significantly increase the chances of survival for the patients 
and specially if the cancer is metastatic and the lesions are detectable. Localization of 
cancer for longer periods also helps in cost effective screening (Badgwell and Bast, 2007). 
To get a positive prediction of 10% or higher for epithelial ovarian cancer, detection method 
should have sensitivity of more than 75% and 99.6% specificity. The concentration of serum 
125 alone is not enough for screening because it’s neither sensitive nor specific. Specificity 
of serum 125 is enhanced when combined with transvaginal ultrasonography (TVS) or by 
monitoring of its concentration over time or both. These findings were also validated by 
United Kingdom Collaborative Trial of Ovarian Cancer Screening in which 202638 
postmenopausal women of age 50-74 years participated and showed sensitivity of yearly 
screening of CA125 combined with TVS as second line test but TVS alone was encouraging. 
When both serum 125 and TVS were combined it enhanced specificity (Menon et al., 2009). 
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Proteomics based biomarkers can also enhance the sensitivity and specificity of serum 
assays for early detection of ovarian tumours (Nossov et al., 2008).  
Screening of germline mutations of BRCA1 and BRCA2 by using risky assessment 
programme BRCAPRO can also be used for early detection of ovarian cancer. In this 
programme patients own history and family history information is used for screening 
purposes (Berry et al., 2002; ACOG, 2009). Patients with the mutations of BRCA1 and 
BRCA2 undergo screening of CA125 and TVS at regular intervals between 30-35 years of 
age or 5-10 years earlier of the age in the family when ovarian cancer was first diagnosed 
(Burke et al., 1997; Daly et al., 2010). Women who are 40 years or older and have mutation 
of germline BRCA1 and BRCA2 are also advised to undergo bilateral salpingo-
oophorectomy (BSO) to lower the risk of ovarian or breast cancer, although the risk of 
primary peritoneal carcinoma is still there even after BSO (Rebbeck et al., 2002; Burke et al., 
1997).  
1.2.7 Treatment of ovarian cancer 
1.2.7.1 Primary Treatment 
Surgery of ovarian cancer is called primary treatment and it consists of staging and 
cytoreduction (debulking). If the cancer is limited only to ovaries, then the surgery can be 
very curative. In surgery, comprehensive staging laparotomy combined with total abdominal 
hysterectomy and bilateral salpingo-oophorectomy is carried out (Giede et al., 2005; Earle et 
al., 2006; Du Bois et al., 2005). Young females with early stage invasive epithelial ovarian 
cancer or lesions which show abnormal cells but less risk of developing into cancer, can 
maintain their fertility by undergoing surgery called salpingo-oophorectomy. This procedure 
helps in preserving the uterus and contralateral ovary (Wright et al., 2009; Fader et al., 
2007). Less invasive techniques can be used for stage I disease for example prophylactic 
oophorectomy. Ovarian cancer patients with disease at stage II, III and IV are recommended 
to undergo cytoreductive surgery (Stier et al., 1996; Eisenhauer et al., 2006). Removal of 
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gross disease should be done at its best. For cytologic examinations aspiration of ascites or 
peritoneal lavage should be done. If the disease has spread more than ovaries, then total 
hysterectomy and bilateral salpingo-oophorectomy need to be done. Removal of omentum 
and resection of suspicious large nodes should be done. Stage III patients should have 
bilateral pelvic and para-aortic lymph node dissection (Panici et al., 2005; Aletti et al., 2009). 
For all stages of ovarian cancer, the methods that may be considered are pelvic dissection, 
bowl resection, diaphragm or other peritoneal surface stripping, splenectomy, partial 
hepatectomy, cholecystectomy, partial gastrectomy or cystectomy, ureteroneocystostomy or 
distal pancreatectomy (Wimberger et al., 2007).  
1.2.7.2 Chemotherapy 
Majority of epithelial ovarian cancer patients undergo postoperative systemic chemotherapy. 
However, if the cancer is stage IA, IB or grade I tumours then there may be no need of 
chemotherapy and it has been observed only with surgery the survival rate is more than 90% 
for these patients. Epithelial ovarian, primary peritoneal and fallopian tubes cancer are 
recommended to undergo primary adjuvant therapy. Stage III patients (debulked) are 
recommended to undergo intraperitoneal chemotherapy according to randomized controlled 
trials (www.cancer.gov). Stage II patients can also undergo intraperitoneal chemotherapy, 
however randomized trials for them have not been published (Armstrong et al., 2006; 
Markman and Walker, 2006; Marth et al., 2007). Intraperitoneal therapy of cisplatin/paclitaxel 
enhanced the survival time by 16 months in stage III ovarian cancer patients as compared to 
standard intravenous therapy. However, the patients with poor performance status can be 
given intravenous paclitaxel/carboplatin (category I) (Giede et al., 2005; Ozols et al., 2003). 
The other alternative regimens for intravenous therapy are docetaxel/cisplatin or 
paclitaxel/cisplatin (both category I). Those patients who have high risk of neuropathy 
(diabetes patients) are recommended to be given docetaxel and carboplatin (Vasey et al., 
2004; McGuire et al., 1996). The cycles of chemotherapy depend on the stage of the 
disease. Patients at early stage are recommended 3-6 cycles of chemotherapy and 
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advanced stage patients (II-IV) are recommended 6-8 cycles of chemotherapy (Bell et al., 
2006).  
1.2.7.3 Treatment of ovarian cancer by PARP inhibition 
A promising advance in the treatment of ovarian cancer is the use of poly(ADP-ribose) 
polymerase (PARP) inhibitors. PARP inhibitors are drugs that interfere with PARP 
function and kill BRCA mutant cells (Lord and Ashworth, 2017). Epithelial ovarian cancer 
patients with known mutation (germ line or somatic) in BRCA have shown very 
promising preclinical data (phase II and phase III) for the clinical use of PARP. 
Effectiveness of PARP has also been observed in patients without BRCA mutation but 
possibly having other mutations due to molecular deficiencies in DNA repair (Markman, 
2017 & Fong et al., 2010). FDA has approved three PARP inhibitors (olaparib, rucaparib 
and niraparib) for commercial use. Each of the three PARP inhibitors have different 
clinical indications and toxicity but so far there is no direct comparison data available of 
these inhibitors. The ongoing trails for the use of these inhibitors for managing treatment 
of ovarian cancer also include novel strategies of combining other antineoplastic agents 
such as antiangiogenic agents, and checkpoint inhibitors with PARP inhibitors 
(Markman, 2017).  
1.2.7.4 Treatment of ovarian cancer by immunotherapy 
Ovarian cancer can also be treated by immunotherapy. Presence of Immunogenic tumour 
associated antigens on ovarian cancer cells can produce a detectable immune response 
(Vlad et al., 2004). Although evidence suggests that the anti-tumour immunity is effective in 
ovarian cancer cells, the success ratio of immunotherapy is very modest at best. 
Immunotherapy for ovarian cancer patients was first used in 1987 by using intraperitoneal 
injections of anti-human fat globulin-1 antibodies (Epenetos et al., 1987). This was the first 
treatment where monoclonal antibodies were used for the treatment of cancer. Other 
antibodies used were the anti-CA125 antibody oregovomab, but it failed. More recent 
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developments, such as the generation of CAR-T cells targeting ovarian tumour antigens 
perhaps hold more promise (Zhu et al., 2017). Despite some reports of good clinical 
response of immunotherapy in ovarian cancer patients, there are no immunotherapy 
treatments approved by FDA. It has been suggested that immunotherapy could be more 
responsive if combined with cytotoxic agents, small molecules inhibitors or radiotherapy 
(Drerup et al., 2015)  
1.2.8 WWOX expression in ovarian cancer 
All normal ovarian epithelial cells express high amount of WWOX. In a study by Nunez et al., 
(2005) expression of WWOX was observed in ovarian carcinoma. Immunoblotting analysis 
showed consistently high levels of WWOX in normal ovarian samples, whereas undetectable 
or reduced levels of WWOX were observed in 37% of ovarian carcinoma. 
Immunohistochemistry analysis of normal human ovarian tissue showed very strong 
expression of WWOX in surface epithelial cells, whereas 30% of ovarian carcinoma (n=444) 
showed almost complete loss of WWOX expression. The other 70% of ovarian carcinoma 
samples showed moderate to strong WWOX protein. Reduced expression of WWOX 
showed a significant correlation with FIGO stage IV (p=0.007) and shorter overall survival 
(p=0.03). Correlation of WWOX and overall survival was observed by using cases from 
MDACC TMA (n=354). A statistical significant correlation was observed between WWOX 
and overall survival, whereas low WWOX protein expression correlated with shorter survival 
(p=0.03). 
Association between WWOX and tumorigenicity was observed in a study by Gourley et al., 
(2009). In this study, ovarian cancer cells PEO1 were transfected with WWOX expressing 
plasmid and a vector. QRT-PCR and immunoblotting analysis showed that parental cells and 
vector transfected cells expressed no WWOX but WWOX transfected cells expressed 
various levels of WWOX. These cells were injected in nude mice and result showed that 
WWOX transfected cells formed no tumours, while parental PEO1 cells and vector 
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transfected cells formed large tumours. The results show WWOX abolished tumorigenicity in 
vivo, however it has no effect in in vitro proliferation when plated n plastic or soft agar.  
Role of WWOX in apoptosis was also checked in adherent ovarian cancer cells. No 
significant difference was observed between parental PEO1, vector or WWOX transfected 
cells. Cells were then exposed to cisplatin (chemotherapy drug) which is used to treat 
ovarian cancer by causing cell death, but no evidence of apoptosis was found by WWOX. 
WWOX abolished tumorigenicity in vivo but not in adherent cells, so assessment of WWOX 
on apoptosis and proliferation was performed in vivo by injecting WWOX transfected and 
control cell in nude mice. Greater heterogenicity within tumours then between tumours was 
observed which showed tumour regression in vivo is not due to altered proliferation.  
Further assessments were done to find out how WWOX suppressed in vivo tumorigenicity by 
examining the interaction between tumour cells and extracellular matrix (ECM). Restoration 
of WWOX in PEO1 cells and overexpression of WWOX in SKOV3 ovarian cancer cells 
showed reduction in migration and attachment with fibronectin, an ECM component involved 
in peritoneal metastasis. Contrary to this, knock down of WWOX in another ovarian cancer 
cells A2780 by siRNA enhanced attachment with fibronectin. There was no difference in rate 
of apoptosis in WWOX expression or WWOX non-expressing cells in adherent cultures. 
However, in detached cell cultures WWOX expression showed more cell death then WWOX 
non-expressing cells. It was further shown that WWOX expression showed reduction of 
membranous integrin A3 protein but not mRNA levels and adhesion of PEO1 cells to 
fibronectin is by integrin A3. This study shows the role of WWOX expression in abolishing 
tumorigenicity in vivo in ovarian cancer by reducing attachment to fibronectin via integrin α3.  
1.2.9 Expression of FHIT in ovarian cancer 
It has been reported by many studies that FHIT gene expression is altered in epithelial 
tumours. Ozaki et al., (2001) examined the role of FHIT in the development of ovarian 
cancer. 33 ovarian carcinomas, 2 borderline tumours and 10 benign adenomas were used in 
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the study to examine in alterations in FHIT using RT-PCR and sequencing. 15% of ovarian 
carcinoma and 1 of the 2 border lines tumours showed aberrant FHIT expression, whereas 
15% of ovarian carcinoma showed loss of normal FHIT but border line or benign tumours did 
not show any loss of FHIT. LOH was observed at D3S1300 and D3S4103 (microsatellite 
markers) in 21% and 20% of ovarian carcinomas. Immunohistochemistry analysis showed of 
loss of FHIT expression in 14% of ovarian carcinoma; however, border line or benign 
tumours did not show loss of FHIT. Loss of FHIT expression was correlated with loss of 
normal FHIT transcript. This study suggests loss of normal FHIT transcription can inactivate 
FHIT expression resulting on genesis of ovarian cancer, mostly in high grade serous 
carcinomas.    
Hendricks et al., (1997) have shown that expression of FHIT in human ovarian carcinomas. 
14 ovarian, 8 cervical and 4 endometrial human cancer cell lines were selected of analysis of 
FHIT expression by RT-PCR. The results showed 63% cervical and 14% ovarian cell lines 
showed aberrant FHIT transcripts, whereas endometroid cell lines did not show any change 
in FHIT. Further analysis of DNA sequencing showed shorter mRNA transcripts with 
primarily missing exons 5, 6 and 7 were missing in aberrant bands along with some other 
exons. Further analysis of DNA by southern blotting revealed 4 of the 5 ovarian carcinomas 
showed altered expression of FHIT and among those 4, three ovarian carcinomas showed 
no normal FHIT transcripts. These findings suggest involvement of FHIT gene in cervical 
tumorigenesis and also FHIT is less important in ovarian and endometroid cancer 
development.   
 
1.3 Colorectal Cancer 
1.3.1 Epidemiology 
Colon cancer also known as bowel cancer is one of the most common gastrointestinal 
malignancies. Larger and small intestine are part of digestive system. Colon cancers mostly 
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start in large intestine but sometimes it can start in small intestine as well. Bowel or 
colorectal cancer is one of the most common types of cancer diagnosed in UK after breast, 
prostate and lung cancer. Every year 40,000 new cases are diagnosed in UK alone and 1 in 
20 people develop colorectal cancer later in their life (NHS Scotland, 2017).  Although 
colorectal cancer can happen at any age but more than 9 out of 10 cases (94%) diagnosed 
in UK are people over the age of 50 years. Six out 10 (59%) cases diagnosed are in people 
over the age of 70. Approximately 268,000 people in UK have been diagnosed with 
colorectal cancer. Early detection of colorectal cancer is treatable and curable. 5 years’ 
survival time depends upon the stage as people at stage 1 can survive more than 5 years. 
Relapse chances are less after 5 years. Every year about 16,000 people die from colorectal 
cancer which makes it second most common cause of cancer death. The death numbers are 
falling after 1970 because of better diagnosis and treatment (Bowel Cancer UK, 2017).  
1.3.2 Pathophysiology 
There are four tissue layers of colon which play an important role in determining the stage of 
colorectal cancer (figure 1.8). These four layers are serosal layer, thick muscle layers, 
submucosa and mucosal layer. The mucosal layer consists of epithelium containing mucus 
secreting factories called goblet cells. This is the inner most layer of colon which come in 
direct contact of the substance that pass through the gut and hence it’s susceptible to 
damage. Crypts of Lieberkühn are housed in mucosal layer. Crypts are formed by epithelia 
of villi which extend into the lamina propria. Crypts contain cells which are involved in host 
defence and signalling. It also contains stem cells which replenish epithelial cells further up 
to the villi. The development of colon cancer takes place inside crypts of Lieberkühn 
(Leblond, 1981; Humphries and Wright, 2008). Formation of the new cells takes place in 
crypts while the old cells move into the lumen and shed. If there is any damage to the cells 
of the crypts it can cause inflammation and hyperproliferation which can result in formation of 
an adenoma. The mucosal layer and submucosa are separated by the basement membrane 
which is located directly against muscularis. The supply of blood and nutrients to gut is 
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provided by muscularis which is also accessible for transference of abnormal cells. The 
outer most layer of colon is serosal layer which is in touch with peritoneal structures. 
 
 
Figure 1.8: Anatomy of colon (Shelton, 2002). The layers of colon wall consist of three layers; 
mucosal layer, thick muscle layer and serosal layer. 
 
Genetic mutations and molecular abnormalities can cause colorectal cancer, however the 
resultant changes that arise due to mutations and abnormalities are not easy to predict. 
 
 
33 
 
Some of the common molecular abnormalities responsible for colorectal cancer have been 
shown in figure 1.9 (Jessup et al., 1997; Glaser et al., 1999; Markowitz and Winawer, 1997). 
 
 
Figure 1.9: Pathogenesis of colorectal cancer (Burt, 1997). It shows molecular abnormalities 
responsible for colorectal cancer. 
 
1.3.3 Types of colorectal cancer 
Based on the histopathology of the malignant cells colorectal cancer is further divided into 
types. 
1.3.3.1 Adenocarcinoma 
Adenocarcinomas arise from the mucus secreting gland cells in the lining of the colon wall.  
This is the most common histologic type of colorectal cancer and more than 90% of 
colorectal cancer cases belong to this category (Pazdur et al., 1999). It typically starts as a 
growth of tissue in colon called polyp. Adenoma is a type of polyp that develops into 
carcinoma. Removal of polyp by colonoscopy can prevent development of cancer. There are 
two types of adenocarcinoma; 
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1.3.3.1.1 Mucinous tumours 
 These tumours are comprised of about 60% mucus which may cause cancer cells to spread 
quickly. These tumours are more aggressive then adenocarcinomas and represent 10-15% 
of colorectal adenocarcinomas. The treatments procedures are same for these two types as 
for adenocarcinomas (Cancer Research UK, 2017). 
1.3.3.1.2 Singlet ring carcinomas 
These carcinomas are aggressive and more difficult to treat. About 1% of adenocarcinomas are 
singlet ring cell carcinomas (Cancer Research UK, 2017).  
1.3.3.2 Rare types of colorectal cancer 
1.3.3.2.1 Squamous cell carcinomas   
Squamous cells along with gland cells make the inner lining of the colon. These are unusual 
carcinomas and indicate chronic cellular changes due to repeated exposure to carcinogens 
(Sasaki et al., 1998). 
1.3.3.2.2 Carcinoid tumours  
Carcinoids are slow growing tumours which can arise in parts of digestive system (stomach, 
small intestine, colon, and rectum). These are called neuroendocrine tumours because they 
grow in hormone producing tissue. There are no early signs or symptoms but appear late in 
disease. The treatment includes surgery and medication (Cancer Research UK, 2017). 
1.3.3.2.3 Sarcomas  
The cancers of bone or muscles are called sarcomas. Sarcomas in the colon are called 
leiomyosarcomas. These sarcomas start in smooth muscles. The treatment for sarcomas is 
different to colorectal adenocarcinomas (Cancer Research UK, 2017). 
1.3.3.2.4 Lymphomas 
Following are the cancers of lymphatic system. Treatment of lymphomas is different to 
adenocarcinomas of colon. 
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1.3.4 Stages and grades of colorectal cancer 
Prognosis of cancer is determined by its pathologic state. The stage of cancer gives an 
indication about the spread of cancer and how big the tumour is. Its gives an indication if the 
tumour has penetrated though the walls of intestine and if the cancer has reached into the 
lymph nodes. It also indicates about distant metastasis. If the tumour spreads through the 
muscularis into the submucosa, it is considered as invasive. Tumour can spread through the 
peritoneal wall or it can spread through the lymphatic or vascular system to the distant sites 
such as liver. Although less frequent but it can also spread into bones, kidneys and adrenal 
glands (Pazdur et al., 1999). There are three different systems used for staging of colorectal 
cancer; the American Joint Committee on Cancer tumour, nodes, metastasis (TNM), Dukes 
and the number stage system.  
1.3.4.1 TNM Staging  
TNM is the most commonly used system. TNM stands for tumour, node and metastasis. 
1.3.4.1.1 Tumour (T)  
Tumour stage describes the size of the tumour in the colon. There are four stages of tumour 
in colorectal cancer (figure 1.10). T1 (tumour only in the inner layer of colon), T2 (penetration 
of tumour into muscular layer of colon), T3 (penetration of tumour into outer lining of colon) 
and T4 (penetration of tumour through the outer lining of colon to the nearby organs) 
(Cancer Research UK, 2017) 
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Figure 1.10: Tumour stages of colon (T1, T2, T3 and T4). 
1.3.4.1.2 Node (N) 
Node (N) describes the spread of cancer into the lymph nodes. There are three stages which 
explain the spread of cancer into the lymph nodes. N0 (no cancer into the lymph nodes), N1 
(spread of cancer into 1-3 lymph nodes near colon), N2 (spread of cancer into 4 or more 
lymph nodes nearby colon) (Cancer Research UK, 2017). 
1.3.4.1.3 Metastasis (M) 
Metastasis (M) explains the spread of cancer to different parts of the body. There are two 
stages; M0 (spread of cancer to other organs), M1 (spread of cancer to other parts of body) 
(Cancer Research UK, 2017). 
1.3.5 Grades  
Grades of cancer show much cancer resembles with normal cells. It also helps in 
determining what type of treatment may be required. There are three grades of colorectal 
cancer; Grade 1 (low grade; look mostly to normal cells), Grade 2 (close to normal cells), 
Grade 3 (high grade; abnormal cells) (Cancer Research UK, 2017). 
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1.3.6 Risk Factors 
There are some factors which are associated with risk of the development of colorectal 
cancer such as age above 40 years, family history, genetic mutations, inflammatory bowel 
disease or adenomatous colonic polyps, diet high in fats, cholesterol and low in fibre. 
Alcohol, smoking and sedentary lifestyle (Kelvin, 1998; Borum, 2001; Potter et al., 1996; 
Pazdur et al., 1999; Cancer facts and figures, 2002). A family history of inflammatory bowel 
disease such as Crohn’s disease or ulcerative colitis is considered as one of the main 
reason for development of colorectal cancer (Burt and Peterson, 1996; Freeman, 2001). It 
has been hypothesized that genetic mutations along with tearing of mucosal wall due to 
inflammatory bowel disease can start malignant cells proliferation (Wong and Harrison, 
2001). People suffering from bowel disease have a life time risk of colorectal cancer (2-18% 
ulcerative colitis; 0.7% Crohn’s disease) (Freeman, 2001; Eaden et al., 2001). The duration 
and intensity of inflammation can cause detectable changes in mucosal layer of colon which 
can result in colorectal cancer (Wong and Harrison, 2001; Bond, 2001).  
There are some types of polys that do not present any risk of colorectal cancer, but 
adenomatous colonic polyps are a growth inside the walls of colon which pose risk of 
colorectal cancer (Markowitz and Winawer, 1997; Jessup et al., 1997). These polyps are 
precancerous and are classified as villous, tubulovillous and tubular. There is a 2-5% risk of 
adenomatous polyp to become cancerous. Small sized polyps (0.5mm) are not risky but if 
the size is more than 2mm then there are 46% chances of malignancy over a time of 10 
years (Kelvin, 1998; Markowitz and Winawer, 1997).   
Genetic mutations are another factor which can enhance the risk of developing colorectal 
cancer. 90-95% of colorectal cancers are sporadic or common cancers, however there is no 
know genetic link for them (Ellis et al., 2000). Malignancies due to unknown risks are called 
‘de novo carcinomas’. Only 5-6% of colorectal cancer cases show genetic mutations and two 
of the most common genetic mutations are familial adenomatous polyposis and hereditary 
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nonpolyposis colorectal cancer (Jessup et al., 1997; Glaser and Grogan, 1999). Both types 
pose high risk of colorectal cancer and 50% of all colorectal cancers belong to these two 
types. The cause for familial adenomatous polyposis is an inherited autosomal dominant trait 
which is linked with virtually 100% incidence of colorectal cancer. 1-5% of colorectal cancers 
are hereditary nonpolyposis colorectal cancer which occurs in people with average age of 42 
years. They are also known as Lynch syndrome which is autosomal dominant condition. 
Some other possible genetic mutations are adenomatous polyposis coli genes, the K-ras 
oncogene, p53 gene and DNA mismatch repair genes (Jessup et al., 1997; Glaser and 
Grogan, 1999).  
1.3.7 Signs and Symptoms  
The symptoms of colorectal cancer depend on the location of tumour as shown in figure 1.11  
 
Figure 1.11: Different sections of colon showing colorectal cancer signs and symptoms (Ellis et al., 
2000; Meyers, 1998; Skibber et al., 2001) 
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Tumours in the ascending colon usually large and bulky and show symptoms of vague, pain, 
anaemia. Sometimes these tumours are misunderstood as reasons for some other disorders 
and are recognised when tumour is in advanced stage. If the cancer is in transverse colon it 
shows symptoms like rectal bleeding, pain and blood in stools. Tumours in the descending 
colon show symptoms like alternating constipation, diarrhoea, colicky abdominal pain, 
nausea and vomiting. Tumours in rectum show symptoms like pain or bleeding, rectal 
fullness, changes in bowel habits and urgency. Symptoms for advanced colorectal cancer 
are severe pain, anorexia and weight loss (Ellis et al., 2000; Meyers, 1998; Skibber et al., 
2001).  
1.3.8 Screening of colorectal cancer 
Early detection of colorectal cancer has proved to be very helpful in improving the survival 
outcomes. Colorectal cancer in the anus is detected by digital rectal exam. They appear as 
tumours of about 7cm in length near the anal verge (Ellis et al., 2000). There are different 
requirements for screening of colorectal cancer in UK. In England men and women aged 60-
74 are advised to undergo faecal occult blood test every two years (Bowel Cancer UK, 
2017). Sigmoidoscopy is also used to screen polyps in distal colon and if polyps are found, 
patients need colonoscopy to avoid the risk of adenomatous colonic polyps in other parts of 
bowel (Bond, 2000).  Baseline colonoscopy is recommended to moderate to high risk 
patients every 3-5 years to check the presence of disease. Genetic testing is also 
recommended to individuals with a strong family history of colorectal cancer, polyps or other 
types of cancers such as ovarian, stomach etc. (Burke et al., 1997; Bond, 2000).  
1.3.9 General treatment strategies 
The treatment strategies for colorectal has changed over last couple of decades. For many 
years’ surgery and radiation therapy were used as main treatment methods of colorectal 
cancer treatment, until it was found 5-fluorouracil (5-FU) based regimens are very effective 
when administered as adjuvant therapy. Various biological modulators such as leucovorin 
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and levamisole are used for the administration of 5-FU. Different schedules such as 
continuous infusion or pulse are used for the administration of 5-FU to improve its response 
rate (Bond, 2000; Benson et al., 2000). Recent advancement in the knowledge of genetic 
abnormalities linked with colorectal cancer has helped in the development of novel therapies 
which target genetic abnormalities associated with colorectal cancer (McLeod et al., 2000).  
1.3.9.1 Conventional therapy  
Surgery is considered as the most common treatment of colorectal cancer; however, it may 
not be applicable for some patients because of the stage of disease (Scoggins et al., 1999). 
Due to advancement in knowledge of response between primary and metastatic disease, 
some clinicians prefer to use systemic therapies before surgery. In cases where the 
penetration of cancer is deep in the colon wall, patients are recommended to undergo 
chemotherapy or chemotherapy plus radiation (Bond, 2000; Cancer facts and figure, 2002). 
The surgical methods are selected based on the location and blood supply of tumour and the 
pattern of lymph nodes. Each surgical procedure has specific indications and morbidities as 
shown in table 1.4 (Ellis et al., 2000; Hurd and Gutman, 1995). 
 
Table 1.4: Surgical procedure, indication and morbidities of colorectal cancer (Ellis et al., 2000; Hurd 
and Gutman, 1995) 
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1.3.9.2 Adjuvant therapy  
After surgery, patients with stage II or stage III colon cancer are recommended to undergo 
adjuvant chemotherapy to avoid recurrence of the tumour from the residual cells left after the 
surgery. Stage II or III rectal cancer patients are recommended to undergo chemotherapy 
plus radiation therapy. Adjuvant therapy comprising 5-fluorouracil and leucovorin is used as 
standard for early stage or advanced stage colorectal cancer patients (NCCN, 2000; Francini 
et al., 1994; Labianca et al., 1995).  
1.3.9.3 Treatment of disease at advanced stage 
5-fluorouracil and leucovorin are used as first line therapy for treatment of metastatic 
colorectal cancer. If the first line therapy fails, then Irinotecan is used as second line therapy. 
Irinotecan (CPT-11) is an antineoplastic agent which was approved in 1996 to be used for 
treatment of colorectal cancer. Few studies showed irinotecan showed a response rate of 
13% and a median survival time of 9 months in metastatic colorectal cancer where 5-FU 
therapy failed to stop the recurrence or progression (Cunningham et al., 1998; Von Hoff D et 
al., 1997). Two studies showed the effect of irinotecan combined with 5-FU and leucovorin 
on untreated metastatic colorectal cancer (Saltz et al., 2000; Douillard et al., 2000) and the 
result showed the response rate was 39%-49%, median survival time was 14.8-17.4 months 
and progression time was 7 months. These results showed improved efficacy of the regimen 
compared with irinotecan alone, so this combined therapy was as first line therapy for 
treatment of colorectal cancer (Vanhoefer et al., 2001; Saltz, 1998; Peeters and Haller, 
1999).   
These chemotherapy drugs show some toxicities such as nausea, diarrhoea, mucositis and 
neutropenia (Berg and Lilienfeld, 2000; Royce et al., 2000; Berg, 1998) which sometimes 
require a change in the therapy administration such as dose reduction to reduce the effects 
of toxicity. Another major issue with colorectal cancer patients is drug resistance because it’s 
a challenge to find an alternative therapy (Jansman et al., 2000).  Patients who either do not 
tolerate standard 5-FU regimens or are elderly, they can be treated with some other 
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approved drugs such as oral fluorinated pyrimidines (capecitabine) (Hoff et al., 2001), 
oxaliplatin (Pelley, 2001) or some other biological targeted treatments (Donehower, 2000). 
IMC-C225 (Erbitux; Im-Clone Systems Incorporated, New York, NY, and Bristol-Myers 
Squibb Company, New York, NY) is a monoclonal antibody which targets the epidermal 
growth factor, is used in combination with irinotecan for the treatment of advanced colorectal 
cancer patients. This treatment has shown promising results in patients who do not have 
many options in terms of therapy resistance (Saltz et al., 2001).  
1.3.10 Association of WWOX with colorectal cancer 
It has been reported by various studies that WWOX expression is either lost or reduced in 
variety of human cancer such as breast, lung, liver, stomach and pancreas (Aqeilan et al., 
2007). A study by Alsop et al., (2008) examined deletions of WWOX in HCT116 colorectal 
cancer cells. This study showed homozygous deletions of 25 to 50kb in WWOX in HCT116 
cells which appeared due to loss of exons 6-8 by heterozygous deletions, some of which 
overlapped to show homozygous loss. The deletion of exon 6-8 showed deletions of 
transcripts which were allele specific and has been observed in some other tumours. The 
conclusion was targeted deletions at FRA16D were observed in HCT116 cells which 
resulted in removal of WWOX gene fragments. Another study by Żelazowski et al., (2011) 
reported the role of deletions of WWOX gene and its expression in colorectal cancer cells. In 
this expression of WWOX was observed in various cancer cell lines such as HCT116, 
SW480, SW620 and HT-29. HCT116 colon cancer cells showed 70% expression level. HT-
29 colorectal adenocarcinoma cells showed very low expression level of WWOX.  SW480 
and SW620 primary tumour cells showed relative WWOX expression which suggests 
WWOX has some role progression of colorectal cancer. The relative WWOX expression 
levels of all four colorectal cancer cell lines as shown in (table 1.5) were compared against 
MCF-7 breast cancer cells which according to study of Płuciennik et al., (2006), breast 
cancer patients showed significantly higher WWOX expression and higher progression free 
survival compared with relative low WWOX levels.  
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Table 1.5: Expression of WWOX in cancer cells 
 
 
Further in the study of Żelazowski et al., (2011) analysis of WWOX promoter methylation 
and loss of heterozygosity (LOH) at two WWOX loci were observed. The results showed no 
evidence of hypermethylation in WWOX promoter region and no LOH. Also, in this study 
correlation between WWOX expression and disease-free survival was analysed by Kaplan 
Meier test. Patients with high WWOX expression in tumours showed higher disease-free 
survival, however there was no significant relationship between among patient’s groups 
stratified on the basis of clinicopathological features. Over all this study showed role of 
WWOX expression in tumour suppression in colon, however molecular mechanisms behind 
this were unidentified.  
1.3.11 Association of FHIT with colorectal cancer 
Involvement of FHIT gene has been reported by some studies in oncogenesis and 
progression of colorectal cancers (Hihi et al., 1997; Hao et al., 2000).  A study by Ohta et al., 
(1996) showed 50% of digestive tract carcinomas (oesophageal, stomach and colon) 
showed aberrations in transcription of FHIT gene.  In another study by Mori et al., (2001) 
expression of FHIT in colorectal cancer tissues was examined. Immunohistochemical 
analysis showed half of the colorectal cancer cases (n=62) were positive for FHIT protein. 
Significant correlation between loss of FHIT protein and progression of carcinoma and lymph 
node metastasis was observed. 50% of sporadic colorectal cancer cases showed loss of 
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FHIT protein which was significantly more frequent in advanced stage cases. Andachi et al., 
(2002) reported loss of FHIT expression in 52 advanced colorectal carcinomas by 
immunohistochemical method. The results showed loss of FHIT in 18 (34%) of the 52 cases. 
Loss of FHIT expression in colorectal carcinomas and premalignant lesions was observed in 
a study by Hao et al., (2000). Immunohistochemical analysis showed FHIT was strongly 
expressed in all normal colonic epithelium. FHIT expression was absent is 44% (n=84) of 
carcinomas. 12 out of 13 metastatic lesions showed reduced FHIT expression. The trend of 
reduced FHIT expression was more in tumours with decreased differentiation and in tumours 
with metastases. These finding suggest an important role of FHIT in the development and 
progression of colorectal carcinomas.  
 
1.4 Paclitaxel treatment and ER stress response in cancer cells 
1.4.1 Paclitaxel 
Paclitaxel (Taxol) is a cytotoxic agent (Figure 1.12) first discovered in the bark of pacific yew 
tree (Taxus brevifolia) in 1962 during a plant screening programme conducted by U.S 
department of agriculture and National cancer institute (NCI). Paclitaxel is used as first line 
therapy for the treatment for various types of cancers such as ovarian cancer (McGuire et 
al., 1996). Most commonly a dose of 200-250mg m-2 (depending upon the patients’ status) is 
given by infusion at intervals of 3 hours and 24 hours. The vehicle used for delivery of 
Paclitaxel consist of 1:1 mixture of Cremophor EL (polyethoxylated castor oil) and ethanol 
which is either mixed with 5 % dextrose solution or 15-20% saline (Singla et al., 2002). 
Plasma protein take up 90% of the drug and 10% is excreted in urine (Rizzo et al., 1990; 
Wiernk et al., 1987 and Rowinsky et al., 1990).  
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Figure 1.12: Chemical structure of paclitaxel. It consists of a texane ring with a four membered 
oxetane side ring at CA and C5 and an active homochiral ester side chain at C13 which binds to 
microtubule in a guanosine triphosphate independent manner to induce toxicity (Kampan et al., 2015) 
 
1.4.1.1 Paclitaxel interference with microtubules 
Paclitaxel has shown its antitumor properties in a number of human malignancies. Initial 
testing of taxol showed that it was effective in mouse tumour models and P388 leukaemia 
(Fuchs and Johnson 1978). Human clinical trials of ovarian cancer patients at advanced 
stage showed that 30% patients showed good response to taxol treatment (McGuire et al., 
1989), and breast cancer patients showed that 56% responded to taxol (Holmes et al., 
1991).  Taxol promotes the assembly of microtubules. Pure tubulin subunits which are 
important for the polymerisation of α and β heterodimers into microtubules in vitro are 
lowered in their concentration by paclitaxel; also, their disassembly due to cold or Ca2+ 
treatment is prevented by paclitaxel (Schiff et al., 1979).  
The formation of microtubules under the influence of paclitaxel makes them very strong and 
stable but dysfunctional resulting in cell death due to disruption of normal tubules functions 
needed for cell division. Different tumour models in animals and cell cultures show paclitaxel 
induced mitotic arrest (Fuchs and Johnson, 1978; Schiff and Horwitz, 1980; Milas et al., 
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1995; Jordan and Wilson, 2004; Orth et al., 2008). Some studies suggest that cells upon 
treatment with paclitaxel are arrested in metaphase and show nearly normal spindles. A few 
cases reported misalignment of the chromosomes at the cell equator (Jordan et al., 1993, 
1996; Waters et al., 1996), and some studies reported multipolar spindles (Chen and 
Horwitz, 2002; Hornick et al., 2008), but so far there is no evidence which show that these 
effects are clinically relevant for anti-tumour activity of paclitaxel.  
Many research papers have shown the link between paclitaxel and apoptosis (Bhalla et al., 
1993; Havrilesky et al., 1995; Chang et al., 1996; Li et al., 1994; Yen et al., 1996; Gan et al., 
1996).  Lieu et al., show that low concentrations of paclitaxel could initiate apoptosis without 
undergoing mitotic arrest and depending upon the cell cycle various apoptotic mechanisms 
could be triggered by paclitaxel (Lieu et al., 1998). Furthermore, mitotic arrest due to 
paclitaxel may not always trigger apoptosis (Huang et al., 2002), and one study reported that 
at low concentration of paclitaxel apoptosis and at high concentration necrosis can take 
place (Yeung et al., 1999). Interestingly another study reported that both necrosis and 
apoptosis can take place in human endothelial cells due to paclitaxel (Mailloux et al., 2001). 
In my study, I focused only on the apoptotic pathways triggered due to paclitaxel.  
1.4.1.2 Paclitaxel induced apoptosis due to cell cycle arrest  
How binding of paclitaxel with microtubules and stabilizing them leads to initiation of 
downstream mechanisms causing apoptosis is not fully understood but recent research in 
the signalling molecules activated by paclitaxel and activation of transcription of various 
genes show that there are multiple mechanism which could be responsible for apoptosis 
(Wang et al., 2000).When tumour cells are treated with Paclitaxel, it induces cell arrest in 
G2-M phase of the cell cycle and initiates apoptosis that leads to cell death (Georgiadis et 
al., 1998). 
It has been suggested that mitotic spindle assembly check point controls this paclitaxel 
induced apoptosis. Chromatids are attached to spindle fibres by their kinetochores (a protein 
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present at centromere). If kinetochores are not properly attached with spindle microtubules, 
it will result in activation of signal transduction cascade which will stop the cell from 
progressing into the next stage of anaphase by inhibiting anaphase promoting complex 
(Kops et al., 2005; Lara-Gonzalez et al., 2012; Foley and Kapoor, 2013), and this involves 
check point genes such as hs-MAD2 (Sorger et al., 1997; Li et al., 1997), BUB1,  (Taylor and 
McKeon, 1997) BUB3, (Sorger et al., 1997; Taylor et al., 1998) PP2A, (Minshull et al., 1996) 
and MAPK (Minshull et al., 1994) . After paclitaxel treatment BUB3 expression was up-
regulated suggesting this could lead to paclitaxel induced apoptosis (Taylor and McKeon, 
1997; Martinez et al., 1999). 
1.4.1.3 Role of p53 in paclitaxel induced apoptosis 
P53 has also been linked to paclitaxel induced apoptosis. Approximately 96% of human 
cancers show mutations of p53 (Wang and Wang, 1996). Although some studies have 
shown no correlation between p53 expression and paclitaxel response (Safran et al., 1996), 
other studies suggest that loss of its normal function in cancer patients could sensitize them 
to paclitaxel therapy (Wahl et al., 1996; Perego et al., 1998; Zaffaroni et al., 1998). This 
increased sensitivity is associated with increased G2 /M arrest (Wahl et al., 1996), and 
altered regulation of downstream targets of p53 such as p21 and MAP4. Upregulation of p21 
by p53 helps the cells to come out of mitotic arrest (Barboule et al., 1997) and if there is no 
p21, the paclitaxel treated cells are killed by apoptosis. Microtubule associated protein 4 
(MAP4) helps in stabilizing microtubules and in the presence of activated p53 it is down 
regulated and in the absence of normal p53 microtubules are stabilized by MAP4, making 
cells more sensitive to paclitaxel treatment (Wang et al., 2000).  
1.4.1.4 Role of Bcl-2 family in paclitaxel induced apoptosis 
Bcl-2 family members are categorized into two types i.e. Antiapoptotic and pro-apoptotic. 
Bcl-2 and Bcl-XL are antiapoptotic proteins and Bcl-XS, Bak, Bad and Bax are pro-apoptotic 
proteins. This family of proteins are also involved in Paclitaxel induced apoptosis (Strobel et 
al., 1996; Strobel et al., 1998). Paclitaxel treatment changes the expression of Bcl-2 family 
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and can trigger post-translational changes in Bcl-2 molecules. Paclitaxel treatment results in 
upregulation of expression levels of Bax and Bak and down regulates expression of Bcl-XL 
(Liu and Stein, 1997; Srivastava et al., 1998), as well as phosphorylation for Bcl-2 in cells 
arrested at G2 /M phase of the cell cycle which enhances paclitaxel induced apoptosis 
(Blagosklonny et al., 1997; Roth et al., 1998). How mitotic arrest by paclitaxel links with Bcl-2 
is an area which remains to be explained. 
1.4.1.5 Paclitaxel induced apoptosis by activation of JNK/SAPK 
Jun amino terminal kinases (JNK) / stress activated protein kinases (SAPK) belong to the 
MAPK (mitogen activated protein kinases) family. These proteins are activated by stress, 
inflammation regulatory cytokines or growth factors and have been linked with apoptosis. It 
has been shown (Wang et al., 1998, Lee et al., 1998 and Amato et al., 1998) that JNK/SAPK 
is activated by Ras- and ASK1 (apoptotic signalling kinase 1) dependent signalling pathways 
after paclitaxel treatment (Figure 1.13). JNK/SAPK signalling transduction pathways were 
analysed using dominant negative signalling protein vectors and the results showed that for 
up to 16 hours of paclitaxel treatment, activation of JNK/SAPK is needed for early phase of 
paclitaxel induced apoptosis. The later stages of apoptosis were possibly due to mitotic 
arrest but not due to activation of JNK/SAPK (Wang et al., 1999). Other studies by 
(Maundrell et al., 1997 and Srivastava et al., 1999) reported that Bcl-2 phosphorylation was 
due to activation of JNK/SAPK after cancer cells were treated with paclitaxel, but this study 
was contrary to the studies of (Wang et al., 1999 and Attalla et al., 1998) which showed that 
JNK/SAPK induced apoptosis was independent of phosphorylation of Bcl-2. These 
contradictions in results could be possibly due to unknown cofactors in particular cell lines 
involved in regulation of Bcl-2 phosphorylation (Wang et al., 2000). 
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Figure 1.13: Induction of paclitaxel induced apoptosis (early phase up to 16 hours of paclitaxel 
treatment) due to activation of JNK/SAPK which can be inhibited by the expression of dominant 
negative signalling proteins of the JNK/SAPK signalling. PTX: paclitaxel; dn: dominant negative 
(Wang et al., 2000). 
 
 
1.4.2 Salubrinal 
Salubrinal (Figure 1.14) is a cell permeable compound which protects cells from ER stress 
induced apoptosis. It is soluble in DMSO, non-toxic, and its micro molar concentrations are 
very cyto-protective against ER stress inducers such as; tunicamycin (Boyce et al., 2005). 
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Figure 1.14: Salubrinal (3-Phenyl-N-[2, 2, 2-trichloro-1-[[(8-quinolinylamino) thioxomethyl] amino] 
ethyl]-2-propenamide) (Boyce et al., 2005). 
1.4.2.1 Salubrinal: PERK inhibitor 
Once ER-stress is induced, PERK is activated by dimerization and phosphorylation, it 
phosphorylates eIF2α, which enhances translation of the ATF-4 transcription factor, and 
UPR genes are expressed (figure 3.3). Salubrinal particularly inhibits the translation initiation 
factor eIF2α de-phosphorylation and protects the cells from ER stress induced apoptosis 
(figure 3.3). It does so by inhibiting the phosphatase activity of protein complex GADD34-
PP1 comprised of a serine/threonine phosphatase PP1 and a non-enzymatic co factor 
GADD34 which dephosphorylate eIF2α (Boyce et al., 2005). The increased phospho-eIF2α 
produced causes global translational repression but enables translation of key ER-stress 
proteins (such as various chaperones), supporting a cyto-protective state. 
1.4.3 Tunicamycin  
Tunicamycin is an antibiotic naturally produced by Streptomyces lyso-superificus (Takatsuki 
et al., 1971). It is a white crystalline powder soluble in DMSO, water and some organic 
solvents. Tunicamycin is a mixture of homologous antibiotics which contain uracil: N-acetyl 
glycos-amine (GlcNAc), an 11-carbon aminodialdose called tunicamine, and an amide linked 
fatty acid (Tsvetanova et al., 2002).  Tunicamycin is a reversible inhibitor of UDP-N-acetyl-D-
hexosamine: polyprenol-phosphate N-acetylhexosamine-1-phosphate transferases (D-
HexNAc-1-P-transferases) including the eukaryotic UDP-N-acetyl-glucosamine—dolichyl-
phosphateN-acetyl-glucosamine-phospho-transferase (DPAGT1; also, called GPT). It has 
been suggested that tunicamycin either works as a non-competitive substrate–product–
transition state analogue of DPAGT1/GPT (Heifetz et al., 1979) or as a substrate analogue 
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inhibitor of D-HexNAc-1-P-transferases, which shows it competes with the UDP-Hex NAc 
(UDP- N-acetyl glycos-amine in eukaryotes) for active site binding (Keller et al., 1979; 
Brandish et al., 1996).  
1.4.3.1 Tunicamycin target N-linked glycosylation in ER 
It has been suggested that tunicamycin works by inhibiting the first step of N-linked 
glycosylation of proteins via DPAGT1 (Keller et al., 1979; Brandish et al., 1996). N-linked 
glycosylation is a process in which glycan (oligosaccharide) is attached to the nitrogen of 
asparagine in the sequence (Asn-X-Ser or Asn-X-Thr). Within this sequence X could be any 
amino acid but not proline and glycan could be any monosaccharide such as N-acetyl-
galactose-amine or N-acetyl-glucose-amine etc. (Imperiali and O’Connor, 1999). Failure in 
the N-linked glycosylation of proteins results in accumulation of unfolded proteins in the ER, 
and therefore activation of the unfolded protein response.  
1.5 The WWOX tumour suppressor and cisplatin chemo-response 
1.5.1 Cisplatin 
In 1965, Dr Rosenberg discovered the biological functioning of cisplatin while studying the 
growth of bacteria Escherichia coli. The experiment was not specifically designed to study 
the activity of cisplatin, but it was about the effects of electric fields on the growth of bacteria. 
The apparatus used for the experiment consisted of platinum electrodes and when electric 
field was applied to bacteria in the presence of these electrodes it produced an inhibitory 
effect on the cell division in bacteria but did not completely stop the growth of bacteria. Upon 
further analysis, it was discovered that when electricity was applied to the platinum 
electrodes, a small amount of the platinum product was formed in the media containing 
ammonium chloride used for growing bacteria (Rosenberg et al., 1965), which produced an 
oxidative form of platinum - cis-diamminedichloroplatinum (II) also named cisplatin 
(Rosenberg et al., 1967).  These exciting results encouraged the scientist to see if these 
inhibitory effects of platinum compounds can inhibit growth of cancer cells in animal tumour 
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models? Rosenberg studied the effects of platinum compounds on mouse tumour models 
and their findings showed that they showed inhibitory effects on sarcoma 180 and leukaemia 
L1210 (Rosenberg and Vancamp, 1969) 
FDA approved cisplatin in 1978 and since then it has been continuously used as an 
anticancer drug for treatment of solid tumours. Cisplatin has been used as first line therapy 
either alone or in combination with other anticancer drugs (paclitaxel) for the treatment of 
many cancers including testicular, ovarian, cervical, head and neck and small cell lung 
cancers. It has been observed that during the start of cisplatin therapy patients’ response is 
good but with time drug resistance issue is very common. Drug resistance along with dose 
limiting toxicity such as nephrotoxicity, compromise the effectiveness of cisplatin. The 
mechanism behind drug resistance of cells could be either acquired or intrinsic (Basu and 
Krishnamurthy, 2010). 
Cisplatin interacts with chromosomal DNA for its antitumor activity (Sherman et al.,1985) but 
studies revealed that the actual amount of cisplatin that interacts with DNA is not much and 
therefore it cannot be postulated that the only biological activity of cisplatin is to inhibit the 
replication of DNA (Eastman, 1990). The efficiency of the chemotherapeutic drug is not only 
its DNA damaging ability, but it also depends on the capability of the cells by which they 
detect and respond to DNA damage (Kerr et al., 1994).  Cells respond to DNA damage by 
repairing it and progressing through the cell cycle and if they cannot repair the damage, they 
will proceed to die (Kerr et al., 1994). Like other chemotherapeutic drugs, cisplatin induces 
apoptosis and therefore the signalling pathways involved in the regulation of apoptosis play 
significant role in deciding the cellular response to cisplatin (Basu and Krishnamurthy, 2010).  
1.5.1.1 Structure of Cisplatin 
Cisplatin or cis-diamminedichloroplatinum (II) is a neutral, square planer, coordination 
complex of divalent Pt (Figures 1.15 and 1.16) (Todd and Lippard, 2009). There are different 
forms of cisplatin based on its structural configuration, but cis configuration is required for its 
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antitumor activity (Zamble and Lippard, 1995). Cisplatin is a deep yellow or yellow orange 
crystalline powder at room temperature which is slightly soluble in water but soluble in 
dimethylprimanide and N, N-dimethylformamdie. Cisplatin is stable under normal 
temperature and pressure but slowly overtime it transforms into the trans-isomer (IRAC 
1981). The structure of cisplatin consists of labile chloride groups and two relatively inert 
amine ligands. Cisplatin hydrolyses in water and the concentration of chloride is an important 
factor in regulating its hydrolysis. Blood plasma has high chloride concentration (103mM), so 
it prevents hydrolysis of cisplatin. When it enters into the cell, the concentration of chloride 
ion goes down to 4mM which eases the aquation process (Sedletska et al., 2005). In 
aqueous conditions cisplatin is a powerful electrophile and interacts with nucleophiles, 
nucleic acids and sulfhydryl groups of proteins (Basu and Krishnamurthy, 2010).            
 
Figure: 1.15 Structure of cisplatin 
 
 
          
Figure: 1.16 Computational molecular structure of cisplatin (Goodsell, 2006) 
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1.5.2 Molecular Mechanism of cisplatin 
1.5.2.1 Accumulation of cisplatin inside cells 
How cisplatin accumulates inside cells? The first thought was cisplatin and its analogues 
enter cell via passive diffusion because its uptake is linear, non-saturable and could not 
battle with platinum analogues (Sherman et al., 1985; Eastman, 1990; Kerr et al., 1994; 
Sedletska et al., 2005). Sometimes decreased intake of cisplatin is associated with cisplatin 
resistance, although few or no changes were observed in the function of plasma membrane 
of cisplatin resistant cell lines, when compared with parent cells (Holzer et al., 2006; Holzer 
et al., 2004; Safaei et al., 2004). It was first proposed by Byfield et al., (1981) that active 
transport of cisplatin into cell takes place via carrier mediated transport. The transporters 
that facilitate the accumulation of cisplatin in cell include Na+, K+ -ATPase and members of 
solute carried (SLC) transporters (Hall et al., 2008; Andrews et al., 1991). Particularly one 
member of the SLC family, the plasma membrane copper transporter-1 (CTR1) was shown 
by some studies to be actively involved in transport of cisplatin into cells as a defect in Ctr1 
gene in yeast decreased the accumulation of cisplatin in yeast (Ishida et al., 2002; Safaei et 
al., 2005). A study by Hozler et al., (2004) also showed that in ovarian cancer cells, both 
cisplatin and copper caused the rapid down regulation of CTR1 via proteasome mediated 
pathway. The proteins involved in cisplatin export from the cell are ATP-dependent 
glutathione-conjugated efflux pump and copper transporters ATP7A and ATP7B (Safaei et 
al., 2004). When cisplatin resistant cells show reduced intracellular cisplatin, it is widely 
considered because of less uptake of cisplatin into the cells rather than increase in drug 
efflux (Kelland, 2007; Gately and Howell, 1993). 
1.5.2.2 Binding of cisplatin with the DNA and signalling pathways 
1.5.2.2.1 Formation of adducts 
 
Several studies suggest that the main biological target of cisplatin is DNA (Sedletska et al., 
2005; Jamieson and Lippard, 1999; Eastman, 1987). The platinum atom of cisplatin forms 
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covalent bonds with the N7 position of purine bases and results in formation of 1, 2- or 1, 3- 
intra-strand crosslinks and a lower percentage of inter-strand crosslinks (Figure 1.17). The 
intra-strand crosslink between two adjacent G residues is considered as an important lesion 
responsible for cisplatin toxicity. The formation of cisplatin-DNA adducts disturbs DNA 
replication and transcription. The structure of DNA is distorted due to binding with cisplatin 
and formation of intra-strand cross links exposes a groove which serves as site for protein 
binding (Wand and Lippard, 2005). Approximately 96% of binding of cisplatin with DNA 
forms intra strand cross links and there is a linear relationship between platinum binding with 
the DNA and the cytotoxicity (Fraval and Roberts, 1979). The adducts formed in the DNA 
initiate signalling of damage recognition proteins. These proteins include hMSH2 or hMutSα 
complex (mismatch repair proteins MMR), HMG1 and HMG2 (non-histone chromosomal 
high mobility group) proteins, the human RNA polymerase I transcription upstream binding 
factor (hUBF) and transcription factor TATA binding protein (TBP) (Donahue et al., 1990; 
Fink et al., 1998; Chaney and Vaisman, 1999). Although the main function of these proteins 
is to sense DNA damage and induce downstream signalling pathways but sometimes they 
are involved in some other functions as well, for example HMG1 interaction with DNA 
adducts promotes cytotoxic effects but also inhibits the repair mechanism (Huang et al., 
1994). This dual function of HMG1 was later verified by a study of He et al., (2000), which 
showed that overexpression of HMG1 in breast cancer cells increased sensitivity towards 
cisplatin.  Other proteins such as hUBF and TBP cause suppressed transcription by RNA 
polymerase I because of sequestering at the damaged DNA sites (Jordan and Carmo-
Fonesca, 2000). Cisplatin can therefore initiate both pro-apoptotic and pro-survival signalling 
pathways (Siddik, 2003).  
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Figure: 1.17 Formation of different DNA lesions due to interaction of Chlorine anions with hydroxy 
groups (mostly at N7 of purines) [www.conconilab.ca/projects/] 
 
1.5.2.2.2 Cisplatin and DNA damage signalling     
 
Formation of DNA adducts by cisplatin activates many pathways and one of them is 
activation of cell cycle check points. DNA damage by cisplatin causes a short-lived S-phase 
arrest and then longer G2/M arrest of the cell cycle (Shapiro and Harper, 1999; Shi et al., 
1994). Although the relationship between cytotoxic effect of cisplatin and cell cycle arrest is 
not very clear but still cell cycle arrest is widely considered as a cytotoxic effect of cisplatin 
because G2/M check point arrest enhances the sensitivity of the cells towards cisplatin 
(Demarcq et al., 1994; O’Connor and Fan et al., 1996). During G2/M arrest, the nucleotide 
excision repair (NER) mechanism tries to protect the cell by repairing the DNA adducts but if 
it fails, cell will proceed to apoptosis. This mechanism of activation of cell cycle check points 
due to DNA adducts leading to repair, are linked with p53 tumour suppressor protein 
(Morgan and Kastan, 1997; Bullock and Fresht, 2001).  
1.5.2.2.3 Activation of p53 and cisplatin induced DNA damage 
 
P53 is a tumour suppressor protein, also known as ‘guardian of genome’ is mutated in 
approximately 96% of human cancers (Hollstein et al., 1991). The involvement of p53 in 
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activation of cell cycle check points, is due to activation of two upstream kinase, ATM (ataxia 
telangiectasia mutated protein) and ATR (ATM- and Rad3-related protein). Among these two 
kinases, cisplatin activates ATR (Damia et al., 2001; Zhao H, Piwnica-Worms, 2001) 
phosphorylating p53 at serine-15 resulting in activation of p53 protein (Appella E, Anderson, 
2001). Further modification of p53 take place by ATR mediated CHK1 kinase which 
phosphorylates serine 20 (Shieh et al., 2000). Several studies reveal the importance of p53 
in cancer cells. Absence of functional p53 in tumour cells makes them resistant to cisplatin 
which could be reversed by reconstitution of WT p53 (Kigawa et al., 2002; Kanamori et al., 
1998). Another study by Pestell et al., (2000) showed that ovarian cancer cell lines (A2780) 
lacking p53 expression sensitized to cisplatin and showed reduction in DNA adduct repair 
and loss of control of G1-S check point.  
Some other proteins which are part of p53 signalling pathways are also involved in p53 
activity and cisplatin cytotoxicity. Aurora kinase A is protein which is overexpressed in 
multiple human cancers and it is an important protein of the p53 pathway, activating it by 
phosphorylation at serine 315, causing ubiquitylation by murine double minute 2 (MDM2) 
and proteolysis. Knockdown of Aurora A kinase reduces the phosphorylation of p53, 
increases the stability of p53 and causes cell cycle arrest at G2/M. Mammalian cells in the 
absence of aurora A became more sensitive to cisplatin induced apoptosis and this can be 
reversed by increased expression of aurora A (Katayama et al., 2004).  
Cyclin G1 is another gene which can be transcriptionally activated by p53 and it plays an 
important role in p53-Mdm2 (multi double minute 2) auto regulated module. Knock down of 
cyclin G1 in MCF7 cells by siRNA caused the accumulation of p53 protein due to DNA 
damage activating ATM protein (Ohtsuka et al., 2003; Ohtsuka et al., 2004).  
There are several other mechanisms by which p53 can determine cisplatin induced cell 
death. P53 induced cell death due to cisplatin requires degradation of FLIP (FLICE -like 
inhibitory protein) (Abedini et al., 2008). P53 counteract and bind to antiapoptotic functioning 
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of Bcl-xL resulting in enhanced cisplatin induced cell death (Kutuk et al., 2009). 
Overexpression of phosphate and tension homolog (PTEN) in cisplatin resistant ovarian 
cancer cells also requires p53 mediated cell death (Yan et al., 2006). Activation of nutrient 
sensor AMP-kinase (AMPK) has been observed in AGS cells and HCT116 colorectal cancer 
cells due to cisplatin and inhibition of AMPK caused induction of p53 resulting in cisplatin 
induced cell death (Kim et al., 2008).  
1.5.2.2.4 Cisplatin and JNK 
 
c-Jun N-terminal kinase (JNK) has a role in regulation of anticancer activity of cisplatin. JNK 
can be activated by stress response or DNA damage. JNK pathway is activated by cisplatin 
via p73, a pro-apoptotic member of p53 family. Cells having defects in JNK pathway showed 
resistance towards cisplatin (Zanke et al., 1996). It has also been reported that JNK along 
with c-Abl are also involved in MMR mechanism which induces cell death due to cisplatin-
DNA adducts (Tsai and Yuan, 2003).  
1.5.2.2.5 Apoptosis induced by cisplatin 
 
Apoptotic cell death induced by cisplatin can involve both the extrinsic pathway and intrinsic 
pathway. Initiation of extrinsic pathway takes place when ligands bind with TNFα (tumour 
necrosis factor-α) receptor family. In next step, adaptor molecules help oligomerization and 
recruitment of pro-caspase-8 and form a complex called death inducing signalling complex 
(DISC). The intrinsic pathway can be activated because of stress response or DNA damage. 
In this pathway cytochrome c is released from mitochondria which activates pro-caspase9 
which form an active apoptosome complex by interacting with APAF-1 (apoptosis promoting 
activating factor -1) (Nunez et al., 1998; Kischkel et al., 1995). 
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1.5.2.2.6 Cisplatin and calcium signalling 
Intracellular chloride ions play an important role in determining the response to cisplatin. 
When the concentration of intracellular chloride ions is low, cisplatin hydrolyses into charged 
reactive species such as monoaquated [cis-(NH) PtCI(HO)]+ and diaquated [cis-
(NH)Pt(HO)]2+ forms (Jennerwein and Andrews, 1995; Aggarwal et al., 1980) which are 
1000 times more reactive than normal cisplatin and functions by inhibiting the respiratory 
activity of the mitochondria. Thus, calcium ions move out from mitochondria causing a 
temporary increase in the cellular calcium levels which disturbs calcium homeostasis and 
disrupts normal cellular functions (Aggarwal, 1993).  
1.5.2.2.7 Cisplatin and MAPK 
Mitogen activated protein kinases (MAPK) are serine/threonine family of proteins kinases 
which are involved in the regulation cell survival and growth by coordination with 
extracellular signals (Chang and Karin, 2001; Marshall, 1995). Some studies show that 
cisplatin activates ERK (extracellular signal regulated kinase) in many types of cells but 
whether this activation prevents or promotes cell death is controversial (Wang et al., 2000; 
Yeh et al., 2002). Activation of ERK by cisplatin causes p53 mediated DNA damage by 
phosphorylating p53 which further up regulates p21, GADD45 (45kd growth arrest and DNA 
damage) and Mdm2 (mouse double minute 2 homolog) (DeHaan et al., 2001).  
1.5.2.2.8 Cisplatin and AKT 
Akt is family member of serine/threonine kinases which is activated downstream of PI3K 
(phosphoinositide 3 kinase) which is very important for its role in cell survival. BAD (Bcl-2 
associated death promotor) is a pro-apoptotic member of Bcl-2 family of proteins. Akt 
phosphorylates BAD at ser 136 due to DNA damage by cisplatin. Cells with cisplatin induced 
DNA damage need phosphorylation of BAD for their viability. A study by Hayakawa et al., 
(2000) showed that cisplatin Induced DNA damage phosphorylates BAD Ser112 by ERK 
cascade and BAD Ser 136 by PI3K-PKB/AKt pathways and inhibition of either of these 
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cascades in ovarian cancer cells sensitized them to cisplatin. These results show that 
inhibition of BAD by either of these cascades can suppress the apoptotic function of BAD.  
1.5.2.2.9 c-Abl and cisplatin induced DNA damage 
C-Abl is a tyrosine kinase receptor which responds to DNA damaging agents. C-Abl can 
move between nucleus and cytoplasm controlled via nuclear localization motifs and nuclear 
export signals which are important for apoptosis induced by DNA damage (Peyer et al., 
2007). C-Abl responds to DNA damage by moving from cytoplasm to the nucleus and then 
form a complex by phosphorylation of MEK kinase 1, activating JNK/SAPK (stress activated 
protein kinase) (Kharbanda et al., 2000). It has also been shown that MMR (mismatch 
repair) recognizes DNA damage induced by cisplatin and activates c-Abl and JNK and cells 
lacking MMR function do not respond to c-Abl (Nehme et al., 1999). P73 which is a member 
of p53 initiate apoptosis by binding with MMR/c-Abl (Gong et al., 1999). The pro-apoptotic 
ability of p73 can be further enhanced by JNK which preventing the proteasomal degradation 
of p73 and increases its stability by binding with a transcription co activator Yap1 and 
triggering recruitment of p300 (Levy et al., 2008). C-Abl is substrate for caspase and it is 
cleaved for cisplatin induced apoptosis (Machuy et al., 2004). 
1.5.2.2.10 DNA damage and repair mechanisms 
 
Cisplatin induced DNA damage can undergo DNA repair mechanism to counter the 
cytotoxicity of cisplatin. Both inter-strand and intra-strand disrupt the structure of DNA which 
is recognised by the cellular proteins for repairing cisplatin induced DNA damage. Cisplatin 
induced DNA damage caused by intra-strand link is mainly repaired by nucleotide excision 
repair (NER). In NER DNA repair mechanism the damaged DNA is repaired by removal of 
cisplatin-DNA adduct. The first step is to find out the location of the lesion in the DNA. Once 
the lesion is recognised it is excised and up to 30 base pair single strand DNA portion 
containing lesion is removed. In the next step the synthesis and ligation of the repair patch at 
the pre-existing strand takes place (Costa et al., 2003). Importance of NER mechanism has 
 
 
61 
 
been shown in some studies such as, deficiency of the gene involved in NER can cause a 
disorder called Xeroderma Pigmentosum (XP). The cells derived from XP patients are very 
sensitive to cisplatin (McKay et al., 2001). 
 Although cisplatin induced DNA damaged is preferably repaired by NER mechanism but 
there are some other DNA repair mechanisms as well such as; double strand base repair 
(DSB), base excision repair (BER), inter-strand cross link repair and direct reversal of 
damage. Depending upon the type of lesion, the repair mechanism responds and fixes the 
DNA damage (Hoeijmakers, 2001). Among all these DNA repair mechanisms, NER is the 
most extraordinary pathway because it can remove most of the DNA lesions which occurs 
due to intra-strand cross links in the DNA due to cisplatin. There are two distinct sub-
pathways by which NER can detect the DNA damage, which are Global genome NER (GG-
NER) and transcription coupled NER (TC-NER) (Bohr et al., 1985; Mellon et al., 1987). 
1.5.2.2.11 The NER mechanism 
 
The detailed mechanism of Global genome NER (GG-NER) and transcription coupled NER 
(TC-NER) pathways is shown in figure 1.18. The first step shows probing and detection of 
lesion in the strand of DNA due to distortion in double helix which is recognised by damage 
sensor protein XPC/HR23B in GG-NER pathway, whereas in TC-NER pathway at the site of 
lesion transcription is stalled and RNA polymerase displaces itself from the site of lesion and 
increases its affinity towards NER proteins CSA and CSB (Cockayne syndrome protein) 
forming a complex and allow them to access the site of DNA damage. These two pathways 
have different mechanisms for detection of the lesion in the DNA strand but once a lesion is 
recognized, the repairing mechanism is same. In next step, further recognition of DNA 
damage and verification takes place by recruitment of XPA and RPA at the site of DNA 
damage and when damage is fully detected then transcription initiation factor IIH (TFIIH) is 
also recruited at the site of DNA damage. This TFIIH complex mediates both transcription 
and DNA repair. Next, the helicases components XPB and XPD of TFIIH are recruited at the 
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site of lesion and they unwind the DNA duplex surrounding the DNA adduct. In next incision 
step, the structure specific endonucleases XPG and ERCC1-XPF incise the DNA adduct at 
positions 3’ and 5’ respectively and remove 24-32 base nucleotides containing the DNA 
lesion. The trimeric proliferating cell nuclear antigen (PCNA) ring, recruited by XPF-ERCC1 
after the 5’ incision, binds DNA Pol δ, DNA Pol κ or DNA Pol ε to fill the gap by synthesis of 
DNA. The filling of the gap is a quick process once the 5’ incision has been done. DNA 
ligase 1 or 3 is used to do sealing and this final step completes the NER pathway (Marteijn 
et al., 2014; Hanawalt et al., 2002).  
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Figure: 1.18 Steps of Nucleotide Excision Repair (NER) mechanism. © R&D systems, Inc 
The two pathways by which NER can detect the DNA damage are Global genome NER (GG-NER) 
and transcription coupled NER (TC-NER). Simplified steps of NER mechanism: Step (1) DNA 
recognition (2) Unwinding of DNA (3) Incision of DNA strand (4)     synthesis of DNA and ligation (5)   
DNA repair completed. Human Rad23 homolog (HHR23B); Xeroderma pigmentosum 
complementation group C (XPC); CSA and CSB (Cockayne syndrome protein); Xeroderma 
pigmentosum complementation group A (XPA); Replication protein A (RPA); transcription initiation 
factor IIH (TFIIH); Xeroderma pigmentosum type B (XPB); Xeroderma pigmentosum type D (XPD); 
Xeroderma Pigmentosum Complementation Group G (XPG) protein; Excision repair 1 endonuclease 
non-catalytic subunit (ERCC1); trimeric proliferating cell nuclear antigen (PCNA) ring.  
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1.5.3 Fragile sites in genome 
Chromosomal aberrations in tumour cells usually take place due to genomic instability. 
Various exogenous factors (UV radiation, ionizing radiation, chemotherapy) and endogenous 
factors (reactive oxygen species) can cause DNA damage (Jackson, 2002). Fragile sites are 
very susceptible to DNA breakage and several studies show they are involved in 
chromosomal aberrations responsible for cancer (O’Keefe and Richard, 2006). Fragile sites 
are regions of the human genome with breaks or gaps on metaphase chromosomes during 
partial inhibition of DNA synthesis (Richards, 2001). Fragile sites are termed as common or 
rare fragile sites based on their frequency in the population and the way they are induced. 
According to Genome Database (GDB), the frequency of rare fragile sites (RFS) is humans 
is less than 5% and they are segregated in Mendelian manner in specific families, whereas 
common fragile sites (CFS) are part of the human chromosomal structure are found in all 
individuals. Rare fragile sites are breakable due to expansion of a CGG repeat or an AT-rich 
island and are also capable of forming stable secondary structures, whereas common fragile 
sites contain no common sequences but show extensive regions of high flexibility and stable 
secondary structure formation. Previous studies suggest that all the fragile sites are late 
replicating portions of the genome and after exposure to inducing agents, replication could 
be even further delayed, and some alleles of fragile sites may remain unreplicated in late G2 
(Hansen et al., 1997; Le Beau et al., 1998; Hellman et al., 2000; Handt et al., 2000; Pelliccia 
et al., 2008).  Rare fragile sites are induced by folate deficient conditions or by chemical 
which bind to AT-rich DNA e.g. beneril (Sutherland et al., 1984).  On the other hand, 
common fragile sites are induced by low doses of an inhibitor of DNA polymerase known as 
aphidicolin (APH) (Glover et al., 1984). Contrary to these findings, a study by Mrasek et al., 
(2010) on peripheral blood lymphocytes of three unrelated individuals showed that 
aphidicolin induced both RFS and CFS showing that they depend less on inducing chemical 
originally described before. Rare fragile sites are caused by repeat sequences which are 
unstable in nature (Sutherland and Baker, 2000) but there are no expanded repeat 
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sequences in common fragile sites (Smith et al., 1998). Some dietary and environmental 
factors such as caffeine, ethanol, pesticides and cigarettes smoke can also significantly 
increase breakage of fragile sites (Richards, 2001). When cells are cultured under normal 
conditions, fragile sites are stable but when they are treated with inhibitors of replication they 
become highly prone to breakages, exchanges and chromosomal rearrangements or 
deletions (Glover and Stein, 1987, 1988). 
1.5.3.1 Role of fragile sites in cancer 
About 90 CFS has been reported in the human genome having variable frequency of their 
expression. The most frequently expressed common fragile sites are FRA3B (3p14.2), 
FRA16D (16q23.2), FRAXB (Xp21.1) and FRA6E (6q26) (Smith et al., 2007). Many cancer 
genes have been reported to be present at or within fragile sites (Popescu, 2003). Studies 
also suggest that many oncogenic viruses target these chromosomal regions and integrate 
within them (Popescu, 2003). All this information suggests the possibility of fragile sites 
contribution towards development of cancer. A recent study by (Gandhi et al., 2010) in 
human papillary thyroid carcinoma suggests that the formation of cancer specific 
translocations was due to contributions of DNA breakages at fragile sites. All the common 
fragile DNAs which has been examined to date show AT-rich flexibility islands and show the 
capability of making secondary structures that are much more stable than other genomic 
regions (Mishmar et al., 1998; Zlotorynski et al., 2003). These fragile regions can span 
mega-bases of DNA having gaps or breaks throughout (McAvoy et al., 2007).  
There are some other proteins which are important for maintenance of fragile sites such as 
ATR (Ataxia-telangiectasia and Rad3 Related)-dependent DNA damage checkpoint pathway 
and breakage of fragile site could enhance if there is deficiency of ATR (Casper et al., 2002; 
Casper et al., 2004) and its downstream targets i.e. BRCA1 (Arlt et al., 2004) and CHK1 
(Durkin et al., 2006). These studies show that at fragile sites under replication stress the 
polymerases involved in replication could detach from the helicase resulting in single-
stranded long DNA (ssDNA) regions which encourage the formation of stable secondary 
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structures. The replication stress activates ATR pathway and ATR bind with its partner 
protein ATRIP (ATR interacting protein) and recognize ssDNA coated with replication protein 
A (RPA) resulting in its activation. Once activated, it phosphorylates CHK1 resulting in 
activation of signalling cascades which end up in cell cycle arrest (Durkin and Glover, 2007).  
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1.4 Hypotheses 
Hypothesis 1: Paclitaxel cytotoxicity is in part mediated through induction of ER 
stress (Chapter 3) 
In this chapter I will attempt to answer the following: 
- Can paclitaxel induce ER stress (in vitro) in ovarian (A2780, SKOV3, PEO1) and colorectal 
(HCT116) cancer cells lines? 
- Can paclitaxel induced cell death be blocked by inhibiting the PERK pathway of ER-stress 
using Salubrinal? 
- Can paclitaxel induced cell death be blocked by inhibiting ER-stress associated apoptotic 
pathways, such as Caspase-4, Caspase-12 or JNK? 
 
Hypothesis 2: Expression of WWOX correlates with good progression free and overall 
survival in patients with high levels of ER stress markers (Chapter 4)  
In this chapter I will attempt to answer the following: 
- Do ovarian cancer patients with higher WWOX protein expression show improved overall 
and progression free survival? 
- Do ovarian and colorectal cancer patients with higher WWOX mRNA expression show 
improved overall and progression free survival? 
- Does the influence of WWOX expression on patient survival depend upon elevated 
expression of the ER-stress marker GRP-78? 
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Hypothesis 3: WWOX increases cisplatin induced cell death in an ER-stress 
dependent manner (Chapter 5) 
In this chapter I will attempt to answer the following: 
- Does cisplatin induce ER-stress response in cancer cell lines? 
- Does WWOX expression increase cisplatin induced cell death in an ER-stress dependent 
manner? 
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Chapter 2 Materials and methods 
2.1. Cell culture  
Various cancer cell lines such as, ovarian cancer (A2780, SKOV3 and PEO1), skin cancer 
(SK-MEL-28), prostate cancer (PC3, LNCap) and colorectal cancer (HCT116, HCT116-
p53null, HCT116-p21null and HCT116-baxnull) were used for experiments. The cells were 
cultured in RPMI-1640 medium (without HEPES) (Gibco, 31870-074) or DMEM(1X) (Gibco, 
11880-28) mixed along with 10% FBS (foetal bovine serum) (PAA Gold A15-152, Sigma # 
F2442), 0.4 mM L-glutamine (PAA, M11-004 or Gibco #25030-024), 100 U/ml penicillin, 100 
μg/ml streptomycin (PAA, P11-010 or Sigma # P4333), 1% amphotericin B (Sigma, A2942) 
in an incubator maintained at 37°C and 5% CO2. A class II laminar flow safety cabinet was 
used to provide sterile environment for the cell culture work.  
2.1.1 Passaging of cell lines 
The adherent cell lines were grown in 75 cm2 flasks until they reached 90-100% confluence 
(dependent upon cell line). The cells were washed with PBS (phosphate buffered saline) 
(Oxoid, BR0014) and then detached from the flask using enzyme trypsin (Sigma, T4549) 
before being split into new flasks containing RPMI medium and placed in an atmosphere of 
5% CO2 at 37°C. 
2.2 Cell culture experiments: 
2.2.1 Cell culture assays 
Cell culture experiments performed were independent of each other and these experiments 
were repeated multiple times.  At first, the suitable number of cells per well and suitable drug 
concentration was selected by treating various cell numbers with various drug 
concentrations. A drug dose which killed at least 50% of the cells after 24 hours was 
selected for the experiments. In the same way, the cell number selected was after looking at 
the survival percentage following drug treatments (see appendices S2.1). The 
concentrations used for the inhibitors were according to the manufacturer’s instructions.  
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2.2.1.1 Cell culture experiments for paclitaxel and inhibitors studies 
In these experiment log-phase various cancer cells per well (table 2.1) (in triplicate for each 
treatment) were plated in 96-well plate and placed in the incubator at 37oC and 5% CO2.  
After 48 hours of incubation, media was removed from the wells and replaced with fresh 
media, DMSO (0.18 %), and media containing different concentration of drug solutions and 
plates were placed in the incubator for 72 hours at 37oC and 5% CO2. Salubrinal (Merck, 
324895) was used as PERK inhibitor. Caspase-4 (Z-YVAD-FMK) (R&D, FMK005), Caspase-
12 (Z-ATAD-FMK) (R&D # FMK013) and JNK inhibitor (SP600125) (Tocris Bioscience 
#1496) were used to inhibit Caspase-4. -12 and JNK respectively. Tunicamycin (Sigma, 
T7765) an inducer of ER-stress, was used as positive control. Paclitaxel (Sigma, T7402) was 
used to see if it generates any ER-stress.  
Table 2.1: Cell type and cell numbers used in the experiments (see appendices S2.1) 
Cell type Cell numbers/well 
A2780 15,000 
SKOV3 6000 
HCT116, HCT116-p53null, HCT116-p21null, 
HCT116-baxnull 
6000 
PEO1-H8 
PEO1-FP2 
12,000 
12,000 
 
2.2.2 Cell culture experiments for gene expression (GRP-78 or XBP-1) analysis 
HCT116, PC3, LNCap and SK-MEL-28 cells (table 2.2) were plated in 6-wells plates and 
placed in incubator for 24 hours at 37oC and 5% CO2.  After 24 hours, media was removed 
from the wells and replaced with either fresh media or paclitaxel drug solutions of various 
concentrations (8nM, 16nM, 32nM, 64nM, 128nM and 40µM) and plates were placed in the 
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incubator. After 72 hours, plates were removed from the incubator and confluence in the 
wells was recorded.  
 
Table 2.2:  Cell types and cell numbers used in PCR experiments 
Cell Type Cells/well (6-well plate) 
HCT116 350,000 
PC3 250,000 
LNCap 300,000 
SK-MEL-28 300,000 
 
2.2.3 Cell culture experiments for WWOX analysis 
A2780, HCT116 and LNCap cancer cells (table 2.3) were plated in 6-wells plates and placed 
in an incubator for 24 hours at 37oC and 5% CO2. Next day, plates were removed from the 
incubator and media was removed from the wells and replaced with either fresh media, DMF 
or cisplatin and plates were placed in the incubator. Plates were removed from the incubator 
after 24 or 48 hours and confluence in the wells was observed under the microscope. Dead 
cells were clearly visible in cisplatin treated wells and confluence was low as compared to 
untreated and DMSO only treated cells.  
 
Table 2.3: Cell types and cell numbers used for WWOX and FHIT experiments 
Cell Type Cell Numbers Cisplatin concentration 
HCT116 350,000 5µg/ml 
A2780 500,000 4µg/ml 
LNCap 600,000 2.5µg/ml 
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2.3 Trichloroacetic acid (TCA) fixing and sulforhodamine B (SRB) staining 
After 72 hours of incubation, the cells in 96-well plates were fixed with 10%TCA 
(trichloroacetic acid) (Sigma T6399) and incubated for 1 hour at 4oC. In the next step, plates 
were washed cold water, dried (by air or 37oC) and stained with 0.4% SRB (sulforhodamine 
B) (Sigma, 230162) solution. Plates were then placed on a shaking platform for about 30 
minutes and then washed with 1% acetic acid (Sigma, 320099) and dried once again (by air 
or 37oC). Cell bound dye was re-solubilized with 10mM Tris (Sigma, 93362) and the 
absorbance was measured at 570nm wavelength using a spectrophotometer.  
2.4 Extraction of RNA from cell lysates and DNASE I treatment of purified RNA in 
solution 
Extraction of RNA was done by using kit (Isolate II RNA mini kit # Bioline-52072). In the first 
step cells were lysed using lysis buffer (from kit) mixed with β-mercaptoethanaol (β-ME). Cell 
were homogenised with the help of a cell scraper. In next step, 70% ethanol was added to 
the filtered lysates. The on-column method for digestion of DNA using enzyme DNASE I was 
proved not successful for me at early stages of my work, so I performed digestion of DNA in 
solution for enhanced removal of DNA contamination traces. For this purpose, DNase I 
enzyme was mixed with reaction buffer (from kit) and incubated for 10 minutes at 37oC. In 
the next step (ethanol precipitation step), sodium acetate (3M, pH 5.2) was added followed 
by absolute ethanol. After centrifugation and drying, RNA pellet was re-suspended in water. 
2.4.1. RNA concentration measurement 
RNA concentration (ng/µl) was quantified and the purity was checked with Nanodrop 2000 
spectrophotometer (Thermo scientific). The purity parameters were between the range of 1.8 
– 2.1 for (260/280) and 2.0 – 2.3 for (260/230). 
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2.5 Synthesis of cDNA 
Once the purity of RNA was checked by Nanodrop, the next step was to calculate the 
volume of RNA in 1µg by using the values obtained from Nanodrop spectrophotometer. 1µg 
equivalent of RNA was used to prepare all the samples of cDNA. For this purpose, Bioline 
tetro cDNA synthesis kit (BIO-65043) was used. This kit contains all the reagents (table 2.4) 
required for the preparation of complementary DNA (cDNA) from messenger RNA. The 
prepared cDNAs will be suitable for PCR using gene specific primers.  The following 
reagents (table 2.4) were used in this method. 
 
Table 2.4: Reagents used for the preparation of cDNA 
 
Reagents Volume 
mRNA (1µg equivalent volume) µl 
Primer: Oligo (dT)18 1µl 
10mM dNTP mix 1µl 
5x RT Buffer 4µl 
RiboSafe RNase 
Inhibitor 
1µl 
Tetro Reverse 
Transcriptase (200u/µl) 
1µl 
DEPC-treated water to 20µl 
 
Samples were mixed gently by pipetting and incubated at 45oC for 30 minutes. The reaction 
was terminated by incubating at 85oC for 5 minutes. The samples were chilled in ice and 
stored at -20oC  
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Two types of cDNA samples were prepared, one with all the reagents and one with 
everything but excluding Ribosafe Rnase inhibitor (R) and tetro reverse transcriptase (T). 
Both types of samples will be run for PCR but samples without RT will help to confirm if there 
is any contamination of DNA in mRNA samples. All the cDNAs used either for reverse 
transcriptase PCR or Real time PCR were checked for genomic DNA contamination.  
2.6 Polymerase chain reaction (PCR) for gene expression of GRP-78, XBP-1 and 
WWOX 
After the preparation of cDNAs from cancer cell lines, in the next step polymerase chain 
reaction (PCR) was performed to see the gene expression of Glucose regulated protein 
(GRP-78), X-box binding protein 1 (XBP-1) and WWOX (primers sequence shown in table 
2.7). The kit used for these experiments was Biotaq Red DNA Polymerase kit (Bio-21108). 
The total volume of the PCR master mix prepared was 25µl. cDNA template added to 
master mix was 2µl. Samples were run in Bio-Rad T100 thermal cycler for 35 cycles.  The 
table 2.5 shows the reagents, volumes and concentrations used for these experiments. The 
table 2.6 show the cycling conditions used for PCR. 
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Table 2.5: Preparation of master mix for PCR 
 
Reagents Final concentration Volume/PCR tube 
5X My Taq red reaction 
buffer 
1X 5µl 
Forward Primer 0.8µM 1µl 
Reverse Primer 0.8µM 1µl 
My Taq red DNA polymerase 1unit 0.2µl 
Water dH2O  15.8µl 
 
 
Table 2.6: PCR cycle conditions (30-35 cycles) 
 
Cycle Steps Temperature oC Time 
Initial heat 94 2 minutes 
denaturation 94 20seconds 
Annealing 55 
53 (For WWOX) 
20seconds 
Extension 72 40seconds 
 72 2 minutes 
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Table 2.7: Primers sequence used for PCR reactions 
Primers Sequence Product size (bp) 
   
GRP-78 F: CGTGGAATGACCCGTCTGTG 
R: CTTTGGTTGCTTGGCGTTGG 
 
252 
XBP-1 F: GCTCGAATGAGTGAGCTGGA 
R: AACTGGGCCTGCACCTG 
 
263 
β-actin F: CTACGTCGCCCTGGACTTCGAGC 
R: GATGGAGCCGCCGATCCACACGC 
 
385 
GAPDH F: TGTTGCCATCAATGACCCCTT 
R: CTCCA CGACGTACTC AGCG 
 
292 
WWOX 
(PCR) 
F: CCGTGTCATTGTGGTCTCCT 
R: TATAAGCCAAGCATCGCCCAA 
 
122 
WWOX 
(QRT-PCR) 
F: CAAGGACGGCTGGGTTTACT 
R: TGGCAAATCTCCTGCCACTC 
 
100 
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At the end of the PCR cycles, samples were transferred from thermocycler onto ice or stored 
at 8oC. 1% agarose gel (Sigma, A9539) was prepared and samples were run on the gel at 
100V for 1 hour and then images of gel were observed under UV (Geldoc- it TS2 imager).  
Only for XBP-1 PCR samples, 2% agarose gel was prepared. 100bp DNA ladder (TrackItTM, 
Invitrogen # 10488-058) was used to match the product length of the desired gene of 
interest.  
2.7 Quantification of gene expression by Real Time Polymerase chain reaction (QRT-
PCR) 
For QRT-PCR, the first step was to optimize conditions for the PCR and achieve a good 
standard curve. For this purpose, different primer sets (WWOX & FHIT) and conditions were 
used and once a desired standard curve was achieved, the next step was to run the cDNA 
sample mixed with the master mix and carry out PCR. The thermocycler machine used for 
these experiments was Rotor Gene 6000 (Rotor-Gene Q). Reference cDNA (prepared from 
1µg RNA in 20µl) was used to prepare a standard curve from 5 serial dilutions (1:5, 1:25, 
1:125, 1:625 and 1:3125). For analysis of the WWOX gene, cDNA from PEO1-H8 cells was 
used; for FHIT gene analysis, cDNA from HCT116 cells was used; for β-actin analysis, 
cDNA from SKOV3 cells was used. Sample cDNA from each treatment was diluted 1:20. 
The QRT-PCR kits used were (Qiagen # 204054, Bioline # 94005 and Biosystems # 
PB20.11-05). Table 2.8 shows the PCR cycling conditions. 
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Table 2.8: QRT-PCR cycling conditions 
Conditions Time Temperature 
PCR initial heat 2 or 5 minutes 95oC 
3 step cycling @ 45 cycles 
Denaturation 10 seconds 95oC 
Annealing 20 seconds 55oC 
Extension 20 or 30 seconds 60oC 
                  Acquiring @ Green                 1 second                                         72oC 
 
2.7.1 Relative quantification analysis of qRT-PCR experiments  
Relative quantification method was used for analysis of qRT-PCR experiments. All 
experiments were repeated in triplicate. The expression of each gene was determined by 
comparing Ct values against the relevant standard curve for that gene. Normalised 
expression for each gene was calculated from the ratios of each gene of interest to β-actin 
expression. Mean normalised expression and standard error were calculated by combining 
the triplicate experiments. Statistical significance was analysed by using Student T-test. P< 
0.05 was considered statistically significant. 
2.8 Kaplan-Meier survival data 
Kaplan-Meier graphs were used to analyse the survival data from both sets of patients i.e. 
IHC and RNAseq (from TCGA). For Kaplan-Meier analysis tables were prepared using excel 
spread sheets containing the raw data and the variables such as survival time and status of 
the event (dead=1/ censored= 0). For analysis of WWOX, FHIT or GRP-78 expression 
alone, patients were split into higher than median expression or lower than median 
expression. For combined analysis of WWOX and GRP-78, patients were divided into four 
equal groups using the median WWOX and median GRP-78 expression levels (giving high 
WWOX/high GRP-78; high WWOX/low GRP-78; low WWOX/high GRP-78 and low 
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WWOX/low GRP-78 groups). Data was analysed by Statistical package for the Social 
Science (SPSS) software, where the Kaplan-Meier analysis and log rank test was 
performed. 
2.9 Ethical approval for IHC data 
Ovarian tumour specimens were available as formalin fixed, paraffin embedded tissue 
blocks from patients who underwent surgery and received treatment at the Hammersmith 
Hospital, London, United Kingdom. All slides were reviewed by Dr Mona El-Bahrawy and 
representative blocks of the tumours were selected for the study. Ethics committee approval 
was obtained from Hammersmith and Queen Charlotte's and Chelsea Research Ethics 
Committee (REC reference: 05/Q0406/178). 
2.10 Protein analysis of NF-kB2 and PAR2 
2.10.1 Western Blotting 
After 24 or 72 hours of drug treatment, cells were washed with cold PBS. Lysis buffer (IX 
Laemmili buffer) (0.5M Tris hydrochloride (pH 6.8), SDS 20% stock, glycerol (100%) stock 
and distilled water) mixed with protease inhibitor cocktail (P8340-1ML) was added to the 
cells and lysates were prepared with the help of cell scrapper. Lysates were homogenised 
with a 27G needle and syringe. Lysates were then centrifuged at 4oC and 12,000 rpm in a 
centrifuge machine. 80µl of lysate was transferred into another tube which was used for BCA 
assay. 12µl of DDT (dithiothreitol) (1M) was added into remaining 120µl of lysate (0.1M final 
conc. of DTT) and tubes containing lysates were heated for 5 minutes at 95oC. All the tubes 
containing lysates were stored at -20oC or used for the next step. To quantify the total 
protein concentration of the lysates, Bicinchoninic acid (BCA) assay kit (PierceR # 23227) 
was per manufacturer’s protocol. Protein samples were prepared by using the right volumes 
of lysates, lysis buffer (IX Laemmili buffer) and loading buffer (IX Laemmili buffer containing 
0.1M DTT and bromophenol blue) and heated for 5 minutes at 95oC. The proteins were 
separated using Mini-ProteanR TGXTM precast gels (12%) (BIO-RAD # 456-1043) using 1X 
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Running buffer (trizma base 25mM, glycine 192mM, SDS 20% and water). Prepared lysate 
samples were loaded in to the wells of the gel along with a protein ladder (EZ RUNTM # 
BP3603) and run @ 200V. In the next step, proteins were transferred onto a nitrocellulose 
membrane (0.45µm) (BIO-RAD # 1620-0115) in the presence of 1X Transfer buffer (trizma 
base 25mM, glycine 192mM, water, methanol and SDS 20%). Once the transfer was 
complete, membranes were then blocked in 5% fat free milk in PBS-T (phosphate buffer 
saline-tween) for 2 hours. Membranes were blocked with primary antibodies (diluted 
appropriately in 5% blocking solution) overnight at 4oC on a shaking platform. Next day, 
membranes were washed six times with PBS-T and blocked with secondary antibodies 
(diluted appropriately in 5% blocking solution) for 1 hour at room temperature on a shaking 
platform. Membranes were washed 6 times with PBS-T.  Membranes were incubated with 
PierceR ECL 2 western blotting substrate per manufacturer’s protocol. X-ray films (CL-
XPosureTM film 5 x7 inches) (Thermo scientific # 34088) were used to visualise the protein 
bands. The details of the antibodies used are in appendix 2.  
2.11 RNA interference experiments 
2.11.1 esiRNA knockdown of NF-kB expression in A2780 and HCT116 cells 
A2780 and HCT116 log phase cells were counted by haemocytometer and approximately 
700,000 cells/well were plated in 6-wells plates in the presence of RPMI media mixed with 
10% FBS, 1% Penicillin/streptomycin, 1% Amphotericin B and 1% L-glutamine and placed in 
the incubator for 24 hours. Next day esiRNA treatments were prepared and for this purpose 
RPMI serum free media was used. 200µl of serum free media was transferred into 3 tubes 
A, B and C. In tube A 4µl (53.3pmol) of esiRNA (Mission esiRNA for human NF-kB2 # 
EHU067311-50UG), in tube B 4µl (53.3pmol) of GFP (Mission esiRNA targeting EGFP # 
EHUEGFP) and in tube C only serum free media was added. 12µl of transfection reagent 
(S1452-100UL) was added into all three tubes and incubated at room temperature for 15 
minutes. Media was removed from the wells of 6-wells plates and replaced with contents of 
tubes A, B, C and a well with serum free media only. Plates were incubated for 24 hours at 
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37oC in the presence of 5% CO2. Next day cells were trypsinized and re-suspended in RPMI 
media and counted in haemocytometer. Approximately 500,000 cells per well were plated in 
new 6-wells plates and placed in incubator. Next day, plates were removed from the 
incubator and media was replaced with either fresh media or DMSO or 4µg/ml cisplatin drug 
solution. After 72 hours’ plates were removed from the incubator and cell lysates were 
prepared for western blotting according to the protocol described in section 2.10.1.  
2.11.2 esiRNA knockdown of NF-kB expression in A2780 using different cell numbers 
In this experiment, different cell numbers were used for siRNA knockdown of NF-kB. 
500,000, 700,000 and 900,000 log phase cells of A2780 were plated in 6 -wells plates in the 
presence of RPMI media mixed with 10% FBS, 1% Penicillin/streptomycin, 1% Amphotericin 
B and 1% L-glutamine and placed in the incubator for 24 hours. The siRNA knockdown was 
done according to the protocol described in section 2.11.  
2.11.3 Knockdown of NF-kB expression in A2780 using different esiRNA 
concentrations 
700,000 log phase A2780 cells were plated in 6 -wells plates in the presence of RPMI media 
mixed with 10% FBS, 1% Penicillin/streptomycin, 1% Amphotericin B and 1% L-glutamine 
and placed in the incubator for 24 hours. The siRNA knockdown was done according to the 
protocol described in section 2.11 but the only difference was 3µl of esiRNA (Mission 
esiRNA for human NF-kB2 # EHU067311-50UG) was used.  
2.12 Fluorescence activated cell sorting (FACS) analysis    
The first step was calibration of the instrument followed by preparation of samples. All 
samples were prepared as single cell suspension and filtered using a 70µm cell strainer prior 
to acquisition. EDTA was used to minimize cell clumping. Samples were kept dilute avoiding 
any clouding. FACS buffer (PBS+2%FCS+0.05% sodium azide) was used for the cells. 
Single cell suspension cultures were loaded on the SIP and acquired. For control unstained 
and single stain fluorescence were used.  
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Chapter 3: The role of ER stress in paclitaxel response  
3.1 Introduction 
3.1.1 ER stress or unfolded protein response (UPR) 
In addition to its role in mitotic arrest, several studies suggest that apoptosis induced by 
Paclitaxel is due to endoplasmic reticulum (ER) stress also known as unfolded protein 
response (UPR) (Liao et al.,  2008). UPR is a stress response to unfolded proteins in the ER 
resulting from disturbance in cellular redox regulation, viral infections or glucose deprivation 
(Ma & Hendershot 2004). The purpose of UPR is to re-establish the normal ER function by 
maintaining the homeostasis, through inhibition of translation and up-regulation of molecular 
chaperones (Chunyan et al., 2005).  
All organisms have a mechanism by which proteins are properly folded for their proper 
functioning. In all eukaryotes, much of the protein assembly takes place in endoplasmic 
reticulum where they are properly folded before being passed on to the Golgi apparatus 
(Kaufman, 2002). Only properly folded proteins can leave ER to other intracellular organelles 
or to be displayed on the cell surface. Misfolded proteins are not allowed to leave ER and 
form a complex with molecular chaperones inside lumen of ER or they are degraded through 
a 26S proteasome governed by a process called ER-associated degradation (ERAD). 
Misfolded proteins can also be destroyed by autophagy (Malhotra and Kaufman, 2007). The 
process of protein folding can only work efficiently if conditions (environmental, genetic and 
metabolic) are suitable or it can affect the survival of the cell. The lumen of ER is an 
oxidizing environment where sulphide bonds are prepared and this process of formation of 
sulphide bonds is governed by multiple protein disulphide isomerase (PDIs) which make 
sure proper disulphide bonds are formed. ER serves as primary site for storage of Ca2+ 
which is very important for folding of proteins and functioning of calcium dependent 
molecular chaperones (GRP-78, GRP-94 and calreticulin). These chaperones, especially 
GRP-94, slow down the protein folding and stabilize them (Ma and Hendershot, 2004). 
 
 
83 
 
Failure in this process results in unfolded protein response (UPR) (Schröder and Kaufman, 
2005).  
3.1.1.1 Signal transduction events associated with ER stress 
In a mammalian cell the unfolded protein response is initiated by one ER chaperone, 
Glucose regulated protein (GRP-78) and three ER transmembrane proteins; Activating 
transcription factor 6 (ATF6), Inositol requiring enzyme 1 (IRE1) and double stranded RNA-
activated protein kinase like ER kinase (PERK) (Figures 3.4 and 3.5) (Harding et al., 2002) 
and (Zhang and Kufman, 2004). During non-stress conditions GRP-78 binds to the luminal 
domains of PERK, IRE1 and ATF6, and maintains them in an inactive state but during stress 
conditions in ER, when misfolded proteins accumulate, GRP-78 prefers to bind to these 
misfolded proteins and release (PERK, IRE1 and ATF6) allowing their activation and results 
in unfolded protein response (Rao & Bredesen, 2004). After dissociation from GRP-78, 
PERK dimerizes, auto phosphorylates, and triggers phosphorylation of eukaryotic translation 
initiation factor 2 on the alpha subunit (eIF2α).  This attenuates mRNA translation, thereby 
preventing influx of newly synthesized polypeptides into the ER lumen of the stressed cell 
(Kaufman, 2004). Some selected mRNAs such as ATF4 evade this inhibition of translation. 
ATF4 on activation can increase levels of chaperones, restore cellular redox homeostasis, 
and help the ER to degrade or fold proteins (Harding et al., 2000).  
During stress conditions, another transmembrane protein IRE1 is released by GRP78. IRE1 
is a bifunctional protein with kinase and endoribonuclease (RNase) activity. It dimerizes, and 
auto phosphorylates to activate its RNase activity. This activation results in removal of a 26-
nucleotide intron from X-box binding protein (XBP1) mRNA. Spliced XBP-1 is a 
transcriptional factor which activates many UPR target genes (Malhotra and Kaufman, 
2007).  
ATF6 is a bZIP family transcription factor. Following the activation of ER stress, GRP-78 
release ATF6, which then translocate to the Golgi apparatus by vesicular transport. ATF6 is 
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cleaved in Golgi apparatus by proteases and the cytoplasmic portion translocates to the 
nucleus where it binds to ER stress element (ERSE) to activate transcription of ER 
chaperone genes such as BIP/GRP-78, GRP-94 and calreticulin (Kaufman, 2004).  
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Figure 3.1: Signal transduction events associated with ER stress (Smith, 2013) 
Misfolded proteins aggregate causing Grp78 to release three ER resident transmembrane proteins 
(PERK, IRE1 and ATF6) and activate them. These signalling pathways lead to unfolded protein 
response (UPR) including inhibition of translation, increased chaperone production, ER associated 
protein degradation (ERAD), autophagy and apoptosis. 
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Figure 3.2: Overview of the unfolded protein response (UPR). Ribosome attaches itself to ER 
membrane for translation of nascent protein. Failure to process these proteins leads to UPR including 
(2) temporary suspension of protein synthesis; (3) increased protein folding capacity by transcriptional 
induction of ER chaperone genes; (4) disposal of the misfolded protein by ER-associated degradation 
(ERAD), or upregulation of apoptosis (5) causing cell death (Smith, 2013).  
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3.1.2 Apoptosis induced by ER stress 
When UPR fails in maintaining the proper protein folding capacity of the ER then ER stress 
signals the induction of apoptosis (Figures 3.5 and 3.6). Various mechanisms which could 
generate ER stress induced apoptosis include: 
1- Apoptosis mediated by CHOP 
2- Apoptosis mediated by IRE1 
3- Apoptosis mediated by caspases 
4- Apoptosis mediated by mitochondria 
3.1.2.1 Apoptosis mediated by CHOP 
 
CHOP a member of CCAAT/enhancer binding protein (C/EBP) family is a bZIP transcription 
factor (Ron and Hebener, 1992). CHOP/GADD153 (growth arrest and DNA damage 153) is 
activated by prolonged ER stress and induces apoptosis (Harding et al., 2000; Okada et al., 
2002). Although it can be transcribed by IRE1, ATF6 and PERK pathways, PERK is 
considered the most significant pathway (Ma et al., 2002; Harding et al., 2000; Okada et al., 
2002). CHOP activates transcription of genes such as GADD34, ERO1α, DR5, TRB3 and 
carbonic anhydrase VI which can initiate apoptosis. eIF2α is de-phosphorylated by GADD34 
on serine 51 resulting in translational recovery which will increase protein synthesis. 
Continuous synthesis of proteins during ER stress can cause cell death by UPR (Marciniak 
et al., 2004; Novoa et al., 2001). Transcription of ERO1α (an oxidoreductase) increases the 
oxidizing capacity of the ER (Marciniak et al., 2004), and carbonic anhydrase VI lowers 
intracellular pH (Sok et al., 1999) which will enhance the amount of misfolded proteins. DR5 
(death receptor 5) can activate caspase cascades (Yamaguchi et al., 2004). Anti-apoptotic 
protein Bcl-2 is transcriptionally repressed by CHOP resulting in downregulation of it 
expression. CHOP increases reactive oxygen species (ROS) which are also involved in ER 
stress induced apoptosis (Harding et al., 2003; Haze et al., 1999).  
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3.1.2.2 Apoptosis mediated by IRE1 
 
IRE1 responds to ER stress by recruiting adaptor protein tumour necrosis factor (TNF) 
receptor associated factor 2 (TRAF2) to the ER membrane (Urano et al., 2000). This is 
controlled by c-jun NH2 –terminal inhibitory kinase (JIK) which communicates with both IRE1 
and TRAF2 (Yoneda et al., 2001). IRE1 and TRAF2 recruit and activate ASK1 and the 
downstream JNK pathway causing apoptosis (Nishitoah et al., 2002; Nishitoah et al., 1998). 
TRAF2 is also involved in activation and regulation of Caspase-12 (Yoneda et al., 2001). 
Cyclin AMP-dependent transcription factor ATF-3 is also activated by IRE1 and TRAF2 
complex, generating apoptosis (Zhang et al., 2001). The mechanisms by which JNK initiate 
apoptosis are not fully clear but perhaps regulate Bcl-2 family of proteins as well (Lai et al., 
2007).  
3.1.2.3 Apoptosis mediated by Caspases 
 
It has been reported that Caspases 2, 3, 4, 7, 9 and 12 participate in apoptosis induced by 
ER stress. Caspase-12 (in mice) is positioned on the cytoplasmic side of the ER and is 
cleaved and activated during ER stress by Calpains (a family of Ca2+ dependent cysteine 
proteases) (Tan et al., 2006; Nakagawa et al., 2000a; Nakagawa et al., 2000b). 
Mitochondrial pro-apoptotic Bcl-2 family members BAX and BAK positioned at the ER 
membrane interacts with Caspase-12 and initiate apoptosis (Cheung et al., 2006; Di Sanoet 
al., 2006; Hitomi et al., 2004). Caspase-12 activates caspase-9, which sequentially activates 
caspase-3 causing apoptosis (Morishima et al., 2002).  
Caspase-7 also responds to ER stress and activates caspase-12 by cleavage (Rao et al., 
2001), as can TRAF2 (Yoneda et al., 2001). The ER stress induced apoptotic role of caspse-
12 in humans is questionable, however, because in human caspase-12 is inactive due to 
several mutations (Fischer et al., 2002). It has been reported that in human caspase-4 is 
homologue of mice caspase-12 and it serves the functions of caspase-12. It has been shown 
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that ER stress is responsible for cleaving caspase-4 and when caspase-4 was knocked 
down it reduced apoptosis induced by ER stress (Hitomi et al., 2004).  
3.1.2.4 Apoptosis mediated by mitochondria 
 
Several studies suggest the role of mitochondrial Bcl-2 family of proteins in ER stress 
induced apoptosis. Both Bax and Bak are present on mitochondria and ER membrane 
(Scorrano et al., 2003; Zong et al., 2003). During ER stress conditions. Bax and Bak 
undergo oligomerization and conformational change in the ER membrane and initiate 
apoptosis by two separate pathways (Zong et al., 2003). In mitochondrial independent 
pathway, the conformation change in the ER allows Ca2+ to move from ER into the 
cytoplasm which lowers the concentration of Ca2+ inside ER (Zong et al., 2003; Scorrano et 
al., 2003). The high concentration of Ca2+ in the cytosol results in activation of m-calpain 
which in turn activates caspase-12, inducing apoptosis as described above (Nakagawa et 
al., 2000a; Morishima et al., 2002; Tan et al., 2006). In mitochondrial dependent pathway, 
Ca2+ from the cytosol enters into mitochondria and causes depolarization of the inner 
mitochondrial membrane resulting in the release of cytochrome c (Crompton, 1999). 
Released cytochrome c activates formation of an apoptosome comprised of apoptosis 
protease activating factor1 (Apaf-1), pro-caspase9, cytochrome c and ATP. This 
apoptosome complex activates caspase-9 which then activates caspase-3 leading to 
apoptosis (Crompton, 1999; Shibue and Tanigichi, 2006). Apart from Bax and Bak, during 
ER stress conditions other BH3 domain family members such as PUMA (p53 up-regulated 
modulator of apoptosis) and NOXA (neutrophil NADPH oxidase factor) are also up regulated 
by p53 (Li et al., 2006).  
BIK (Bcl2 interacting killer) is also present in ER and its pro-apoptotic nature helps ER for 
the deployment of Bax and Bak at its surface (Mathai et al., 2005). Expression of Bcl2 is 
supressed due to high expression of CHOP which cause activation of pro-apoptotic Bcl2 
proteins (McCullough et al., 2001). JNK can phosphorylate Bcl2 resulting in inhibition of Bcl2 
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binding to pro-apoptotic Bax and Bid proteins (Bassik et al., 2004). JNK can also 
phosphorylate Bim (Bcl2 interacting mediator of cell death), releasing Bim to activate 
caspase-12 during ER stress conditions (Lei and Davis, 2003). These findings show the role 
of CHOP and JNK in mediating ER stress induced apoptosis by regulating mitochondrial 
Bcl2 proteins. 
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Figure 3.3: ER stress pathways involved in apoptosis. I: PERK activates and phosphorylates eIF2α 
which enhances translation of ATF4 transcription factor which upregulate target genes via ERSE 
promotor resulting in induction of CHOP. Activated CHOP downregulates the expression of the anti-
apoptotic protein Bcl-2 and induces GADD34 and ERO1. II: After activation IRE1 binds JIK and 
recruits TRAF2, which leads to the activation ofASK1 and JNK. JNK phosphorylates Bcl-2 and BH3-
only protein (Bim), initiating mitochondria-mediated apoptosis (not shown). III: Attached on the inner 
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side of ER membrane, TRAF2 dissociate from procaspase-12 (pCP12) hence allowing activation of 
procaspase-12. Under ER stress conditions Bax and Bak residing in the ER membrane oligomerize 
and permits the release of Ca2+ from the ER to the cytosol, resulting in activation of m-Calpain, which 
subsequently cleaves and activates pCP12. Activation of caspase-12 (CP12) cleaves and activates 
procaspase-9, which then activates downstream caspases such as caspase-3. In addition, Ca2+ 
released from the ER is taken up by the mitochondria, altering mitochondrial inner membrane 
depolarization and allow cytochrome c to move into the cytoplasm. The cytochrome c forms an 
apoptosome (consisting of Apaf-1, cytochrome c, ATP, and procaspase-9), activation of procaspase- 
9, and subsequent downstream caspases leading to cell apoptosis (Lai et al., 2007). 
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3.2 Experimental Approach 
In this chapter the aim was to see induction of ER stress in ovarian cancer cells (A2780, 
SKOV3, PEO1-H8 and PEO1-FP2) and colorectal cancer cells (HCT116, HCT116-p53null, 
HCT116-p21null, HCT116-baxnull) following paclitaxel treatment, and to determine the key 
ER-stress pathway(s) used by paclitaxel to kill cancer cells. The key ER stress pathways 
under investigation were PERK and apoptotic pathways involving Caspase-4, Caspase-12 
and JNK. Before the start of experiments the first step was the optimization of suitable drug 
dose concentrations to be used for experiments (see details in appendices section S2). 
Ovarian and colorectal cancer cells were treated with paclitaxel to induce ER stress and 
salubrinal was used to inhibit induction of ER stress via PERK pathway.  Inhibitors such as 
Z-YVAD-FMK and Z-ATAD-FMK were used to inhibit ER stress related apoptotic 
components Caspase-4 and Caspase-12 respectively, while SP600125 was used to inhibit 
c-jun (JNK) arm of apoptosis. Tunicamycin was used as positive control of ER stress 
activation. Cell survival experiments were performed by using SRB staining technique. SRB 
is a dye widely used to study in vitro cytotoxicity. SRB works by binding to protein 
constituents of the cells in a stoichiometric manner. The principle behind this technique is, 
the extracted dye from stained cells is directly proportional to the cell mass. In my 
experiments the survived cells after treatment with drugs or inhibitors will retain this dye 
which on measurement with spectrophotometer will show the cell survival.  The aim was to 
characterise the ER-stress related cell death mechanisms induced due to paclitaxel 
treatment. After treatment of cancer cells with paclitaxel, ER stress may be induced via 
PERK pathway which will be inhibited by salubrinal. Similarly, ER stress induced by 
apoptosis will be inhibited by using inhibitors of Caspase-4, Caspase-12 and c-jun (JNK). 
Induction of paclitaxel induced ER stress in cancer cells will be confirmed by using these 
inhibitors. 
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3.3 Results 
3.3.1 Paclitaxel treatment and PERK pathway inhibition in A2780 and SKOV3 
In this experiment, ovarian cancer cells A2780 and SKOV3 were treated with paclitaxel in 
combination with salubrinal (Table 3.1). The aim of these experiments was to determine if 
salubrinal could protect the cells from paclitaxel and tunicamycin. Results of A2780 (Figure 
3.4) show the relative cell survival percentage of drug and inhibitor treated cells as 
compared to untreated and DMSO treated cells. In A2780 relative cell survival of paclitaxel 
treated cells was 58% as compared to untreated or No Drug (ND) 100% which shows 
paclitaxel has reduced the number of cells possibly due to ER stress induced apoptosis. 
Cells treated with tunicamycin (an ER stress inducer) showed cell survival of 88% as 
compared to ND but it is not significantly less. Cells treated with two different concentrations 
of salubrinal (an ER stress inhibitor) (30µM and 60µM) did not show any significant effect on 
cell number as compared to ND. Cells with DMSO treatment showed almost no change in 
their relative cell survival which was 98% as compared to ND. Combination of paclitaxel and 
two different salubrinal concentrations (60µM and 30µM) showed relative cell survival of 
52% and 50% respectively as compared to 58% of pacliatxel only treated cells which show 
that salubrinal did not reverse the effects of pacliatxel. Cells treated with combination of 
tunicamycin and two different concentrations of salubrinal (30µM and 60µM) showed 90% 
and 88% relative cell survival respectively  as compared to 88% of tunicamycin only treated 
cells. It is unsurprising that salubrinal did not reverse the effect of tunicamycin because 
tunicamycin itself did not cause any significant change in cell survival as compared to ND.  
Results of SKOV3 (Figure 3.4) show the relative cell survival percentage of drug and 
inhibitor treated cells as compared to untreated and DMSO treated cells. Paclitaxel treated 
cells showed 10% relative cell survival as compared to ND possibly due to ER stress 
induced apoptosis. Combination of paclitaxel and two different salubrinal concentrations 
(60µM and 30µM) showed relative cell survival of 16% and 18% respectively showing that 
salubrinal did not reverse the effects of paclitaxel massively. Tunicamycin treated cells 
 
 
95 
 
showed 90% relative cell survival as compared to ND. The combination of tunicamycin and 
two concentrations of salubrinal (60µM and 30µM) showed 96% and 92% realtive cell 
survival showing the reversal effect of salubrinal is negligible. Salubrinal only (60µM and 
30µM) treatments showed no significant effect on cell number as compared to ND. DMSO 
also did not show any effect on  cell number as compared to ND.  
Surprisingly in these results my positive control of ER stress i.e. tunicamycin did not show 
any significant effect on cell numbers as compared to ND. This suggests maybe it is not 
inducing ER stress in these ovarian cancer cells. However, paclitaxel showed less cell 
numbers as compared to ND, but surprisingly salubrinal did not reverse this effect which 
raises this question that may be the reduced cell number in paclitaxel treated cells was not 
due to ER stress but some other cytotoxic effect of paclitaxel which salubrinal could not 
reverse. 
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Table 3.1: Explanation of codes for drugs and inhibitors combinations used in graphs 
ND No drug 
Sal 60 Salubrinal 60µM 
Sal 30 Salubrinal 30µM 
Tun Tunicamycin 200ng/ml 
T+S60 Tunicamycin 200ng/ml + 
Salubrinal 60µM 
T+S30 Tunicamycin 200ng/ml + 
Salubrinal 30µM 
Pac Paclitaxel 
P+S60 Paclitaxel+ Sal 60µM 
P+S30 Paclitaxel+ Sal 30µM 
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Figure 3.4:  Relative cell survival in ovarian cancer cell lines after ER stress inhibition by salubrinal. 
(A) A2780 cells were treated with paclitaxel (P or Pac) (16 nM), salubrinal (Sal or S) (30 μM and 60 μM), tunicamycin (Tun or T) (200 ng/ml), or in 
combination with each other. (B) SKOV3 cells were treated with paclitaxel (P or Pac) (20 nM), salubrinal (Sal or S) (30 μM and 60 μM), tunicamycin (Tun or T) 
(200 ng/ml), or in combination with each other. After 72 hours, spectrophotometric analysis was used (post SRB staining) to observe cell number. 
Experiments were repeated seven times for A2780 and six times for SKOV3. Means ± SEM are shown. 
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3.3.2 Paclitaxel treatment and PERK inhibition in HCT116 isogenic cells 
Drug responses differ between cell lines due to different genetic backgrounds. Since 
salubrinal failed to reverse paclitaxel response in A2780 or SKOV3 cells, we tried repeating 
these experiments using colorectal cancer HCT116 isogenic cell lines. These were HCT116 
cells but lacking p53, p21 and bax genes, so they are named as HCT116, HCT116-p53null, 
HCT116-p21null and HCT116-baxnull.  
 
3.3.2.1 Is the PERK pathway required for the paclitaxel-induced reduction in cell 
number in HCT116 isogenic cell lines?  
The aim of these experiments was to see if PERK pathway is required for paclitaxel induced 
reduction in cell numbers. HCT116 isogenic cell lines were treated with paclitaxel, salubrinal, 
tunicamycin alone or in combination with each other and surviving cell numbers determined 
by SRB staining. The results showed that (Figure 3.5) paclitaxel reduced the number of cells 
as compared to ND and DMSO treated cells. 
After paclitaxel treatment HCT116 showed (62%), HCT116-p53null (78%), HCT116-p21null 
(54%) and HCT116-baxnull (59%) cell numbers as compared to untreated and DMSO 
treated cells. The cells treated with combination of paclitaxel and two different 
concentrations of salubrinal (60μM and 30μM) did not show reversal of the paclitaxel 
response but rather an even greater reduction in cell survival, HCT116 (34% & 36%), 
HCT116-p53null (34% & 40%), HCT116-p21null (28% & 34%) and HCT116-baxnull (30% & 
36%) respectively as compared to paclitaxel-only treated cells.  
Tunicamycin treated HCT116 cells showed (45%), HCT116-p53null (45%), HCT116-p21null 
(68%) and HCT116-baxnull (48%) relative cell numbers as compared to ND cells. The cells 
treated with combination of tunicamycin and salubrinal (60μM and 30μM) showed that 
HCT116 showed (30% and 32%), HCT116-p53null (28% and 30%), HCT116-p21null (28% 
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and 36%) and HCT116-baxnull (28% and 36%) cell numbers as compared to tunicamycin 
only. These results show salubrinal did not reverse the effects of tunicamycin.  Interestingly 
salubrinal itself caused a reduction in cell survival and both concentration of salubrinal 
showed approximately 40%-44% cell numbers as compared to ND. Salubrinal is an ER 
stress inhibitor but it looks like it is having some type of cytotoxic affect as well which is 
contrary to what we observed in the results of ovarian cancer A2780 and SKOV3 cells 
(Figure 3.4). 
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Figure 3.5: Relative cell survival in colorectal cancer cell lines after ER stress inhibition by Salubrinal HCT116 isogenic cell lines were treated with either 
paclitaxel (P or Pac) (1nM), salubrinal (S) (30 μM and 60 μM), tunicamycin (T or Tun) (75 ng/ml), or in combination with each other. After 72 hours, 
spectrophotometric analysis was used (post SRB staining) to observe cell survival. Experiments were repeated three times independently of each other. 
Means ± SEM are shown
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3.3.2.2 Is Caspase-4 required for the paclitaxel-induced reduction in cell number in 
HCT116 isogenic cell lines?  
The data from the previous section suggest that PERK pathway is not relevant to paclitaxel 
response, so in these experiments importance of UPR associated caspases was observed. 
The aim of these experiments was to see if I can reverse the effects of paclitaxel induced 
cell death in HCT116 isogenic cell lines by inhibiting caspase-4 using a specific caspase-4 
inhibitor (Z-YVAD-FMK) which was a cell permeable, fluoromethyl ketone (FMK) peptide with 
no cytotoxic effects. It inhibits apoptosis by irreversibly binding to catalytic site of caspase-4 
protease.   
HCT116 isogenic cells were treated with caspase-4 inhibitor, tunicamycin, paclitaxel or in 
combination with each other. Results show that paclitaxel treatment alone did not show any 
big difference in cell numbers as compared to ND (Figure 3.6). HCT116, HCT116-p53null, 
and HCT116-baxnull cells showed approximately 98% and HCT116-p21null cells showed 
88% survival as compared to ND. The combined treatment of paclitaxel and caspase-4 
inhibitor did not show much difference in cell numbers as compared to paclitaxel alone for all 
four cell lines. Previously I have shown paclitaxel causes reduced cell numbers as compared 
to ND, but in these experiments, paclitaxel did not show a visible reduction in cell numbers 
which is different to previous results.  This suggests a possible problem with the paclitaxel 
treatment in these experiments, although the result was consistent in all three replicate 
experiments.  
However, tunicamycin treated cells showed a reduction in cell numbers as compared to ND. 
All four cell lines showed cell numbers between 58%-62% as compared to ND, but combined 
treatment of caspase-4 inhibitor and tunicamycin showed no reversal of this response in 
HCT116, HCT116-p53null and HCT116-baxnull cells. Whereas in HCT116-p21null 
combined caspase-4 inhibitor and tunicamycin treatment showed 79% cell survival 
compared to tunicamycin alone (68%). This reversal effect of caspase-4 inhibitor looks 
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minimal. DMSO (95%-100%) only treatment showed almost no change as compared to ND 
in all four cell lines. Overall these results could not establish any involvement of caspase-4 in 
paclitaxel or tunicamycin response, although there may have been a problem with the 
paclitaxel response in these experiments.  
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Figure3.6: Relative cell survival in colorectal cancer cell lines after ER stress inhibition by inhibitor for Caspase-4 (Z-YVAD-FMK) 
HCT116 isogenic cell lines were treated with either paclitaxel (Pac) ( nM), Caspase-4 (Z-YVAD-FMK) inhibitor (10 μM), tunicamycin (Tun) (75 
ng/ml), or in combination with each other. After 72 hours, spectrophotometric analysis was used (post SRB staining) to observe cell survival. 
Experiments were repeated three times independently of each other. Means ± SEM are shown. 
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3.3.2.3 Is Caspase-12 required for the paclitaxel-induced reduction in cell number in 
HCT116 isogenic cell lines?  
I used specific Caspase-12 inhibitor (Z-ATAD-FMK), a synthetic peptide which irreversibly 
inhibits caspase-12 and its activity. This inhibitor is a cell permeable fluoromethyl ketone 
(FMK) peptide with no cytotoxic effects. The aim was to determine whether caspase-12 
inhibition could reverse paclitaxel or tunicamycin response.  
HCT116 isogenic cells were treated with caspase-12 inhibitor, tunicamycin, paclitaxel or in 
combination with each other. Paclitaxel treated HCT116, HCT116-p53null, HCT116-p21null 
showed approximately 90% and HCT116-baxnull showed 79% cell survival as compared to 
ND (Figure 3.7). The combined treatment of paclitaxel and caspase-12 inhibitor did not show 
much difference in cell numbers as compared to paclitaxel itself. But my main drug paclitaxel 
itself did not showed reduced cell numbers as it showed in my previous experiments; 
suggesting this data may not be reliable.  
Tunicamycin treatments showed reduced cell numbers in all four HCT116 isogenic cell lines 
but the combined treatment of tunicamycin and caspase-12 inhibitor did not reverse the 
effects of tunicamycin. Caspase-12 inhibitor treatment alone and DMSO treatment did not 
show any significant difference as compared to ND.  
My data shows no indication of Caspase-4 or Caspase-12 involvement in paclitaxel 
response. However, the lack of clear cytotoxic effect of paclitaxel in these experiments 
makes this result uncertain. I had planned to repeat these experiments again with fresh 
reagents, however subsequent data made this unnecessary (see below). 
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Figure3.7: Relative cell survival in colorectal cancer cell lines after ER stress inhibition by inhibitor for Caspase-12 (Z-ATAD-FMK) 
HCT116 isogenic cell lines were treated with either paclitaxel (Pac) (1nM), Caspase-12 (Z-ATAD-FMK) inhibitor (10 μM), tunicamycin (Tun) 
(75 ng/ml), or in combination with each other. After 72 hours, spectrophotometric analysis was used (post SRB staining) to observe cell 
survival. Experiments were repeated three times independently of each other. Means ± SEM are shown. 
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3.3.2.4 Is JNK pathway required for the paclitaxel induced reduction in cell numbers?  
Another important regulator of ER-stress mediated apoptosis is the JNK pathway. Here in 
my experiments I have used JNK (SP600125) inhibitor which is a powerful, cell permeable 
anthrapyrazolone inhibitor of JNK that competes with ATP to inhibit the phosphorylation of c-
Jun. I hypothesize that treatment of cancer cell with paclitaxel and tunicamycin will induce 
ER stress induced apoptosis and JNK inhibitor will inhibit this ER stress induced apoptosis. 
HCT116 isogenic cells were treated with JNK inhibitor, tunicamycin, paclitaxel or in 
combination with each other (Figure 3.8). Paclitaxel treated HCT116 showed (68%), 
HCT116-p53null (50%), HCT116-p21null (34%) and HCT116-baxnull (80%) cell survival as 
compared to ND (Figure 3.18). When combined treatment of paclitaxel and JNK inhibitor 
was used HCT116 showed (40%), HCT116-p53null (59%), HCT116-p21null (35%) and 
HCT116-baxnull (55%) cell numbers as compared paclitaxel only. Although paclitaxel has 
showed reduced cell numbers in these experiments, JNK inhibition failed to reverse the 
effects of paclitaxel and in some cell, lines appears to have further reduced cell survival.  
Tunicamycin only treated HCT116 and HCT116-p21null showed (60%) cell numbers, while 
HCT116-p53null showed (45%) and HCT116-baxnull showed (80%) cell numbers as 
compared to ND.  When combined treatment with tunicamycin and JNK inhibitor, HCT116 
showed (44%), HCT116-p53null (45%), HCT116-p21null (40%) and HCT116-baxnull (70%) 
as compared to tunicamycin only treatment. In all these cell lines JNK inhibition did not 
reverse the effect of tunicamycin and in some cell lines appears to have further reduced cell 
survival. 
Consistent with its effects in combination with paclitaxel or tunicamycin, JNK inhibitor 
treatment alone caused a reduction in cell survival, HCT116 showed (70%), HCT116p21-null 
(58%), HCT116-p53null and HCT116-baxnull showed (80%) cell numbers as compared to 
ND. DMSO only treatment did not show any difference as compared to ND.  
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In these experiments paclitaxel and tunicamycin showed visible reduction in cell numbers in 
HCT116 isogenic cells as compared to ND but JNK inhibitor did not reverse these effects. 
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Figure3.8: Relative cell survival in colorectal cancer cell lines after ER stress inhibition by inhibitor for JNK (SP600125) 
HCT116 isogenic cell lines were treated with either paclitaxel (Pac) (1nM), JNK inhibitor (SP600125) (10 μM), tunicamycin (Tun) (75 
ng/ml), or in combination with each other. After 72 hours, spectrophotometric analysis was used (post SRB staining) to observe cell 
survival. Experiments were repeated three times independently of each other. Means ± SEM are shown. 
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3.3.3 Paclitaxel treatment and ER stress inhibition in PEO1 cells 
Unpublished preliminary work in Dr Paige’s group had identified a link between paclitaxel 
response and ER-stress in the PEO1 cell line. Given that none of the inhibitors used in the 
above experiments were shown to reverse paclitaxel response we decided to repeat these 
experiments using PEO1 cells. In these experiments, ovarian cancer cells lines PEO1-H8 
and PEO1-FP2 were treated with paclitaxel in combination with salubrinal. PEO1 is an 
ovarian cancer cell line but PEO1-H8 is a transfected version of PEO1 cells expressing the 
WWOX protein (which may influence paclitaxel response, unpublished data) and PEO1-FP2 
is vector only transfected cell line (Gourley et al., 2005; Gourley et al., 2009).  
3.3.3.1 Paclitaxel treatment and PERK pathway inhibition in PEO1 cells 
In these experiments, I used WWOX and vector only transfected cell lines. My previous 
results of ovarian and colorectal cell lines did not show any positive effects of the inhibitors I 
used in those experiments. As described in introduction the literature shows WWOX 
sensitises cancer cells towards apoptosis, and preliminary data in our group has suggested 
a link between paclitaxel response and ER-stress in PEO1 cells. Therefore, my aim was to 
see if using WWOX transfected cells could enhance the ER-stress induced apoptosis (more 
reduction in cell numbers) and enable us to see reversal of these effects by inhibiting PERK 
pathway. 
Results (Figure 3.9) show that paclitaxel treated PEO1-H8 cells showed 36% cell numbers 
as compared to ND. Combined treatment of paclitaxel with two salubrinal concentrations 
(60μM and 30μM) showed 25% and 20% cell numbers respectively, indicating that salubrinal 
has not reversed the effects of paclitaxel but has enhanced them.  
Tunicamycin treated PEO1-H8 cells showed 32% cell numbers as compared to ND. 
Combined treatment of tunicamycin with two salubrinal concentrations (60μM and 30μM) 
showed 40% and 35% cell survival respectively. Salubrinal did not reverse the effects of 
tunicamycin.  
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Both salubrinal only treatments showed 85% cell numbers as compared to ND. DMSO only 
treatment did not show any reduction in cell numbers as compared to ND 
Results (Figure 3.9) show that paclitaxel treated PEO1-FP2 cells showed 24% cell numbers 
as compared to ND. Combined treatment of paclitaxel with two salubrinal concentrations 
(60μM and 30μM) showed 15% and 12% cell numbers respectively. This shows salubrinal 
has not reversed the effects of paclitaxel but had enhanced them.  
Tunicamycin treated PEO1-FP2 cells showed 80% cell numbers as compared to ND. 
Combined treatment of tunicamycin with two salubrinal concentrations (60μM and 30μM) 
showed 55% and 54% cell numbers respectively. Salubrinal did not reverse the effects of 
tunicamycin which is positive control for ER stress, but again has enhanced them.  
Both salubrinal only treatments showed 59% and 60% cell numbers as compared to ND. 
DMSO only treatment did not show any reduction in cell numbers as compared to ND. 
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  1 
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Figure 3.9: Relative cell survival in ovarian cancer cells after ER stress inhibition by salubrinal 3 
PEO1-H8 and PEO1-FP2 cells were treated with paclitaxel (Pac or P) (16 nM), salubrinal (Sal or S) (30 μM and 60 μM), tunicamycin (Tun or T) (200 ng/ml), 4 
or in combination with each other. After 72 hours, spectrophotometric analysis was used (post SRB staining) to observe cell survival. Experiments were 5 
repeated four times. Means ± SEM are shown. 6 
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3.3.4 Examining the induction of ER stress markers caused by paclitaxel and 
tunicamycin by reverse transcriptase- polymerase chain reaction (PCR) 
My results show no indication that inhibiting the PERK pathway, JNK pathway or caspases 4 
or 12 can reverse the effect of paclitaxel in any of the cell lines used above. This was true 
even in the PEO1-H8 and PEO1-FP2 cell lines for which previous unpublished data had 
suggested a link between paclitaxel response and ER-stress. This could indicate that these 
specific components of the ER-stress pathway are not required for paclitaxel response, that 
paclitaxel does not induce the ER-stress at all in these cells, or that there are technical 
issues (such as efficacy of the inhibitors) affecting the results. To explore these possibilities, 
I next decided to screen a panel of cell lines to identify a suitable model system in which 
paclitaxel clearly induces ER-stress, as previously seen in Dr Paige’s group (unpublished 
data). 
The aim therefore is to see if paclitaxel induces markers of ER stress or not. Under stress 
conditions in the ER, proteins are misfolded. Cells try to adapt to the misfolded proteins and 
try to stabilize them to maintain cellular homeostasis.  This adaptation towards misfolded 
proteins in the ER protects the cells by increasing the folding capacity inside ER and 
enhancing the production of chaperons such as GRP-78. Therefore, if paclitaxel treatment 
induces ER-stress we should see an increase in GRP-78 expression. ER stress also 
activates IRE1. IRE1 is a bifunctional protein with kinase and endoribonuclease (RNase) 
activity. It dimerizes, and auto phosphorylates to activate its RNase activity. This activation 
results in removal of a 26-nucleotide intron from X-box binding protein (XBP1) mRNA. 
Spliced XBP-1 is a transcriptional factor which activates many UPR target genes (Malhotra 
and Kaufman, 2007). Generally, XBP-1 mRNA is expressed as un-spliced form and so it 
encodes un-spliced XBP-1 also termed as pXBP-1 (U). Under ER stress environment this 
un-spliced mRNA transforms into spliced form and encodes spliced version of XBP-1, also 
termed as pXBP-1 (S). If paclitaxel does induce ER-stress, we should see an increase in 
XBP-1 (S). I am using various doses of paclitaxel at two times points in my experiments. The 
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aim is to see if ER stress is generated in cancer cells after treatment with paclitaxel after 24 
or 72 hours. A range of different cell lines was used to increase the chances of identifying a 
suitable model system in which paclitaxel induces ER-stress. 
3.3.4.1 Can paclitaxel treatment generate ER stress? 
For these experiments the first step was optimizing the conditions for PCR. The intensity of 
the PCR product on the agarose gel depends upon the amount of starting template added.  
For this purpose, preliminary experiments were performed using different numbers of PCR 
cycles and different amounts of template (data not shown). The conditions where PCR 
amplification was not saturated were selected for the experiments. For GRP-78 and XBP-1 
(S) 35 cycles and for actin or GAPDH 30 cycles were selected. Prostate (PC3 and LNCap) 
and skin cancer (SK-MEL-28) cell lines were treated with a range of doses of paclitaxel or 
DMSO for 24 or 72 hours, and expression of GRP-78 and XBP-1(S) by RT-PCR was 
analysed. 
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3.3.4.1.1 Paclitaxel treatment and ER stress induction in PC3 cells 
 
The results in (Figure 3.10) show that no amplification was observed in the ‘no reverse 
transcriptase’ controls showing that no genomic DNA contamination was present. Similar 
intensity of beta actin expression was seen in all samples showing equal loading of template. 
There was a slight increase in expression of GRP-78 at 32nM and 64nM concentrations as 
compared to 16nM and the DMSO treated controls, but it does not show increased and 
spliced XBP-1. Also, when I repeated this experiment it showed no change in either GRP-78 
and XBP-1 expression levels, suggesting that ER-stress is not induced by paclitaxel in these 
cells. In the same cell at 24 hours’ time point also showed similar results (Gel images not 
shown).  
 
 
Figure 3.10: Gel images of PC3 after treatment with paclitaxel for 72 hours. 
Samples include NTC (no template control), paclitaxel treated samples (16nM, 32nM, 64nM) and 
DMSO (0.0002%, 0.0004%, 0.0009%) treated samples. (+) represents cDNA samples from the 
different treatments and (-) indicates no reverse transcriptase controls to confirm that no genomic 
DNA was present.  
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3.3.4.1.2 Paclitaxel treatment and ER stress induction in LNCap cells 
 
LNCap cells were treated with paclitaxel for 24 or 72 hours. The results (Figures 3.11; 3.12) 
show that no amplification was observed in the ‘no reverse transcriptase’ controls showing 
that no genomic DNA contamination was present. Similar intensity of beta actin expression 
was seen in all samples showing equal loading of template except for the 40µM dose- which 
is likely due to the large amount of cell death that was observed in the wells treated with this 
dose leading to low mRNA yield. The results show there was no increase in expression 
levels of GRP-78 and XBP-1 as compared to untreated at both time points (24 hours, Figure 
3.24 or 72 hours, Figure 3.25). This shows there was no induction of ER-stress following 
paclitaxel treatment in these cells. 
 
 
 
Figure 3.11: Gel images of LNCap after treatment with paclitaxel for 24 hours.  
Samples include NTC (no template control), UT (untreated), and paclitaxel (16nM, 32nM, 100nM, 
1µM and 40µM) treated samples. (+) represents cDNA samples from the different treatments and (-) 
indicates no reverse transcriptase controls to confirm that no genomic DNA was present.  
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Figure 3.12: Gel images of LNCap after treatment with paclitaxel for 72 hours.  
Samples include NTC (no template control), UT (untreated), and paclitaxel (8nM, 16nM, 32nM, 64nM 
and 128 nM) treated samples. (+) represents cDNA samples from the different treatments and (-) 
indicates no reverse transcriptase controls to confirm that no genomic DNA was present.  
3.3.4.1.3 Paclitaxel treatment and ER stress induction in SK-MEL--28 cells 
 
In this experiment melanoma cells SK-MEL-28 were treated with doses of paclitaxel. The 
results (Figure 3.13) show that no amplification was observed in the ‘no reverse 
transcriptase’ controls showing no genomic DNA contamination was present, except for the 
128nM dose. Similar intensity of beta actin expression was seen in all samples showing 
equal loading of template. The results (Figure 3.13) showed there was no increase in 
expression levels of GRP-78 or XBP-1(S). Again, it shows there was no induction of ER-
stress.  
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Figure 3.13: Gel images of SK-MEL-28 after treatment with paclitaxel for 72 hours.  
Samples include NTC (no template control), UT (untreated), and paclitaxel (8nM, 16nM, 32nM, 64nM 
and 128 nM) treated samples. (+) represents cDNA samples from the different treatments and (-) 
indicates no reverse transcriptase controls to confirm that no genomic DNA was present.  
 
These results do not indicate that paclitaxel induced ER stress in these cell lines. I also 
examined the expression of GRP78 and XBP-1(S) in HCT116 cells (appendices S9.1) but 
results again showed no change in expression following paclitaxel treatment and indicate 
that these lines are not a suitable working model where I can see induction of ER stress.  
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3.3.5 Discussion 
3.3.5.1 ER stress inhibition in ovarian and colorectal cancer cells (in vitro) 
Paclitaxel is an anti-mitotic drug that binds to microtubules and stabilises them which leads 
to mitotic cell cycle arrest (Bhalla et al., 1993). How binding of paclitaxel with microtubules 
and stabilizing them leads to initiation of downstream mechanisms causing apoptosis is not 
fully understood but research in the signalling molecules activated by paclitaxel show that 
there are multiple mechanisms which could be responsible for apoptosis (Wang et al., 2000). 
In my study, I hypothesize that cell death induced by paclitaxel is due to ER stress.  
3.3.5.1.1 ER stress inhibition via PERK  
 
PERK activates and phosphorylates eIF2α resulting in translation attenuation and enhancing 
the translation of ATF4 (a transcription factor) which induces expression of UPR target 
genes. The hypothesis behind these experiments was, paclitaxel kills the cells by activation 
of the PERK pathway of ER-stress.  
The results showed paclitaxel reduced cell numbers as compared to untreated cells, but 
salubrinal (PERK inhibitor) did not protect the cell death caused by paclitaxel. This shows 
that the inhibitor for PERK is not working or that the way paclitaxel is killing the cells is not 
due to PERK activation. However, this could be investigated by repeating salubrinal 
treatment of cells, and using some of the cells in SRB cell survival assay to show that there 
is still no effect on survival, and using the rest to extract protein and measure phospho-eIF2a 
levels to see whether salubrinal had stopped PERK working or not? (If it is working it should 
affect the amount of phospho-eIF2a present). Previous studies have shown that paclitaxel 
induced ER stress mediated cell death in cancer cells. A study by Liao et al. (2008) showed 
that when leukemic U937 cells were treated with paclitaxel for 3-6 hours, it activated PERK 
pathway which was observed as increased expression of GADD34 and ATF4 mRNA. This 
study also showed that after 6-12 hours of treatment, there was increased expression of 
CHOP mRNA. ATF4, CHOP and GADD34 are all targets of PERK that have been linked to 
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ER-stress induced apoptosis. But in my experiments inhibiting PERK did not affect cell 
death. There is some resemblance between my results and a study by Drexler, (2009). This 
study showed that apart from the protective role of salubrinal, it can also work as pro-
apoptotic in leukemic cells. In this study K562 (chronic myeloid leukaemia) cells were treated 
with proteasome inhibitor (PSI), histone deacetylase inhibitor VPA and salubrinal either 
alone or in combination with each other. PSI induces ER stress and VPA protects from 
transcriptional repression in leukemic cells. The results showed that salubrinal did not 
reduce the cytotoxic effects of PSI and PSI+VPA but instead stimulated apoptosis. These 
findings of Drexler et al., resemble to my results (Figure 3.5 and 3.9) where salubrinal 
combined with paclitaxel did not reduce the toxicity of paclitaxel but instead showed more 
reduction in cell numbers as compared to paclitaxel only treatment. Drexler et al. showed 
that Salubrinal and VPA alone were not toxic to the cells; however, in my results (Figure 3.5 
and 3.9) salubrinal itself showed toxicity and showed reduced cell survival as compared to 
untreated or DMSO treated cells. Further analysis by Drexler et al. showed that the 
enhanced cell death due to combination of salubrinal with other two inhibitors was due to 
continuous synthesis of nascent proteins and this was confirmed by using translational 
inhibitor CHX. The results of (Drexler, 2009) are in agreement with another study by (Bastola 
et al., 2016) where VCP inhibitors were used alone or in combination with salubrinal in 
ovarian cancer cells. Valosin containing protein (VCP) also known as p97 AAA-ATPase was 
found to be a necessary gene in ovarian cancer cells as compare to non-ovarian cancer 
cells. VCP is associated with ERAD, cell cycle and autophagy. DBeQ, CB-5083 and ML240 
were used as inhibitors of VCP.  The findings of this study showed the inhibitors of VCP 
reduced viability of cells, caused G1 cell cycle arrest, induced cell death by apoptosis 
(Annexin V assay and DAPI staining) and triggered UPR (confirmed by using tunicamycin as 
positive control). Consistent with the findings of (Drexler, 2009) in leukemic cells, findings of 
(Bastola et al., 2016) showed that when ovarian cancer cells (OVCAR10, SKOV3, OVSAHO, 
OVCAR8, OVCAR5 and RMG1) were treated with a combination of salubrinal and VCP 
inhibitors it increased cytotoxicity at 8 hours and 72 hours. This was due to synergistic effect 
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of salubrinal and VCP inhibitors. The fact that salubrinal can work as pro-apoptotic was also 
confirmed by another study of (Koizumi et al., 2012) which showed that in SW1353 
(chondrosarcoma cells) salubrinal enhanced radiation induced cell death. Another study by 
(Teng et al., 2014) showed that salubrinal in combination with TRAIL (Tumour necrosis 
factor related apoptosis inducing ligand) enhanced the expression of Bim (a CHOP regulated 
pro-apoptotic protein). 
I also used tunicamycin (an established ER stress inducer) as a positive control for ER 
stress. Tunicamycin works by inhibiting the first step of N-linked glycosylation of proteins via 
DPAGT1 resulting in aggregation of misfolded proteins leading to UPR (Keller et al., 1979; 
Brandish et al., 1996). In the colorectal cancer cells, the results of tunicamycin are like 
paclitaxel results. The combination of tunicamycin and salubrinal showed more reduction in 
cell numbers as compared to tunicamycin only. This is consistent with the findings of 
Drexler, (2009) and Bastola et al. (2016) above.   Surprisingly in my results in the ovarian 
cancer cell lines tunicamycin did not show any significant reduction in cell numbers, raising 
the possibility that it was not inducing ER stress. My results in these cells were opposite to a 
study by Long at al., (2005) which show that when PC12 cells were treated with a range of 
doses of tunicamycin for 37 hours, it showed ER stress induced apoptosis and salubrinal 
inhibited the ER stress mediated apoptosis induced by tunicamycin is a dose dependent 
manner. In this study when salubrinal was converted into a bio-tinylated derivative by 
addition of a trichloro-methyl group, it enhanced the activity of salubrinal. The results of this 
study were consistent to another study by Boyce et al., (2005) which showed that when 
PC12 cells were treated with tunicamycin it induced ER stress and salubrinal protected the 
cells from apoptosis up to 36 hours. This study also confirmed that salubrinal induces eIF2α 
phosphorylation in dose dependent manner in PC12 cells and when a derivate of salubrinal 
did not protect cells from apoptosis, it was found it did not induce phosphorylation of eIF2α. 
Another reason why ovarian cancer cells in my results did not respond to tunicamycin could 
be due to an issue with the uptake of the tunicamycin. In a study by Reiling et al., (2011) it 
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was shown that MFSD2A (a member of facilitator super family of proteins) is required for the 
uptake of tunicamycin into the cells. MFSD2A is located on the plasma membrane and 
knock down of MFSD2A by siRNA or gene depletion showed that it induced tunicamycin 
resistance and it’s over expression enhanced the sensitivity towards accumulation of 
tunicamycin in the cells. Cancer cells are prone to mutations and may be in the ovarian 
cancer cells in my study MFSD2A did not function properly and it affected the uptake of 
tunicamycin into the cells. 
My results of ovarian cancer cells also show similarity to a study by Gazit et al., (1999) which 
showed that MCF-7 breast cancer cell lines showed resistance towards tunicamycin but not 
to thapsigargin. Interestingly, another study by McCormack et al., (1997) showed that mouse 
lymphoid cells showed resistance towards thapsigargin but responded to tunicamycin by 
inducing transcription. This shows depending upon the genetic background some cancer 
cells may respond to ER stress and some may not. This shows that induction of ER stress 
can show contradictory consequences in different cancer cells.  
3.3.5.1.2 ER stress inhibition via Caspase -12 and -4  
 
Caspase12 and caspase 4 are involved in ER stress induced apoptosis (Nakagawa et al., 
2000; Hitomi et al., 2004). So far, the presence of functional caspase-12 in humans is 
controversial and caspase-4 is considered as its alternative in humans. The results of 
Caspase-4 inhibitor (Z-YVAD-FMK) showed that paclitaxel alone and combined with 
caspase-4 inhibitor did not show cell death in HCT116 isogenic cell lines excluding HCT116-
p21null which showed 20% cell death as compared to untreated, but caspase-4 inhibitor did 
not reverse it. Similarly, in the caspase-12 inhibitor experiments, paclitaxel showed little 
reduction in cell numbers (10-15%) as compared to untreated and caspase-12 inhibitor did 
not reverse it. It has been shown by many studies that paclitaxel causes cell death due to its 
cytotoxicity (Bhalla et al., 1993; Wang et al., 2000) but it is not evident in my results, and 
likely suggests a problem with the drug solution used.  
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However, tunicamycin showed reduction in cell numbers in both experiments of caspase-12 
and caspase-4 inhibitor treatments. In both experiments tunicamycin showed about 40-50% 
reduction in cell numbers as compared to untreated cells, and combination of caspase-4 
inhibitor or caspase-12 inhibitor with tunicamycin did not protect the cells from ER stress in 
all HCT116 isogenic cell lines apart from p21-null where it showed a minimal, but not 
statistically significant, reversal of tunicamycin effect.  
In these experiments caspase-12 and caspase-4 inhibitors were used to block their 
functioning and protect the cells from ER stress induced apoptosis, but it did not reverse the 
effects of tunicamycin. Previous studies suggest that human caspase-4 and mouse caspase-
12 respond to ER stress by inducing apoptosis and cell lacking the expression of caspase-
12 and caspase-4 were not fully protected from ER stress (Nakagawa et al., 2000; Hitomi et 
al., 2004). Contrary to this study, (Obeng and Boise, 2005) showed that when murine cells 
FL5.12 and human cells U266, lacking caspase-4 and caspase-12, when treated with ER 
stress inducing agents such as tunicamycin, thapsigargin or brefeldin-A, showed induction of 
ER stress, and Bcl-xL expression in both cell lines inhibited apoptosis induced by ER stress 
inducing agents. This study also showed that cell death induced by tunicamycin was due to 
caspase-dependent necrosis and in human myeloma cells; caspase-4 activity is not induced 
by tunicamycin. However, other studies, e.g. (Kalai et al., 2003), show that caspase-12 
expression is more restricted in murine organs and cells, suggesting there are some other 
mechanisms of ER stress present in the cells. Tunicamycin has showed reduction of cell 
numbers in my experiments but caspase-12 and -4 inhibitors did not reverse it and this could 
be because cell death by tunicamycin may not involve caspase-12 and caspase-4 and so 
the inhibitors of these two caspases did not reverse tunicamycin effects, although it is also 
possible that the inhibitors did not effectively inhibit caspase function in these experiments.  
 
 
 
 
 
123 
 
3.3.5.1.3 ER stress inhibition via JNK in colorectal cancer cells 
 
JNK is another arm of ER stress induced apoptosis. SP600125 is an anthrapyrazolone 
inhibitor of JNK that competes with ATP to inhibit the phosphorylation of c-Jun. In my results 
paclitaxel showed reduction in cell numbers in all HCT116 isogenic cells and only HCT116-
baxnull showed less reduction in cells numbers as compared to other three cell lines. The 
involvement of JNK signalling pathway in paclitaxel induced cell death was verified by using 
JNK inhibitor SP600125. Results show JNK did not reverse the effect of paclitaxel. 
Previously it has been shown by many studies that paclitaxel activates JNK in ovarian 
cancer and some other types of cancers and paclitaxel induced cell death is due to 
activation of JNK (Kolomeichuk et al., 2008; Lee at al., 1998; Selimovic et al., 2008; Sunters 
et al., 2006; Wang et al., 1999). Again, these results could indicate that paclitaxel response 
does not require JNK activity, or that the inhibitor was not effective at blocking JNK function 
in these experiments.  
However, not all studies have shown JNK to enhance paclitaxel induced cell death. In a 
study by Seino et al., (2016) the role of basal JNK activity towards sensitivity/resistance to 
paclitaxel was examined. Ovarian cancer cells were treated for 3 days with SP600125 to 
specifically inhibit the basal JNK activity ensuring there will be no interference of basal JNK 
with paclitaxel induced activation of JNK. The results showed that prior treatment with 
SP600125 followed by paclitaxel significantly enhanced the cell death as compared to 
combined SP600125 and paclitaxel treatment, suggesting inhibition of basal JNK activity 
may increase the sensitivity of ovarian cancer cells to paclitaxel. These results agree with 
my results of combined treatment with paclitaxel and SP600125 in HCT116 wild-type cells 
and HCT116-baxnull cells. In my experiments, I treated my cells with SP600125, one hour 
prior to paclitaxel treatment and the results in these lines showed an enhanced reduction in 
cell numbers.  
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In the other two cells lines HCT116-p53null and HCT116-p21null cells, paclitaxel killed cells 
but SP600125 showed very little effect on this response. 
In the same experiment tunicamycin treatment showed reduction in cell numbers as 
compared to untreated, but SP600125 did not reverse its effects. As described earlier JNK is 
involved in ER stress induced apoptosis which has been explained by many studies such as 
a study by Urano et al., (2000), where it was reported that when AR42J cells (rat pancreatic 
acinar) were treated with ER stress inducing agents (tunicamycin, thapsigargin, dithiothreitol) 
it induced ER stress mediated apoptosis and C-Jun terminal kinase JNK was activated due 
to UPR. These findings are in agreement with another study by (Yoneda et al., 2001) where 
it was reported that JIK functions as regulator of JNK signalling during ER stress. When JIK 
was overexpressed, it enhanced the interaction between IRE1α and TRAF2 and JNK was 
activated by the influence of ER stress inducing agent tunicamycin. However, in my 
experiments combined treatment of tunicamycin and SP600125 showed no increasing of the 
cell numbers as compared to tunicamycin only treatment. It should be noted that although 
SP600125 is a JNK inhibitor and its function is to inhibit the pro-apoptotic activity of the JNK, 
but SP600125 itself can also become pro-apoptotic. It was shown in a study by Lu et al., 
(2010) that SP600125 synergistically enhanced DHA induced apoptosis in human lung 
adenocarcinoma cells (ASTC-a-1) by mitochondrial mediated cell death pathways. It has 
been shown previously that Dihydroartemisinin (DHA) can inhibit cancer cell growth by 
apoptosis. DHA mediates apoptosis through cell cycle arrest, activation of caspases and 
reduction of Bcl/bax expression etc. (Singh and Lai, 2004; Hou et al., 2008; Chen et al., 
2009). The results showed SP600125 alone did not affect the growth of the cells but when 
ASTC-a-1 cells were pre-treated with SP600125, it enhanced DHA induced apoptosis. Role 
of JNK was also examined and it was reported that JNK was neither activated nor involved 
in the apoptosis induced by SP600125 and DHA. Further result showed that 1-hour pre-
treatment with SP600125 enhanced the DHA induced apoptosis by translocation of Bax to 
mitochondria, release of cytochrome C and activation of caspase-9 and -3. Similarly, in my 
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results I pre-treated my cells with SP600125 for 1 hour and then mixed with the drug 
solutions, and this produced a small additional reduction in surviving cells compared to 
tunicamycin alone, though this was not significant. The ability of JNK to work as pro-
apoptotic or anti-apoptotic depends upon the cell types, type of death stimuli and activation 
of other signalling pathways (Jing and Anning, 2005). 
JNK inhibitor (SP600125) affects proliferation by inducing mitotic arrest at G2/M phase and 
apoptosis in many human cancer cell lines such as breast cancer, prostate cancer, multiple 
myeloma and erythroleukemia (Hideshima et al., 2003; Jacobs-Helber and Sawyer, 
2003; Du et al., 2004; Mingo-Sion et al., 2004). In my experiments, treatments of HCt116 
isogenic cells with SP600125 alone showed 20% reduction is cell numbers in HCT116-
p53null and HCT116-baxnull. HCT116 and HCT116-p21null cells treated with SP600125 
showed 30% and 42% reduction in cell survival as compared to untreated. Although 
previous studies and manufacturing companies suggest SP600125 is not toxic to cell, but 
my results show it is somehow having some negative effect on cell numbers. A study by 
(Jemaa et al., 2012) show the cytotoxic effects of SP600125 on HCT116 cells and p53-
deficient (TP53−/−) HCT116 cells. The results showed that SP600125 induced 
polyploidization and cell death in p53 deficient cells by targeting MPS1 (mitotic kinase) as 
compared to wild type HCT116 cells. This is contrary to my results where HCT116 wild-type 
(30%) showed more reduction in cell numbers as compared to HCT116-p53null (20%). 
Another study by (Mili et al., 2016) showed the time dependent and dose dependent effects 
of SP600125 on HeLa cells for 24, 48 and 72 hours. The results of this study showed that 
various doses of SP600125 (10μM, 15μM and 20μM) induced a significant G2/M arrest of 
the cell cycle at 48 hours by enhanced phosphorylation of histone H3 and endoreduplication. 
SP600125 also induced delayed apoptosis due to Bcl-2 expression along with activation of 
caspase-3 and PARP cleavage. The findings of this study are similar to my results where 
SP600125 showed reduction in cell numbers depending upon the cell type possibly due to 
mitotic arrest or apoptosis. 
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3.3.5.1.4 Role of p53 pathway in paclitaxel response 
 
I used four HCT116 isogenic cell lines. HCT116 cells were wild type and mutant HCT116-
p53null, HCT116-p21null and HCT116-baxnull cells lack different components of the p53 
pathway - p53, p21 and Bax respectively. The reason for using these mutant cell lines was 
to examine if they show different response to paclitaxel induced cell death as compared to 
wild type HCT116. HCT116 isogenic cell lines lacking p53, p21 and Bax did not show any 
prominent difference in paclitaxel and tunicamycin response compared with wild type 
HCT116. All four cell lines showed almost similar reduction in cell numbers when treated 
with paclitaxel or tunicamycin. Similarly, the response of inhibitors (salubrinal, JNK-inhibitor, 
Caspase-4 inhibitor and Caspase-12 inhibitor) did not show any difference in their inhibitory 
activity in p53-null, p21-null and Bax-null cells line compared to HCT116, providing no 
evidence for the p53 pathway in paclitaxel response. Previous studies suggest involvement 
of p53, p21 and Bax in response to paclitaxel/ER stress. Loss of normal p53 in patients 
sensitizes them to paclitaxel (Wahl et al., 1996; Vikhanskaya et al., 1998). Approximately 
60% of human cancers exhibit p53 mutations (Wang and Wang, 1996). Low expression of 
p53 enhances cells progression to G2/M arrest leading to mitotic arrest (Wahl et al., 1996). 
Another study by Barboule et al., (1997) shows the relevance of p21 in MCF-7 cancer cells. 
This study shows that for paclitaxel induced mitotic arrest, p21 is not needed but it helps 
cells in exiting from mitotic arrest. Bax is a pro-apoptotic member of Bcl-2 family of proteins. 
This family of proteins are also involved in paclitaxel induced apoptosis (Strobel et al., 1996; 
Strobel et al., 1998). Although literature suggest involvement of the cell cycle regulating 
proteins p53, p21 and mitochondrial apoptotic protein Bax in response to paclitaxel, in my 
experiments all four HCT116 isogenic cell lines showed similar results.  
The results in all HCT116 isogenic cells show that paclitaxel treatment showed reduction in 
cell numbers as compared to untreated. Combined treatment of paclitaxel and salubrinal did 
not reverse the effects of paclitaxel and instead showed more reduction in cell numbers as 
compared to paclitaxel only treatment.  
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3.3.5.1.5 ER stress inhibition in WWOX transfected ovarian cancer cells 
 
My results of ER stress inhibition in A2780, SKOV3 and HCT116 isogenic cell lines did not 
show any evidence of reversal of ER stress, and we were concerned that these cell lines 
might not be suitable for examining the ER-stress related response to paclitaxel.  
Previous work within Dr Paige’s group (unpublished data) has shown induction of ER-stress 
due to paclitaxel treatment in PEO1 cell lines. So, the purpose of doing these experiments in 
PEO1 cells was to see if I can repeat those results again. Dr Paige’s group previously 
showed that WWOX transfection into WWOX-null ovarian cancer cells, abolished in-vivo 
tumorigenicity due to alteration of integrin α3-mediated interactions between cancer cells 
and extracellular matrix (ECM), without any associated changes in in-vitro growth nor 
baseline or cisplatin induced apoptosis rates (Gourley et al., 2009). Recently, Dr Paige’s 
group (unpublished data) showed that WWOX induces apoptosis following exposure or cells 
to paclitaxel and not cisplatin, and these effects were due to ER stress but not anti-mitotic 
action of paclitaxel. These results showed that paclitaxel triggered ER stress in ovarian 
cancer cells and when cells transfected with WWOX were treated with tunicamycin (an 
inducer of ER stress) they also showed decreased cell survival compared to vector 
transfected controls. The data also showed that this induction of ER stress was unaltered by 
WWOX but WWOX re-expression caused a significant shift towards an apoptotic response 
to ER stress, which can be reversed by WWOX siRNA. The key findings of this unpublished 
data were WWOX tumour suppressor sensitizes ovarian cancer cells to paclitaxel via ER 
stress induced apoptosis.   
These findings were the reason I used WWOX and vector transfected PEO1 cells because 
WWOX overexpression can cause a significant shift towards an apoptotic response to ER 
stress. My results of PEO1-H8 showed reduction in cell numbers in paclitaxel and 
tunicamycin treated cells as compared to untreated but again salubrinal did not reverse the 
effect of paclitaxel and tunicamycin.  In case of PEO1-FP2 paclitaxel showed reduction in 
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cell numbers as compared to untreated cells, which again were not reversed by salubrinal. 
Curiously, however, there was no obvious increase in paclitaxel response in the WWOX-
transfected cells compared to the vector transfected controls, and it is not clear why this 
might be. Genetic analysis of these clones may be required to ensure that the frozen lines 
have been correctly labelled.  
The results from the in vitro studies of ovarian and caner lines failed to show any evidence of 
induction of ER stress. Although, in vitro studies showed reduction in cell number after 
treatment with paclitaxel and tunicamycin but there was no evidence suggesting it was due 
to ER stress. Whilst it would be important to confirm that the inhibitor drugs have effectively 
blocked their target proteins, we had grown more and more concerned that the cell lines 
used were not a suitable model for investigating the cytoprotective role of ER-stress 
inhibition. To identify a suitable model, additional cell lines were screened by RT-PCR for 
evidence of ER-stress induction following paclitaxel treatment. For this purpose, the ER 
stress markers used in this study were GRP-78 and XBP-1(S).  
3.3.5.2 Examining the effects of paclitaxel on ER stress markers (GRP-78 and XBP-1) 
 
My results show the gene expression of ER stress markers GRP-78 and XBP-1(S) in 
prostate cancer cells PC3 after 72 hours of paclitaxel treatment. There was a slight increase 
in the expression of GRP-78 which was dose dependent but there was no increase in 
spliced expression of XBP-1(S). Increased expression of GRP-78 in these results was an 
indication of generation of ER stress but when this experiment was repeated three times, 
this data was not reproducible. Similarly, there was no sign of ER-stress induction following 
paclitaxel treatment in LNCap or SK-MEL-28 cells. I selected GRP-78 and XBP-1(S) 
because several studies suggest that paclitaxel enhance the expression of both of these ER 
stress markers. For example, in the study by Mhaidat et al., (2011) it was showed that when 
colorectal cancer cells SW480 were treated with 40µM dose of paclitaxel it showed an 
increased protein expression of GRP-78 which was time dependent. Tunicamycin treatment 
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was used as positive control for ER stress and it also showed a timely increase in protein 
expression of GRP-78 after paclitaxel treatment. Next in the same study, GRP-78 
expression was knocked down with siRNA and it sensitized SW480 cells to paclitaxel 
induced apoptosis. My results are contrary to these results of (Mhaidat et al., 2011). I also 
used 40µM of paclitaxel for 24 hours (Figure 3.24) for LNCap cells, but it did not show any 
increase in the expression of GRP-78. Although it showed me enhanced expression of 
spliced XBP-1 but due to low mRNA yield, the concentration of cDNA of 40 µM samples was 
not equivalent to other samples and it can be seen by looking at the expression of B-actin 
which showed a thin band which was unequal as compared to the other samples. Also, this 
drug concentration was too strong for the cells because when observed under the 
microscope the confluence of the cells was very low and lots of dead cells were floating in 
the media. Another study using breast cancer cells (Wang et al., 2009) showed that 24 
hours’ treatment of paclitaxel and vinblastine (another chemotherapy drug) enhanced the 
protein expression of GRP-78 in three different breast cancer cell lines (ZR75-30, MCF-7 
and T47D). This increase in the protein expression of GRP-78 was dose dependent (0.1µl, 
0.5µl, 1µl, 2.5µl and 5µl) and time dependent (4-24 hours). In this study, further analysis of 
western blotting showed that, in MCF-7 cells paclitaxel and vinblastine induced the splicing 
of XBP-1, caspase-7 cleavage and phosphorylation of JNK and eIF2α. Again, the increase in 
all these ER stress proteins was dose and time dependent. Similar to the study of (Mhaidat 
et al., 2011), this study also showed that down regulation of GRP-78 by siRNA enhanced the 
sensitivity of breast cancer cells towards paclitaxel and vinblastine. So, these studies clearly 
show paclitaxel enhances GRP-78 and XBP-1 protein expression.  
3.4 Conclusion 
It is unclear why I could not find evidence of ER-stress activation following paclitaxel 
treatment in this broad range of cancer cell lines and different tumour types used. Further 
work is clearly needed to examine this and to explore the role of ER-stress in paclitaxel 
response. However, because of the lack of suitable model cell line for this work it was 
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decided to stop the in vitro investigation of paclitaxel response, and instead look for 
supportive evidence in clinical patient samples (see Chapter 4). 
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Chapter 4: Clinical relevance of ER stress and WWOX tumour suppressor 
4.1 Introduction 
In chapter 3, I have showed in vitro investigation of ER stress pathway in response to 
paclitaxel in various cancer cell lines. The studies (relative cell survival & gene expression) 
in chapter 3 did not demonstrate evidence linking ER stress pathway to paclitaxel chemo 
response, therefore I did not pursue that further. Although I could not see evidence of 
paclitaxel induced ER stress response in my experiments, but there are many studies that 
show paclitaxel induced ER stress response in cancer cells, such as a study by Wang et al., 
(2009) showed that taxol induced upregulation of GRP-78 and some other components of 
ER stress response in breast cancer cells and inhibition of GRP-78 sensitized breast cancer 
cells to paclitaxel induced apoptosis. Another study by Mhaidat et al., (2011) showed that 
paclitaxel induce activation of GRP-78 and when GRP-78 is inhibited, it sensitized colorectal 
cancer cells to paclitaxel induced apoptosis. Also, I have unpublished data from another 
study (Janczar et al.,) that suggests that WWOX enhances paclitaxel induced apoptosis by 
altering the ER-stress caused by paclitaxel into an apoptotic (rather than cytoprotective) 
outcome. Normal epithelial ovarian cells express WWOX but its expression is down 
regulated in ovarian tumours (Gourley et al., 2005). Loss of WWOX expression in linked with 
increased tumorigenesis and poor prognosis. 30% of ovarian carcinomas show loss of 
WWOX expression (Nunez et al., 2005). 
4.1.1 Immunohistochemical staining (IHC) Analysis 
IHC is a technique where monoclonal or polyclonal antibodies are used to determine the 
tissue distribution of an antigen of interest. It is widely used for diagnosis of cancers. The 
tumour tissues used for the study were from the patients who had chemotherapy and 
surgery at Hammersmith Hospital. Tumour samples are taken and preserved in paraffin. IHC 
study was done by Dr Mona El-Bahrawy and the anonymised patients’ clinical data was 
provided by Dr Katherine Costello and Ms Nona Rama. The study was done according to 
approved ethics of Imperial College, London.  
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4.1.2 TCGA Analysis 
There are nearly 200 different forms of cancer and many subtypes which make this disease 
very complex. Each type of cancer has different molecular profile and need specific 
treatment depending upon its type and sub-stage (Hanahan and Weinberg, 2000). Each 
cancer type has different epigenetic changes, somatic mutations, copy number variations 
and altered gene expressions. Understanding of all these genetic aberrations is very 
important for the treatment of cancer and to plan strategies about how to improve the 
therapeutics and better diagnostics (Stratton et al., 2009; Lengauer et al., 1998).  
The Cancer Genome Atlas (TCGA) is a collaboration between the National Cancer Institute 
(NCI) and National Human Genome Research institute (NHGRI). In 2005 TCGA was 
launched as a public funded project to analyse the genomic data from high quality tumour 
sample through large scale genome sequencing and making it available on TCGA Data 
Portal. The data portal provides information about clinical information of patients that 
participated in the programme, metadata about the samples collected from patients, 
histopathology of samples and molecular information collected from samples such as; 
mRNA/miRNA expression, protein expression, copy number, etc). In addition to tumour 
samples, TCGA also included high quality non-tumour samples from the participants and 
analysed the germ line DNA to find the abnormalities in tumour samples compared with the 
normal samples to understand the oncogenic process. Comprehensive multi-dimensional 
maps of 33 types of cancer showing important genomic changes are available on TCGA 
website (The Cancer Genome Atlas, 2017).  The information on TCGA website is available 
to public and researchers around the world. The findings can help for improved diagnosis, 
treatment and the measures to prevent cancer.   
4.1.3 Experimental Approach 
In this chapter I have looked at clinical samples to see whether I can find clinical evidence to 
support that paclitaxel response involves the ER stress pathway. The aims are (i) Does 
WWOX correlate with patient survival? (looking at PFS and OS. Looking at WWOX mRNA 
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and protein), (ii) Does GRP-78 correlate with patient survival? (looking at PFS and OS. 
Looking at WWOX mRNA and protein), and (iii) Does WWOX only affect patient survival in 
patients with low expression of the ER-stress marker GRP-78 (i.e. in patients without 
inherent activation of ER-stress). I have two approaches- analysing RNA expression in 
ovarian and colorectal cancers that are part of the TCGA study and analysing protein 
expression in ovarian cancers by IHC in collaboration with Dr Mona El-Bahrawy. IHC scoring 
data of ovarian cancer patients was provided to me by Dr Mona El-Bahrawy (details in 
section 4.2.1). For TCGA study I downloaded RNA-seq expression FPKM (fragments per 
kilo base of transcripts per million mapped reads) files for ovarian and colorectal cancer 
patients. RNA sequencing is a recently developed high throughout technology for 
transcriptome total RNA profiling which uses deep sequencing technologies. As compared to 
other methods, RNAseq can measure levels of transcripts and their isoforms very precisely. 
By using RNAseq, identification and quantification of rare and common transcripts, isoforms, 
novel transcripts, gene fusions and non-coding RNAs can be done swiftly in large samples 
(Wang et al., 2009). From the downloaded FPKM files, I extracted the required RNA 
expression information of WWOX and GRP-78 and used it for Kaplan Meier survival 
analysis.  
4.2 Results 
4.2.1 Immunohistochemical staining (IHC) of ovarian cancer tissue samples for 
analysis of WWOX and GRP-78 expression 
From the anonymised tumour bank list provided by Ms Nona Rama, patients were selected. 
In order to keep the study based on homogeneous sample set of advanced ovarian cancer, I 
selected only tumours that were serous ovarian cancer, and were either stage 3 or 4 along 
with some stage 1c. Although 1c is officially considered as an early stage disease, the 
presence of cancer in lymph nodes indicate that this tumour actually has actually spread and 
often a 1c patient does have tumour cells that have spread into the peritoneum (i.e. stage 3) 
but are not yet detectable tumour masses. Also, I selected only those tumours that had been 
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treated using carboplatin and taxol. I am interested in the taxol response, but taxol is almost 
never given alone and so patients treated with carbo-taxol are the best I could get. I 
identified 50 samples for use in this study and was provided with anonymised overall and 
progression free survival data for these. From total of 50 patients, 46 had undergone carbo-
taxol treatment while the other 4 also had treatment but it’s not known. There were 36 stage 
3 and 12 stage 4 patients. 1 patient was stage 1c and 1 patient with unknown stage. Table 
4.1 show the summary of patients’ clinical data.  
 
Table 4.1: Summary of patient clinical data 
 
Number of patients 50 
Treatment 
Carbo-taxol 
Not Known 
 
46 (92%) 
4 (8%) 
Histology - Serous 50 (100%) 
FIGO Stage 
1c 
3 
4 
Not known 
 
1 (2%) 
36 (72%) 
12 (24%) 
1 (2%) 
Median PFS time (±SD) 1.61 years 
Number of relapsed patients 43 (86%) 
Median OS time (±SD) 3.2 years 
 
PFS = progression free survival, OS = overall survival, SD = standard deviation 
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4.2.1.1 IHC results in ovarian cancer 
 
IHC of the ovarian cancer patients’ tissue samples was done by Dr Mona El-Bahrawy and 
the scoring data of WWOX and GRP-78 staining was provided to me. From the total of 50 
cases, 17 cases showed weak cytoplasmic WWOX staining, 29 cases showed moderate 
cytoplasmic WWOX staining and 4 cases showed strong cytoplasmic WWOX staining. For 
GRP-78, there were 26 weak cytoplasmic stained cases and 24 moderate cytoplasmic 
cases. However, some tumours showed some degree of on nuclear WWOX staining as well 
as shown in table 4.2. 
 
Table 4.2: IHC results in ovarian cancer cells 
 
 
Cytoplasmic WWOX staining 
Weak 
Moderate 
Strong 
 
 
 
17 (34%) 
29 (58%) 
4 (8%) 
 
Nuclear WWOX staining 
<50% of tumour cells 
>50% of tumour cells 
 
 
 
 
7 (14%) 
3 (6%) 
 
Cytoplasmic GRP78 staining 
Weak 
Moderate 
 
 
 
 
26 (52%) 
24 (48%) 
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4.2.1.2 Analysis of GRP-78 expression by IHC and its effects on overall survival time 
Table 4.3 below shows that there are 24 patients in high GRP-78 group and 26 patients in 
low GRP-78 group. Patients with moderate cytoplasmic GRP78 IHC staining were classified 
as high GRP-78 group, whereas patients with weak cytoplasmic IHC staining of GRP-78 
were classified as low GRP-78 group. In high GRP-78 group 8 patients had died and 16 
patients (66.7%) were still alive, whereas in low GRP-78 13 patients had died and 13 
patients (50%) were still alive. Figure 4.1 show the graph showing Kaplan Meier survival 
curves for high and low GRP-78 groups. The vertical lines on blue and green survival curve 
represent cases which were censored. The blue curve represents better survival time in 
group of patients with high expression of GRP-78 compared to green curve which represents 
the group of patients with low GRP-78 expression. The p value (p=0.082) although not 
significant shows a trend towards significance (Table 4.4). 
 
Table 4.3:  Summary of patients in low and high GRP-78 groups 
Case Processing Summary 
GRP-78 Status Total N 
Dead 
Patients 
Patients still alive 
N Percent 
GRP-hi 24 8 16 66.7% 
GRP-low 26 13 13 50.0% 
Overall 50 21 29 58.0% 
     
 
 
Table 4.4: Log Rank comparison of high GRP-78 and low GRP-78 patient groups 
 
 
Overall Comparisons 
 Chi-Square df P value 
Log Rank (Mantel-Cox) 3.032 1 0.082 
 
 
(df) represents degree of freedom 
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Figure 4.1: Kaplan Meier curves of ovarian cancer patients showing overall survival. The 
blue curve represents patients with high GRP-78 expression and green curve represents 
patients with low GRP-78 expression. The vertical line in blue curve represents the censored 
observations.  
4.2.1.3 Analysis of WWOX expression by IHC and its effects on overall survival time 
 
Table 4.5 below shows that there are 33 patients in high WWOX group and 17 patients in 
low WWOX group. Patients with moderate and strong cytoplasmic WWOX IHC staining were 
classified as high WWOX group, whereas patients with weak cytoplasmic IHC staining of 
WWOX were classified as low WWOX group. In high WWOX group 14 patients had died and 
19 patients (57.6%) were still alive, whereas in low WWOX 7 patients had died and 10 
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patients (58.8%) were still alive. Figure 4.2 shows the Kaplan Meier survival curves for high 
and low WWOX groups. The results show both curves blue (high WWOX) and green (low 
WWOX) overlap each other and this show there was no effect of WWOX on overall survival 
time. Table 4.6 show (p=0.895) the survival difference between both curves was not 
significant. 
 
Table 4.5:  Summary of patients in low and high WWOX groups 
Case Processing Summary 
 WWOX Status Total N 
Dead 
Patients 
Patients still alive 
N Percent 
WWOX-hi 33 14 19 57.6% 
WWOX-low 17 7 10 58.8% 
Overall 50 21 29 58.0% 
 
 
Table 4.6: Log Rank comparison of high WWOX and low WWOX patient groups 
 
 
 
Overall Comparisons 
 Chi-Square df P value  
Log Rank (Mantel-Cox) 0.017 1 0.895 
 
(df) represents degree of freedom 
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Figure 4.2: Kaplan Meier curves of ovarian cancer patients showing overall survival. The 
blue curve represents patients with high WWOX expression and green curve represents 
patients with low WWOX expression. The vertical line in blue curve represents the censored 
observations. 
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4.2.1.4 Analysis of combined WWOX/GRP-78 expression by IHC and its effects on 
overall survival (OS) time 
Table 4.7 below shows that there were 19 patients for high-WWOX/high-GRP-78 and 12 
patients for low-WWOX/low-GRP-78 groups. Similarly, there were 14 patients for high-
WWOX/low-GRP-78 and 5 patients for low-WWOX/high-GRP-78 groups. For high-
WWOX/high-GRP-78 group 7 patients had died and 12 (63.2%) were still alive, whereas for 
high-WWOX/low-GRP-78 group 7 patients had died and 7 (50%) were still alive. Similarly, 
for low-WWOX/high-GRP-78 group 1 patient had died and 4 (80%) were still alive, whereas 
for low-WWOX/low-GRP-78 group 6 patients had died and 6 (50%) were still alive. Figure 
4.3 show the overall survival graph plotted by Kaplan Meier analysis showing curves for all 
four groups. All four groups are overlapping each other. The blue curve representing (high- 
WWOX/high-GRP-78) and yellow curve representing (low-WWOX/high-GRP-78) show better 
survival then purple (low-WWOX/low-GRP-78) and green curve (low-WWOX/high-GRP-78), 
reflecting the better survival seen in the high GRP-78 patients (shown in Figure 4.1). 
However, none of these differences reach significance (table 4.8, p=0.358) because of the 
small group size and the number of cases censored.   
 
Table 4.7:  Summary of patients in low or high WWOX or GRP-78 groups 
 
 
 
 
 
 
 
 
 
 
Case Processing Summary 
WWOX & GRP-78 Status Total N 
Dead 
Patients 
Patients still alive 
N Percent 
W-H/GR-H 19 7 12 63.2% 
W-H/GR-L 14 7 7 50.0% 
W-L/GR-H 5 1 4 80.0% 
W-L/GR-L 12 6 6 50.0% 
Overall 50 21 29 58.0% 
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Table 4.8: Log Rank comparison of high or low WWOX or GRP-78 patient groups 
 
 
 
 
 
 
(df) represents degree of freedom 
 
 
 
 
Figure 4.3: Kaplan Meier curves of ovarian cancer patients showing overall survival time. 
The curves blue, green, yellow and purple represents (high-WWOX/high-GRP-78), (high-
WWOX/low-GRP-78), (low-WWOX/high-GRP-78) and (low-WWOX/low-GRP-78) 
respectively. The vertical lines in both curve represents the censored observations. 
Overall Comparisons 
 Chi-Square df P value 
Log Rank (Mantel-Cox) 3.224 3 0.358 
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4.2.1.5 Analysis of GRP-78 expression by IHC and its effects on progression free 
survival (PFS) time 
Table 4.9 below shows that there are 24 patients in high GRP-78 group and 26 patients in 
low GRP-78 group. In high GRP-78 group 21 patients had relapsed and 3 (12.5%) patients 
were still disease-free, whereas in low GRP-78 group 22 patients had relapsed and 4 
patients (15.4%) were still disease-free. Figure 4.4 show the graph showing Kaplan Meier 
curves for high and low GRP-78 groups. Both blue (high GRP-78) and green (low GRP-78) 
curves are overlapping each other which show that there was no difference in terms of PFS 
within both groups. Table 4.10 show (p=0.829) there was no significant difference within 
both groups. 
Table 4.9:  Summary of patients in low and high GRP-78 groups 
 
 
 
 
 
 
Table 4.10: Log Rank comparison of low and high GRP-78 
 
 
 
 
(df) represents degree of freedom 
 
Case Processing Summary 
GRP-78 Status Total N 
Patients who 
have 
relapsed 
Disease free patients 
N Percent 
GRP-hi 24 21 3 12.5% 
GRP-low 26 22 4 15.4% 
Overall 50 43 7 14.0% 
Overall Comparisons 
 Chi-Square df P value 
Log Rank (Mantel-Cox) 0.047 1 0.829 
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Figure 4.4: Kaplan Meier curves of ovarian cancer patients showing PFS. The blue curve 
represents patients with high GRP-78 expression and green curve represents patients with 
low GRP-78 expression. The vertical line in blue curve represents the censored 
observations. 
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4.2.1.6 Analysis of WWOX expression by IHC and its effects on progression free 
survival (PFS) time 
Table 4.11 below shows that there are 33 patients in high WWOX group and 17 patients in 
low WWOX group. In high WWOX group 26 patients had relapsed and 7 patients (21.2%) 
were still disease-free, whereas in low WWOX group all patients had relapsed. Figure 4.5 
show the graph showing Kaplan Meier curves for high and low WWOX groups. Blue curve 
representing high WWOX is overlapping green curve (low WWOX) from start to middle of the 
observation and then blue curve appears high showing better PFS. Although the difference 
is not significant (p=0.181, table 4.12) this may be due to small group sizes and the number 
of censored patients, and this data might indicate a trend towards significance.   
Table 4.11:  Summary of patients in low and high WWOX groups 
 
 
 
 
 
 
Table 4.12: Log Rank comparison of low and high WWOX 
 
 
 
 
(df) represents degree of freedom. 
Case Processing Summary 
WWOX Status Total N 
Patients who 
have 
relapsed 
Patients still alive 
N Percent 
WWOX-hi 33 26 7 21.2% 
WWOX-low 17 17 0 0.0% 
Overall 50 43 7 14.0% 
Overall Comparisons 
 Chi-Square df P value 
Log Rank (Mantel-Cox) 1.786 1 0.181 
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Figure 4.5: Kaplan Meier curves of ovarian cancer patients showing PFS. The blue curve 
represents patients with high WWOX expression and green curve represents patients with 
low WWOX expression. The vertical line in blue curve represents the censored observations. 
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4.2.1.7 Analysis of combined WWOX/GRP-78 expression by IHC and its effects on 
progression free survival (PFS) time 
Table 4.13 below shows that there were 19 patients for high-WWOX/high-GRP-78 and 12 
patients for low-WWOX/low-GRP-78 groups. Similarly, there were 14 patients for high-
WWOX/low-GRP-78 and 5 patients for low-WWOX/high-GRP-78 groups. For high-
WWOX/high-GRP-78 group 16 patients had relapsed and 3 (15.8%) were still disease-free, 
whereas for high-WWOX/low-GRP-78 group 10 patients had relapsed and 4 (28.6%) were 
still disease-free. For low-WWOX/high-GRP-78 group all 5 patients had relapsed, whereas 
for low-WWOX/low-GRP-78 group all 12 patients had relapsed. Figure 4.6 shows the 
progression free survival graph plotted by Kaplan Meier analysis. All four groups overlap 
each other and there is no significant difference (p=0.542) between all four groups as shown 
in table 4.14.  
 
Table 4.13:  Summary of patients in low or high WWOX or GRP-78 groups 
 
Case Processing Summary 
WWOX & GRP-78 Status Total N 
Patients who 
have 
relapsed 
Patients still disease 
free 
N Percent 
W-H/GR-H 19 16 3 15.8% 
W-H/GR-L 14 10 4 28.6% 
W-L/GR-H 5 5 0 0.0% 
W-L/GR-L 12 12 0 0.0% 
Overall 50 43 7 14.0% 
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Table 4.14: Log Rank comparison of high or low WWOX or GRP-78 patient groups 
 
 
 
 
 
 
(df) represents degree of freedom 
 
 
 
 
Figure 4.6: Kaplan Meier curves of ovarian cancer patients showing PFS. The curves blue, 
green, yellow and purple represents (high-WWOX/high-GRP-78), (high-WWOX/low-GRP-
78), (low-WWOX/high-GRP-78) and (low-WWOX/low-GRP-78) respectively. The vertical 
lines in both curve represents the censored observations. 
 
Overall Comparisons 
 Chi-Square df P value 
Log Rank (Mantel-Cox) 2.150 3 0.542 
 
 
148 
 
4.2.2 Analysis of RNA sequencing data of ovarian and colorectal cancer tumours  
In order to look for evidence that might support a link between ER-stress and chemo 
response, I have looked for correlations between patient survival data and the RNA 
sequencing data of ovarian and colorectal tumours downloaded from TCGA Data Portal. As 
for the analysis of the IHC data above, I have analysed expression of the WWOX gene, and 
the ER-stress biomarker GRP78. From the TCGA database, RNA sequencing data of the 
required genes was selected and combined with the patient survival data in Microsoft Excel 
and, using SPSS software, Kaplan Meier analysis was performed, and survival data was 
analysed.  
The downloaded RNA sequencing data from TCGA was from 376 ovarian cancer tumours 
(table 4.15, 4.16) and 388 colorectal cancer tumours (table 4.17). FPKM normalized RNAseq 
data was downloaded to allow direct comparison between the tumours. The cases were 
classified as high WWOX (higher than median WWOX expression) or low WWOX (median 
or lower WWOX expression), and high GRP78 (higher than median GRP78 expression) or 
low GRP78 (median or lower GRP78 expression). Kaplan Meier analysis and log rank test 
was used to examine the overall survival rate in the different groups to see if high or low 
expression shows any difference in terms of survival time. 
Table 4.15: Summary of ovarian cancer patient’s ethnicity (TCGA) 
Ethnicity Number of patients 
Asian 11 
Black 25 
White 326 
Native American 2 
Pacific Islander 1 
Unknown 10 
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Table 4.16: Summary of ovarian cancer patient’s clinical data (TCGA) 
 
 
Total number of patients 
 
376 
 
Number of Dead patients 
 
230 
 
Number of Alive patients 
 
146 
 
Median age of diagnosis 
 
59 years 
 
Minimum age of diagnosis 
 
30.5 years 
 
Maximum age of diagnosis 
 
87.6 years 
 
Median survival time 
 
2.8 years 
 
Minimum survival time  
 
0.02 years 
 
Maximum survival time 
 
15 years 
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Table 4.17: Summary of colorectal cancer patients’ clinical data (TCGA) 
 
Total number of patients 388 
Number of Dead patients 92 
Number of Alive patients 296 
Median age of diagnosis 69.3 years 
Minimum age of diagnosis 34.1 years 
Maximum age of diagnosis 90 years 
Male patients 207 
Female patients 181 
Median survival time 1.93 years 
Minimum survival time  0.01 year 
Maximum survival time 12.3 years 
Stage 1 69 
Stage 2 163 
Stage 3 114 
Stage 4 49 
Unknown stage 11 
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4.2.2.1 The effect of WWOX expression on overall survival (OS) time in ovarian cancer 
patients 
The effect of WWOX expression on overall survival time in 376 ovarian cancer patients was 
analysed by Kaplan Meier analysis. The table 4.18 below show the case processing 
summary of ovarian cancer patients. From the total 376 patients, there were 188 patients for 
both high and low WWOX expression groups and among them for both high and low WWOX 
group, 115 patients had died and 73 patients (38.8%) were still alive. Figure 4.7 show the 
graph showing Kaplan Meier curves for high and low WWOX groups. The blue curve 
representing high WWOX expression is overlapping green curve representing low WWOX in 
the start of analysis but in the middle and end the high WWOX expression curve separates 
from green and shows greater survival. However, there is no statistical difference between 
both groups as shown in table 4.19 (p=0.218).  
 
 
Table 4.18:  Summary of patients in low and high WWOX groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Case Processing Summary 
WWOX high/low Total N 
Dead 
Patients 
Patients still alive 
N Percent 
WWOX High 188 115 73 38.8% 
WWOX low 188 115 73 38.8% 
Overall 376 230 146 38.8% 
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Table 4.19: Log Rank comparison of high WWOX and low WWOX patient groups 
 
 
 
Overall Comparisons 
 Chi-Square df P value 
Log Rank (Mantel-Cox) 1.514 1 0.218 
 
(df) represents degree of freedom 
 
 
 
Figure 4.7: Kaplan Meier curves of ovarian cancer patients showing overall survival (OS) 
time. The blue curve represents patients with high WWOX expression and green curve 
represents patients with low WWOX expression. The vertical lines in both curve represents 
the censored observations. 
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4.2.2.2 The effect of GRP-78 expression on overall survival (OS) time in ovarian cancer 
patients 
Table 4.20 below shows that there were 188 patients each for both low and high GRP-78 
expression groups. For high GRP-78 group 119 patients had died and 69 patients (36.7%) 
were still alive. In low GRP-78 group 111 patients had died and 77 patients (41%) were still 
alive. Figure 4.8 shows the overall survival graph plotted by Kaplan Meier analysis showing 
curves for both high and low GRP-78 expressing groups. Both curves (blue for high GRP-78 
and green for low GRP-78) overlap each other for most part of the observation and show 
same trend. At the start of observation both groups show lot of events (deaths). The table 
4.21 below show P value (p=0.492) confirming there was no significant difference between 
both groups in terms of survival time.  
 
Table 4.20:  Summary of patients in low and high GRP-78 groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Case Processing Summary 
GRP-78 H/L Total N 
Dead 
Patients 
Patients still alive 
N Percent 
GRP High 188 119 69 36.7% 
GRP Low 188 111 77 41.0% 
Overall 376 230 146 38.8% 
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Table 4.21: Log Rank comparison of high GRP-78 and low GRP-78 patient groups 
 
 
 
 
 
 
(df) represents degree of freedom 
 
 
 
Figure 4.8: Kaplan Meier curves of ovarian cancer patients showing overall survival (OS) 
time. The blue curve represents patients with high GRP-78 expression and green curve 
represents patients with low GRP-78 expression. The vertical lines in both curve represents 
the censored observations. 
Overall Comparisons 
 Chi-Square df P value 
Log Rank (Mantel-Cox) 0.473 1 0.492 
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4.2.2.3 The effect of combined WWOX/GRP78 expression on overall survival (OS) time 
in ovarian cancer patients 
Table 4.22 below shows that there were 104 patients each for high-WWOX/high-GRP-78 
and low-WWOX/low-GRP-78 groups. Also, there were 84 patients each for high-WWOX/low-
GRP-78 and low-WWOX/high-GRP-78 groups. For high-WWOX/high-GRP-78 group 70 
patients had died and 34 (32.7%) were still alive, whereas for high-WWOX/low-GRP-78 
group 45 patients had died and 39 (46.4%) were still alive. Similarly, for low-WWOX/high-
GRP-78 group 49 patients had died and 35 (41.7%) were still alive, whereas for low-
WWOX/low-GRP-78 group 66 patients had died and 38 (36.5%) were still alive. Figure 4.9 
show the overall survival graph plotted by Kaplan Meier analysis showing curves for all four 
high or low WWOX or GRP-78 expressing groups. All four curves show lot of event (deaths) 
at the start of the observation. For most part of the observation all four curves overlapped 
each other. At the end of the observation blue (high-WWOX/high-GRP-78), green (high-
WWOX/low-GRP-78) and yellow curves (low-WWOX/high-GRP-78) were overlapping each 
other but appear to be higher compared with purple curve representing low-WWOX/low-
GRP-78. Graph shows there was no effect of high or low WWOX or GRP-78 on the survival 
time as show by the table 4.23 showing P value (p=0.142) which means no statistical 
significance.  
Table 4.22:  Summary of patients in low or high WWOX or GRP-78 groups 
 
 
 
 
 
 
 
 
 
Case Processing Summary 
WWOX/GRP78 Total N 
Dead 
Patients 
Patients still alive 
N Percent 
WH/GRh 104 70 34 32.7% 
WH/Grlo 84 45 39 46.4% 
WLo/GRh 84 49 35 41.7% 
WLo/Grlo 104 66 38 36.5% 
Overall 376 230 146 38.8% 
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Table 4.23: Log Rank comparison of low or high WWOX or GRP-78 patient groups 
 
Overall Comparisons 
 Chi-Square df P value 
Log Rank (Mantel-Cox) 5.436 3 0.142 
 
 
(df) represents degree of freedom 
 
 
Figure 4.9: Kaplan Meier curves of ovarian cancer patients showing overall survival (OS). 
The curves blue, green, yellow and purple represents (high-WWOX/high-GRP-78), (high-
WWOX/low-GRP-78), (low-WWOX/high-GRP-78) and (low-WWOX/low-GRP-78) 
respectively. The vertical lines in both curve represents the censored observations. 
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4.2.2.4 The effect of WWOX expression on overall survival (OS) time in colorectal 
cancer patients 
The effect of WWOX expression on overall survival time in 388 colorectal cancer patients 
was analysed by Kaplan Meier analysis. The table 4.24 below show the case processing 
summary of colorectal cancer patients. There are 195 patients for high WWOX expression 
and 193 patients for low WWOX expression group. For high WWOX group, 46 patients had 
died and 149 patients (76.4%) were still alive. For low WWOX group, 46 patients had died 
and 147 patients (76.2%) were still alive. Figure 4.10 show the graph showing Kaplan Meier 
curves for high and low WWOX expressing groups. The blue curve representing high 
WWOX expression is overlapping green curve representing low WWOX in the start of 
analysis and at the end, but high WWOX expression group appears high in the middle of the 
observation. However, this difference was not significant and does not represents a 
beneficial effect of WWOX for the patients in terms of overall survival because there is no 
statistical difference between both groups as shown in table 4.25 (p=0.856).  
 
Table 4.24:  Summary of patients in low and high WWOX groups 
 
Case Processing Summary 
WWOX STATUS Total N 
Dead 
Patients 
Patients still alive 
N Percent 
WWOX-high 195 46 149 76.4% 
WWOX-low 193 46 147 76.2% 
Overall 388 92 296 76.3% 
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Table 4.25: Log Rank comparison of low and high WWOX patient groups 
 
 
 
 
 
 
 
(df) represents degree of freedom 
 
 
Figure 4.10: Kaplan Meier curves of colorectal cancer patients showing overall survival (OS) 
time. The blue curve represents patients with high WWOX expression and green curve 
represents patients with low WWOX expression. The vertical lines in both curve represents 
the censored observations. 
Overall Comparisons 
 Chi-Square df P value 
Log Rank (Mantel-Cox) 0.033 1 0.856 
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4.2.2.5 The effect of GRP-78 expression on overall survival (OS) time in colorectal 
cancer patient 
Table 4.26 below shows that there are 195 patients for high GRP-78 and 193 patients for 
low GRP-78 expression groups. For high GRP-78 group 45 patients had died and 150 
patients (76.9%) were still alive. In low GRP-78 group 47 patients had died and 146 patients 
(75.6%) were still alive. Figure 4.11 show the overall survival graph plotted by Kaplan Meier 
analysis showing curves for both high and low GRP-78 expressing groups. The blue curve 
representing high GRP-78 appears high at the start of observation and at the end of 
observation but it overlaps green curve (low GRP-78) in the middle. High GRP-78 curve 
gives an impression of better survival but table 4.27 show (p=0.160) that it was not 
significant. This result suggests a possible trend for better survival associated with high 
GRP-78. 
 
Table 4.26:  Summary of patients in low and high GRP-78 groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Case Processing Summary 
GRP-78 status Total N 
Dead 
Patients 
Patients still alive 
N Percent 
GRP-high 195 45 150 76.9% 
GRP-low 193 47 146 75.6% 
Overall 388 92 296 76.3% 
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Table 4.27: Log Rank comparison of low and high GRP-78 patient groups 
 
 
 
 
 
 
(df) represents degree of freedom 
 
 
Figure 4.11: Kaplan Meier curves of colorectal cancer patients showing overall survival time. 
The blue curve represents patients with high GRP-78 expression and green curve 
represents patients with low GRP-78 expression. The vertical lines in both curve represents 
the censored observations. 
 
Overall Comparisons 
 Chi-Square df P value 
Log Rank (Mantel-Cox) 1.978 1 0.160 
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4.2.2.6 The effect of combined WWOX/GRP78 expression on overall survival (OS) time 
in colorectal cancer patients 
Table 4.28 below shows that there were 106 patients each for high-WWOX/low-GRP-78 and 
low-WWOX/high-GRP-78 groups. Also, there were 89 patients for high-WWOX/high-GRP-78 
and 87 patients for low-WWOX/low-GRP-78 groups. For high-WWOX/high-GRP-78 group 20 
patients had died and 69 (77.5%) were still alive, whereas for high-WWOX/low-GRP-78 
group 26 patients had died and 80 (75.5%) were still alive. Similarly, for low-WWOX/high-
GRP-78 group 25 patients had died and 81 (76.4%) were still alive, whereas for low-
WWOX/low-GRP-78 group 21 patients had died and 66 (75.9%) were still alive. Figure 4.12 
show the overall survival graph plotted by Kaplan Meier analysis showing curves for all four 
high or low WWOX or GRP-78 expressing groups. All four curves show lot of event (deaths) 
at the start of the observation. For most part of the observation blue (high-WWOX/high-GRP-
78), green (high-WWOX/low-GRP-78) and yellow curves (low-WWOX/high-GRP-78) overlap 
each and appear high compared with purple curve representing low-WWOX/low-GRP-78. 
Graph shows there was no effect of high or low WWOX or GRP-78 on the survival time as 
show by the table 4.29 showing P value (p=0.300) which means no statistical significance.  
 
Table 4.28:  Summary of patients in low or high WWOX or GRP-78 groups 
 
 
 
 
 
 
 
Case Processing Summary 
WWOX/GRP78 Total N 
Dead 
Patients 
Patients still alive 
N Percent 
WH/GR h 89 20 69 77.5% 
WH/GR lo 106 26 80 75.5% 
W Lo/GR h 106 25 81 76.4% 
W Lo/GR lo 87 21 66 75.9% 
Overall 388 92 296 76.3% 
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Table 4.29: Log Rank comparison of low or high WWOX or GRP-78 patient groups 
 
Overall Comparisons 
 Chi-Square df P value 
Log Rank (Mantel-Cox) 3.665 3 0.300 
 
(df) represents degree of freedom 
 
 
Figure 4.12: Kaplan Meier curves of colorectal cancer patients showing overall survival time. 
The curves blue, green, yellow and purple represents (high-WWOX/high-GRP-78), (high-
WWOX/low-GRP-78), (low-WWOX/high-GRP-78) and (low-WWOX/low-GRP-78) 
respectively. The vertical lines in both curve represents the censored observations. 
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4.3 Discussion 
4.3.1 Association of GRP-78 with OS or PFS 
Previous studies show that paclitaxel induces ER stress response in cancer cells (Mhaidat et 
al., 2009). GRP-78 is considered as marker of ER stress and regulates multiple arms of 
unfolded response. GRP-78 is transcriptionally regulated by a conserved ER stress 
response element in its promoter (Kim et al., 2008). Increased expression of GRP-78 has 
been observed in many cancers such as breast, ovarian, lung and prostate cancer (Lee et 
al., 2006; Pootrakul et al., 2006; Gazit et al., 1999). GRP-78 expression is also associated 
with cancer progression, metastasis, anti-apoptotic effects and drug resistance (Fu and Lee, 
2007; Lee, 2007). All these suggest there is a correlation between paclitaxel, ER stress and 
GRP-78. 
In the IHC study there were 50 patients, all stage III or IV and all had received taxol 
treatment. The high GRP-78 patients showed better survival time compared with low GRP-
78 group (p=0.08). Based on these findings it can be said that there is a possible correlation 
of GRP-78 protein expression with overall survival in ovarian cancer patients. In the few 
studies where correlation between expression of GRP-78 and over survival times have been 
observed, most show that low GRP-78 expression predicts longer overall survival compared 
to high GRP-78 expression. For example, Niu et al. (2015) reported that high protein 
expression of GRP-78 in pancreatic ductal adenocarcinoma showed significantly poor 
overall survival (p=0.0007) compared to low expression. This study also showed high GRP-
78 expression in tumour tissues compared with normal tissues suggesting it has a role in 
progression of cancer. In a study by Yu et al., (2016) IHC analysis of 89 NSCLC tumour 
samples showed high GRP-78 expression predicted shorter overall survival (p=0.043). Only 
one published study (Thornton et al., 2013) showed that high expression of GRP-78 predicts 
better overall survival. In this study, Stage II colorectal cancer patients who underwent only 
surgery, showed improved survival rate with high GRP-78 expression compared with low 
GRP-78 (p=0.032). However, stage III patients did not show any difference in terms of 
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overall survival between high and low GRP-78 groups. Interestingly stage III patients with 
high GRP-78 expression after undergoing 5-FU chemotherapy (vs non-chemotherapy) 
showed improved 5-year survival rate (52% vs 28%) compared to low GRP-78 expression 
patients (28% vs 32%). Also, stage III patients showed 7 months longer median survival in 
high GRP-78 group compared with low GRP-78. Unlike Thornton et al., in my study it is 
stage III cancer patients with high GRP-78 expression who show better overall survival not 
stage II. Thornton et al. further showed all patients (regardless of stage) who had 5-FU 
chemotherapy showed increased overall survival in patients with high GRP-78 compared 
with low GRP-78 group. Although my study is focused on taxol whose mechanism of action 
is different to 5-FU, this suggests the possibility of a common mechanism of GRP-78-
mediated chemo sensitization. In my study, even prior to taxol treatment, patients already 
have high GRP-78 showing that ER stress is inherently activated in these patients. This 
would suggest that it is playing a cytoprotective role (inducing chaperones and increasing 
the rate of protein processing) instead of apoptotic, and that the apoptotic response to 
prolonged ER-stress is being suppressed. Possibly, however, the further induction of ER-
stress upon taxol treatment may result in it shifting from being cytoprotective to apoptotic.  
Interestingly, GRP-78 expression correlates with overall survival but not progression free 
survival in my IHC study. A similar difference between association with OS and PFS is 
reported in the study of Ma et al., (2015) in which 163 peripheral blood samples from NSCLC 
were analysed for expression of GRP-78 and correlation between overall survival and 
relapse free survival was observed. In their study, Kaplan Meier analysis showed that high 
GRP-78 expression showed low overall survival time but, like my data, no correlation was 
seen between GRP-78 expression and relapse free survival time. It is not clear why GRP-78 
shows better survival in OS but not in PFS, and this question needs further investigation. 
I also observed the impact of expression of GRP-78 mRNA on clinical outcome of patients 
treated with paclitaxel in a publicly available RNAseq dataset of ovarian cancer patients 
(TCGA). There were 376 patients, and all received platinum plus taxane treatment. Kaplan 
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Meier analysis showed no correlation of GRP-78 with overall survival (p=0.492) in ovarian 
cancer patients, unlike the results of my IHC study of ovarian cancer.  Other studies have 
also suggested a link between GRP-78 mRNA expression and patient survival. For example, 
Mozos et al. (2011) showed that high GRP-78 mRNA expression in B-cell Lymphoma 
showed poor overall survival compared to low GRP-78 mRNA expression (p=0.048). A 
possible reason for the difference between the results of my TCGA and IHC study could be 
because of differences within these cohorts; however, both patient groups represent high 
stage ovarian serous cancer patients treated with platinum plus taxane therapy. Another 
possible factor that might explain the difference between these two studies is that IHC is 
protein analysis while TCGA is mRNA analysis. Proteins are responsible for cellular 
mechanisms, and although mRNA translates into protein it does not necessarily mean high 
mRNA expression will always show high amount of protein. However, Mezos et al. do show 
that high GRP-78 mRNA expression predicted shorter overall survival, consistent with the 
GRP-78 protein correlations reported by Niu et al. (2015) and Yu et al. (2016). A third 
possibility is that the large number of censored patients in this study affected the statistical 
analysis.  
Effect of GRP-78 on overall survival in colorectal cancer patients from TCGA was also 
analysed. There were 388 patients in this group and but not all of them received taxane 
treatments. Taxanes are not a standard treatment for colorectal cancer and there are 
multiple different drug combinations that might be used, so probably these patients received 
one of several different drug combinations that are not too similar to each other. So, this 
study investigates the role of ER stress in colorectal cancers but not as part of taxane 
response. The results showed there may be a possible correlation of GRP-78 with overall 
survival (p=0.160). Although the results were not significant the high GRP-78 curve in the 
graph shows a trend towards better survival. These results show similarity to the IHC results 
of ovarian cancer where a possible correlation of GRP-78 with OS was observed. These 
results hint about the possible correlation between GRP-78 and OS, independent of taxane 
treatment, even though it was not seen in ovarian TCGA results.  
 
 
166 
 
4.3.2 Association of WWOX with OS or PFS 
It has been established by many previous studies that WWOX is a tumour suppressor gene 
and its loss promote development of tumours or cancers of various types such as endocrine 
or exocrine carcinomas and renal cell carcinoma (Lin et al., 2013; Iliopoulos et al., 2006). 
WWOX also plays an important role in regulation of cellular apoptosis. The effect of WWOX 
protein expression on overall survival in ovarian cancer patients in the IHC study show that 
there was no correlation between them (p=0.895). Similarly, there was no correlation of 
WWOX with PFS (p=0.181). In the analysis of RNAseq data from TCGA, no correlation of 
WWOX was observed with overall survival in ovarian cancer patients (p=0.218), or colorectal 
cancer patients (p=0.856). These results were therefore all in agreement.  
Aldaz et al. (2014) showed the prognostic value of WWOX mRNA expression in breast and 
ovarian carcinomas. The information was extracted from a publicly available gene 
expression data set (Oligo-microarrays). Patients were divided into low and high WWOX 
groups. Kaplan Meier analysis of breast cancer patients showed that low expression of 
WWOX correlated with short relapse free survival and shorter progression free survival in 
ovarian cancer patients. Ludes et al. (2007) also observed correlation between WWOX 
expression and survival time in Wwox+/+ and Wwoxgt/gt mice (hypomorphs). The Kaplan 
Meier survival curves showed that Wwoxgt/gt mice had significantly shorter survival time 
compared with wild type Wwox+/+ mice. Nunez et al. (2005b) also showed correlation 
between WWOX expression and overall survival. Reduced expression of WWOX in ovarian 
cancers showed a significant correlation with FIGO stage IV (p=0.007) and shorter overall 
survival (p=0.03). Correlation of WWOX and overall survival was observed by using cases 
from MDACC TMA (n=354). A statistical significant correlation was observed between 
WWOX and overall survival, whereas low WWOX protein expression correlated with shorter 
survival (p=0.03). All three studies suggest low WWOX expression is correlated with low 
survival, contrary to my results of IHC or RNA expression analysis which show no effect of 
WWOX on survival.  
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WWOX is a tumour suppressor gene and its loss is associated with development of tumours. 
WWOX is also associated with cellular apoptosis (Iliopoulos et al., 2006). Considering these 
functions of WWOX I had predicted that, in my study of IHC and RNA expression, high 
WWOX expressing patients would show better survival time, but in fact WWOX showed no 
effect in terms of survival. One possibility of no effect of WWOX on survival in my studies 
could be due to the fact that WWOX expression is down regulated or lost in tumours and 
though I have divided the patients in RNA expression study into high WWOX and low 
WWOX expressing groups but many patients of high WWOX group have expression which 
apparently does not look very high compared to low WWOX group. The expression levels for 
188 low WWOX group were 0.253885-1.951157, whereas for 132/189 patients from the high 
WWOX group expression was only slightly higher (1.951157-3.794393) whilst 57/189 
patients from the high WWOX group expression was much higher (4.004566-14.0381). 
Therefore, the median expression value may not be the optimal threshold for defining high 
and low expressing groups. Also, about 76% of colorectal patients were censored (table 
4.25) but only 38.8% of ovarian patients (table 4.18) were censored, which can also affect 
the statistical analysis and hence affected the survival curves. Similarly, in IHC study total 
group was of 50 patients and among that 17 were low WWOX and rest were moderate or 
high WWOX expressing patients. Increased number of patients may have shown a clearer 
survival effect.  
 
WWOX exhibits LOH or homozygous deletion in several tumour types (Driouch et al., 1997). 
Apart from predominant full-length transcripts (variant 1), spliced transcripts of WWOX have 
also been observed in tumour sample which can potentially interfere with normal function of 
WWOX in dominant negative fashion, especially variant 4 (lacking exon 6-8) (Paige et al., 
2001). Gourley et al., (2005) reported that ovarian tumours express significantly low 
expression of variant 1 compared to normal ovaries which was not associated with any 
particular clinical subgroup. Low levels of Variant 4 were expressed which show association 
with advanced stage ovarian cancer. The survival analysis showed that tumours co-
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expressing variant 4 and variant 1 showed poor survival compared with variant 1 expressing 
tumours. Also, variant 4 was frequently present in non-malignant ovarian tissue. These 
results show WWOX variant 1 is tumour suppressor in ovarian cancer, but variant 4 
functions are not known. Comparing this study of Gourley et al, with my results of IHC or 
RNA expression it can be speculated that co-expression of these variants may also be a 
reason that no correlation was observed in survival.  
 
4.3.3 Association of WWOX/GRP-78 with OS or PFS 
The impact of WWOX/GRP-78 together was observed on overall survival or progression free 
survival in both studies (IHC and TCGA). There were four groups’ high-WWOX/high-GRP-
78, high-WWOX/low-GRP-78, low-WWOX/high-GRP-78 and low-WWOX/low-GRP-78. The 
aim was to see if any of these combinations predicts high survival rate in ovarian or cancer 
patients. In IHC study of ovarian cancer patients no correlation between all these four groups 
and overall survival was observed (p=0.358), although both groups with high GRP78 
showed better survival than the two low-GRP78 groups. In the same set of patients, no 
correlation between WWOX / GRP-78 status and progression free survival was observed 
(p=0.542). The ovarian and colorectal cancer patients from TCGA data set also showed 
similar results. No correlation between WWOX / GRP-78 status and overall survival was 
observed (p=0.142) in ovarian cancer patients, or in colorectal cancer patents (p=0.300). 
Overall both studies showed no effect of combined GRP / WWOX status together on survival 
time.  
In a study by Janczar et al. (unpublished data) it was shown that paclitaxel triggers ER 
stress response in ovarian cancer cells and WWOX transfection decreases survival of cells 
treated with tunicamycin (an ER stress inducer). It was further shown that induction of ER 
stress was unaltered by WWOX, but WWOX re-expression caused a significant shift towards 
an apoptotic response to ER stress which could be reversed by siRNA. The clinical 
relevance of these findings was observed in a publicly available microarray gene expression 
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dataset (GEO GSE9899) of 260 ovarian cancer patents. Kaplan Meier analysis showed high 
WWOX mRNA expression predicted longer PFS in patients treated with paclitaxel (n=195, 
p=0.01) but not in patients which did not have paclitaxel treatment (n=65, p=0.66). 
Interestingly, WWOX affected PFS only in patients whose tumours expressed low-GRP-78 
(p=0.003), whilst the high GRP-78 expressing group did not show any correlation of WWOX 
with PFS (p=0.469). We hypothesised that the patient samples with high GRP-78 expression 
(pre-treatment) may have intrinsically activated ER stress which is not dependent on 
paclitaxel. Cancers in which ER stress is inherently active would be expected to benefit from 
the cytoprotective functions of ER-stress but would presumably be resistant to ER-stress 
induced apoptosis. It was therefore speculated that WWOX status had no impact on these 
patients as paclitaxel would only be able to kill the cancer cells through its mitotic arrest 
function, and not through an ER-stress related mechanism. In contrast, in low-GRP-78 
expressing patients, we hypothesise that ER-stress is not inherently active, and therefore 
could be activated by paclitaxel treatment. In these tumours, we speculated that WWOX 
status could influence the apoptotic outcome of ER-stress, and thus higher WWOX 
expression predicted longer PFS. The data from this study show a correlation between 
WWOX and UPR. Contrary to findings of this study the Kaplan Meier analysis data from my 
IHC and TCGA study did not show any correlation between WWOX and UPR. Whilst it can 
again be speculated that patients with high GRP-78 expression may have intrinsic ER stress 
activated, such that treatment with paclitaxel did not induce ER stress associated apoptosis, 
and hence there was no impact of WWOX status. However, surprisingly, in my analysis low 
GRP-78 also showed same results like high GRP-78. 
4.4 Conclusion 
My results do show some evidence that ER-stress is related to patient survival, and higher 
GRP78 (indicating inherently activated ER-stress) appeared to provide an overall survival 
advantage in two of the three patient cohorts studied. However, this is independent of 
WWOX status, and is not clearly related to paclitaxel response (since this is an association 
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with inherent ER-stress activation). Whilst further work is required to address the 
inconsistencies with earlier data from our group, these findings, like those in chapter 3, do 
not provide supportive evidence linking ER-stress and paclitaxel response. Therefore, for the 
remainder of my PhD work I instead focussed on cisplatin response in cancer cells. 
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Chapter 5 Role of WWOX in mediating cisplatin induced cell death   
5.1 Introduction 
5.1.1 Involvement of WWOX in cancer 
WWOX is a WW domain containing oxidoreductase tumour suppressor gene, located at the 
second most commonly expressed fragile site called FRA16D. It has been established by 
many previous studies that WWOX is a tumour suppressor gene and its loss promote 
development of tumours or cancers of various types such as endocrine or exocrine 
carcinomas and renal cell carcinoma (Lin et al., 2013; Iliopoulos et al., 2006). 
Immunohistochemical staining of different histological types of ovarian carcinomas (serous, 
endometrioid, clear cell and mucinous) showed variable expression of WWOX compared 
with normal ovarian tissues which strongly expressed WWOX (Nunez et al., 2005).  Another 
study by Qin et al., (2006) showed that prostate cancer cells (LNCap, PC3 and DU145) 
showed a significant reduction in WWOX mRNA and protein expression as compared to 
non-cancerous prostate cells (PWR-1E) and immunohistochemical staining showed down 
regulation of WWOX in 84% of prostate cancer tumours (Qin et al., 2006). Down regulation 
of WWOX expression in human cervical cancer was shown in a study by Qu et al., (2013), 
and when WWOX was re-expressed in HeLa cells, it inhibited their proliferation and induced 
apoptosis, while knockdown of WWOX in SiHa cells enhanced proliferation and inhibited 
apoptosis. All these studies show down regulation of WWOX is associated with cancer 
development.  Tumour suppressor function of WWOX was shown by Bednarek et al., (2001). 
WWOX expressing breast cancer cells MDA-MB-435/WWOX and MDA-MB-435/vector were 
injected in nude mice and results showed WWOX strongly inhibited tumorigenicity. Work 
from my own lab showed that WWOX is disrupted by homozygous deletion (Paige et al., 
2001) and its expression is decreased in ovarian cancer (Gourley et al., 2005). Transfection 
of WWOX in ovarian cancer cells suppressed in vivo tumorigenicity in nude mice and 
generated apoptosis in in vitro suspension cell culture but had no effects on in vitro growth 
rate in adherent cultures (Gourley et al., 2009). The same study showed that WWOX 
expression resulted in reduced attachment with fibronectin (an extracellular matrix involved 
 
 
172 
 
in peritoneal metastasis). An apoptotic mechanism behind WWOX tumour suppression was 
shown by another study of lung and prostate cancer cell lines lacking WWOX expression. 
Prostate cancer cells (DU145) were transfected with WWOX and then cells were injected in 
nude mice (5-week-old and 5 mice per group). Same number of uninfected cells was 
injected in control mice (10 mice). Control mice showed tumour progression whereas mice 
injected with transfected WWOX cells suppressed tumorigenicity (Qin et al., 2006). In a 
similar study, lung cancer cells lines (H460, a549 and U2020) were transfected with Ad-
WWOX and injected in 5 nude mice. Five control mice were injected with Ad-GFP. After 28 
days’ tumours formation was checked and WWOX infected mice showed almost no tumours 
whereas control mice showed tumours (Fabbri et al., 2005).  
p63 and p73 proteins are the family members of p53 protein. These three proteins are very 
important transcription factors and their structure shows that they have three domains 
common in them by which they perform their function. The three domains include an 
oligomerization domain (OD), a DNA binding domain and a transactivation domain (TA). 
ΔNp63 is an isoform (truncated gene) of p63 that acts as a dominant negative repressor of 
p63 function (Melino et al., 2002; Yang et al., 2002). The expression of ΔNp63α by various 
mechanisms is also involved in chemotherapy resistance (Sen et al., 2011). In a recent 
study by Salah et al., (2013) it was shown that WWOX can sensitize cancer cells to 
chemotherapy drugs. In this study the link between WWOX and ΔNp63α was observed and 
it showed that when cancers cells expressing only ΔNp63α were treated with cisplatin they 
showed low cell death rate but cancer cells expressing both WWOX and ΔNp63α on 
treatment with cisplatin, showed increased rate of cell death by approximately 14-fold. This 
clearly shows that the linkage between WWOX and ΔNp63α was responsible of increased 
sensitivity of cancer cells to cisplatin and it is thought that WWOX does this by restricting the 
ΔNp63 to the cytoplasm which results in suppression of transcription of ΔNp63 (Salah et al., 
2013).  
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5.1.2 Involvement of FHIT in cancer 
FRA3B is the most commonly expressed common fragile site in human genome and it was 
first common fragile site to be studied in detail (Smeets et al., 1986). Further studies showed 
that like WWOX, FHIT is a gene located at this CFS which is also a target of deletion in 
multiple cancers, and expression of FHIT was suppressed in many tumour types. In a study 
of mice by Dumon et al., (2001), human FHIT gene was expressed in heterozygous Fhit+/- 
knockout mice by adenoviral or adeno-associated vectors. The Fhit+/- knockout mice were 
vulnerable to development of tumour on treatment with carcinogens. Expression of human 
FHIT gene inhibited tumour development in mice. Similarly, in another study FHIT gene was 
re-expressed by adenoviral vector in various ovarian and lung cancer cell lines lacking FHIT 
expression, and this induced apoptosis in all cell lines (Roz et al., 2002). 
 Nishizaki et al., (2004), showed the combined effects of FHIT and p53 on NSCLC 
proliferation and apoptosis in vitro and in vivo using adenoviral transfer of FHIT and p53. The 
results showed that FHIT and p53 together suppressed the tumour growth in vitro and in vivo 
(xenografts in nude mice). Further investigations showed that MDM2 (Mouse double minute 
2 homolog), which is a negative regulator of p53, was inactivated by FHIT but p53 being in 
stabilized form worked as tumour suppressor along with FHIT. Hence this study shows FHIT 
along with p53 can improve the therapies from treatment of lung or other cancers (Nishizaki 
et al 2004).  
 (Andriani et al., 2006) investigated the extrinsic pathways activated by FHIT and intrinsic 
pathways activated by cisplatin at the same time in NSCLC (H460 cells) to see if it could 
enhance the cell death. FHIT gene was re-expressed in FHIT negative NSCLC by 
adenovirus, which slightly increased the sensitivity to cisplatin. As evident by previous 
studies, this study also showed that wild type p53 was important for this sensitivity to 
cisplatin. This study shows FHIT as an important gene to overcome the drug resistance due 
to cisplatin therapy (Andriani et al., 2006).  
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Cisplatin is widely used as a chemotherapy drug for the treatment of different types of 
cancer. Its mechanism of action involves forming DNA-damaging adducts. The adducts 
initiate signalling by DNA damage recognition proteins, activating repair mechanism to fix the 
damaged DNA and when it fails to repair the DNA then it leads to apoptosis. Common fragile 
sites are sensitive to DNA damage, leading to stalled replication and chromosomal breaks 
that might affect the expression of nearby genes. Cancer cells show down regulated 
expression of WWOX and FHIT as compared to normal cells. As explained by many studies 
WWOX and FHIT inhibit proliferation of cancer cells and initiate apoptotic pathways to kill the 
cancer cells. In other words, both of these fragile site-associated genes are beneficial for the 
survival of cancer patients. Here in my study I originally hypothesised that WWOX would 
enhance cisplatin cytotoxicity and that this may be via the ER-stress pathway. However, my 
initial data demonstrated that this was not the case and led to a revised hypothesis that 
treatment of cancer cells line with cisplatin will induce DNA damage that may affect common 
fragile sites, leading to down regulation of nearby tumour suppressors such as WWOX and 
FHIT. 
5.2 Experimental Approach 
In this chapter the aim was to see if cisplatin can induce ER stress mediated by WWOX in 
ovarian, colorectal or prostate cancer cell lines. Before the start of experiments the first step 
was to find out a suitable dose (IC50) to be used for experiments. Cancer cells were treated 
with various doses of cisplatin and cells were observed under the microscope (appendices 
Figures S3.1, S3.2 and S3.3) and the dose which killed approximately 50% of cells was 
selected for use in experiments.  Ovarian cancer cells A2780, colorectal cancer cells 
HCT116 and prostate cancer cells LNCap were treated with cisplatin and quantitative PCR 
was performed (Chapter 2 materials and methods). Each experiment consists of three 
treatments i.e. untreated, cisplatin treated and DMF treated cells. Since cisplatin was 
dissolved in dimethyl formamide (DMF) (appendices S6.1) so cells were also treated DMF 
only to see if the effect on cells was due to cisplatin or DMF. Each experiment was repeated 
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three times and final average values were used to plot graphs and analyse relative 
expression levels of WWOX (Chapter 2 material and methods). Correct PCR product was 
confirmed by the analysis of melt curve in Rotor gene 6000 software. Unexpectedly in these 
experiments, rather than showing that WWOX increased cisplatin induced cell death, I 
discovered that cisplatin resulted in loss of WWOX expression. Subsequent experiments 
were then performed to determine if the loss of WWOX expression was related to its location 
at a common fragile site, or to cisplatin induced transcriptional regulation. 
5.3 Results 
5.3.1 Expression of WWOX following cisplatin treatment 
Following cisplatin treatment, expression of WWOX was analysed in ovarian cancer cells 
A2780, colorectal cancer cells HCT116 and prostate cancer cells LNCap. 
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5.3.1.1 Expression of WWOX in A2780 cells 
Cisplatin treatment reduced the expression of WWOX mRNA in ovarian cancer A2780 cells by 65% after 24 hours and by 
85% after 48 hours (Figure 5.1) as compared to DMF and untreated cells (p<0.05).  
 
 
             
 
Figure 5.1 
Down regulation of WWOX expression in A2780 cells after 24 hours and 48 hours of cisplatin treatment.  Graph shows expression of WWOX 
mRNA relative to B-actin measured by qRT-PCR in A2780 cells following 24 hours’ and 48 hours’ growth in the presence of 4μg/ml cisplatin, vehicle 
(DMF) or no drug. Means of triplicate experiments ± SEM shown. T-test was perfomed to find out significance among the treatments. (*, p<0.05). 
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                        5.3.1.2 Expression of WWOX in HCT116 cells 
Cisplatin treatment reduced the expression of WWOX mRNA in colorectal cancer cells HCT116 by 60% after 24 hours and by 75% after 
48 hours (Figure 5.2) as compared to DMF and untreated cells (*, p<0.05).                 
 
                        
 
Figure 5.2 
Down regulation of WWOX expression in HCT116 cells after 24 hours and 48 hours of cisplatin treatment.  Graph shows expression of WWOX 
mRNA relative to B-actin measured by qRT-PCR in HCT116 cells following 24 hours’ and 48 hours’ growth in the presence of 5μg/ml cisplatin, vehicle 
(DMF) or no drug. Means of triplicate experiments ± SEM shown. T-test was performed to find out the significance among the treatments. (*, p<0.05) 
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5.3.1.3 Expression of WWOX in LNCap cells 
No significant change in the expression of WWOX mRNA was identified in prostate cancer cells LNCap after 24 or 48 hours of cisplatin 
treatment compared to untreated or DMF (Figure 5.3).  
                 
                     
 
Figure 5.3 
 WWOX expression in LNCap cells after 24 hours and 48 hours of cisplatin treatment.  
Graph shows expression of WWOX mRNA relative to B-actin measured by qRT-PCR in LNCap cells following 24 hours’ and 48 hours’ growth in the 
presence of 2.5μg/ml cisplatin, vehicle (DMF) or no drug. Means of triplicate experiments ± SEM shown.
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5.3.1.4 Expression of WWOX in HCT116 and HCT116-p53null cells after 24 hours of 
cisplatin treatment 
In this experiment, I used colorectal cancer cells HCT116 along with another cell line, 
HCT116 lacking p53 expression, to investigate the mechanism of DNA damage. P53 is a 
key regulator of DNA damage response. So, if cisplatin induces DNA damage that disrupts 
the common fragile sites and results in reduced WWOX expression this may require p53. I 
intended to analyse 24 hours and 48 hours (as I did for the earlier experiments), but 24 
hours experiments showed a clear loss of WWOX expression, and so the 48 hours’ time 
point was then not needed. I wanted to do qRT-PCR, but the machine broke down, therefore 
I used semi quantitative PCR instead. Although it was not quantitative PCR but the concept 
of technique in this experiment was like the qRT-PCR performed in above experiments. I 
used different amounts of template to prepare six different standard dilutions (1:1, 1:5, 1:25, 
1:50, 1:75, and 1:100). The template cDNA (1µg) used was from a WWOX transfected 
ovarian cancer cell line (PEO1-H8) having high amount of WWOX in it. Figure 5.4-A shows 
amount of product related to amount of template and the product formation did not reach 
saturation when using 1:5 dilution or less.  
Next, I analysed untreated, DMF (dimethylformamide) or cisplatin (5µg/ml) treated HCT116 
and HCT116-p53null cells, using 1:25 dilutions of template (Figure 5.4-B). Expression of 
WWOX was seen in both cell lines when untreated or treated with DMF. In cisplatin treated 
HCT116 cells, WWOX expression can no longer be seen (confirming the qRT-PCR results 
from above figure 5.6). In the HCT116-p53null cells cisplatin treatment also causes loss of 
WWOX expression demonstrating p53 is not required for the altered WWOX expression. No 
amplification of either product was seen in –RT controls (not shown) confirming the RNA 
samples were genomic DNA free. 
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Figure: 5.4-A 
 WWOX (122bp) and GAPDH (292bp) expression of PEO1-WWOX transfected templates used as 
standards. No template (NT) show no contamination. (For detailed image see appendices S8.1) 
 
 
Figure 5.4-B  
Gel images of HCT116 and HCT116p53null after treatment with cisplatin.  
Expression of WWOX (122bp) and GAPDH (292bp) in HCT116 and HCT116-p53null cells with or 
without 5μg/ml cisplatin exposure. UT represents (untreated), DMF (dimethylformamide used as 
vehicle) and CIS represent cisplatin treatments. (For detailed image see appendices S8.1) 
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5.3.2 Expression of FHIT following cisplatin treatment 
In my experiments above I observed change in expression of tumour suppressor WWOX 
gene after cisplatin treatment. Here in these experiments I hypothesize that if the change in 
WWOX expression due to cisplatin was related to this being a CFS associated gene, then I 
would expect other CFS associated genes to show the same effect. FHIT is another tumour 
suppressor gene located on a very commonly expressed CFS. So, is it also affected by 
cisplatin? 
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5.3.2.1 Expression of FHIT in A2780 cells 
Cisplatin treatment reduced the expression of FHIT mRNA in ovarian cancer cells A2780 by 60% after 24 hours and by 
80% after 48 hours (Figure 5.5) as compared to DMF and untreated.             
                  
 
Figure 5.5  
FHIT expression in A2780 cells after 24 hours and 48 hours of cisplatin treatment. Graph shows expression of FHIT mRNA 
relative to B-actin measured by qRT-PCR in A2780 cells following 24 hours’ and 48 hours’ growth in the presence of 4μg/ml cisplatin, 
vehicle (DMF) or no drug. Means of triplicate experiments ± SEM show
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                        5.3.2.2 Expression of FHIT in HCT116 cells 
There was no change in the expression of FHIT mRNA in colorectal cancer cells HCT116 after 24 hours of cisplatin 
treatment, but 48 hours’ treatment showed that cisplatin decreased the expression of FHIT by 25% as compared to DMF 
or untreated (Figure 5.6) but this did not reach statistical significant. 
             
                 
Figure 5.6  
FHIT expression in HCT116 cells after 24 hours and 48 hours of cisplatin treatment. Graph shows expression of FHIT mRNA 
relative to B-actin measured by qRT-PCR in HCT116 cells following 24 hours’ and 48 hours’ growth in the presence of 5μg/ml cisplatin, 
vehicle (DMF) or no drug. Means of triplicate experiments ± SEM shown. 
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5.3.3 Analysis of RNA sequencing data of ovarian and colorectal cancer tumours 
5.3.3.1The effect of FHIT expression on OS in ovarian cancer patients 
Table 5.1 below shows that there were 188 patients each for both low and high FHIT 
expression groups. For high FHIT group 116 patients had died and 72 patients (38.3%) were 
still alive. In low FHIT group 114 patients had died and 74 patients (39.4%) were still alive. 
Figure 5.7 shows the overall survival graph plotted by Kaplan Meier analysis showing curves 
for both high and low FHIT expressing groups. Both curves (blue for high FHIT and green for 
low FHIT) overlap each other and show same pattern. This show there was no difference in 
terms of effect of FHIT on survival time in both groups. The table 5.2 below show P value 
(p=0.623) confirming there was no significant difference between both groups.  
 
Table 5.1:  Summary of patients in low and high FHIT groups 
 
Case Processing Summary 
FHIT STATUS Total N 
Dead 
Patients 
Patients still alive 
N Percent 
Fhit high 188 116 72 38.3% 
Fhit Low 188 114 74 39.4% 
Overall 376 230 146 38.8% 
 
Table 5.2: Log Rank comparison of high FHIT and low FHIT patient groups 
 
 
 
 
(df) represents degree of freedom 
 
Overall Comparisons 
 Chi-Square df P value 
Log Rank (Mantel-Cox) 0.242 1 0.623 
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Figure 5.7 
Kaplan Meier curves of ovarian cancer patients showing overall survival time. The blue curve 
represents patients with high FHIT expression and green curve represents patients with low FHIT 
expression. The vertical lines in both curve represents the censored observations. 
 
 
 
 
 
 
 
 
186 
 
5.3.3.2The effect of FHIT expression on OS time in colorectal cancer patients 
Table 5.3 below shows that there are 195 patients for high FHIT and 193 patients for low 
FHIT expression groups. For high FHIT group 51 patients had died and 144 patients (73.8%) 
were still alive. In low FHIT group 41 patients had died and 152 patients (78.8%) were still 
alive.  Figure 5.8 below shows the overall survival graph plotted by Kaplan Meier analysis 
showing curves for both high and low FHIT expressing groups. Green curve representing 
low FHIT appears high compared with blue curve representing high FHIT expressing 
patients. This actually suggests a trend that has not quite reached significance (p=0.077, 
table 5.4). However, the trend is only in the middle of the curve, and at later times (from 
3000 days) there is no clear effect of FHIT expression on survival.  
 
Table 5.3:  Summary of patients in low and high FHIT groups 
 
 
 
 
Table 5.4: Log Rank comparison of high FHIT and low FHIT patient groups 
 
 
 
 
(df) represents degree of freedom 
 
Case Processing Summary 
FHIT Status Total N 
Dead 
Patients 
Patients still alive 
N Percent 
FhitHigh 195 51 144 73.8% 
FhitLow 193 41 152 78.8% 
Overall 388 92 296 76.3% 
Overall Comparisons 
 Chi-Square df P value 
Log Rank (Mantel-Cox) 3.135 1 0.077 
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Figure 5.8 
Kaplan Meier curves of colorectal cancer patients showing overall survival time. The blue curve 
represents patients with high FHIT expression and green curve represents patients with low FHIT 
expression. The vertical lines in both curve represents the censored observations. 
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5.4 Analysis of NF-κB2 and PAR2 Protein expression in various cancer cell lines after 
24 or 72 hours of cisplatin treatment 
5.4.1 Expression of NF-κB2 in A2780 cells (Western Blotting) 
The decreased expression of WWOX following cisplatin treatment could be the result of 
altered transcriptional regulation. WWOX transcription has been reported to be regulated by 
NF-κB2 (the p50 isoform of NF-κB), with increased NF-κB2 levels causing decreased 
WWOX expression (Fu et al., 2011). I therefore investigated whether there was any increase 
in NF-κB2 activation following cisplatin treatment that might explain the decreased WWOX 
expression. Various cell lines were treated with cisplatin for 24 or 72 hours, protein was 
extracted and the expression of p50 (the cleaved, activated form of NF-κB2) was examined 
by immunoblotting. 
A2780 cells show an increased expression of NF-κB2 (54KDa) in cisplatin treated cells after 
24 or 72 hours as compared to untreated and DMF treated cells (figures 5.9 and 5.10). This 
pattern of increased NF-κB2 expression was similar in all the three independent replicates.  
 
 
Figure 5.9 
Protein expression of NF-κB2 (54KDa) in A2780 cells after 24 hours of 4μg/ml cisplatin treatment. 
Actin (42KDa) was used as loading control. 
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Figure 5.10 
Protein expression of NF-κB2 (54KDa) in A2780 cells after 72 hours of 4μg/ml cisplatin treatment. 
Actin (42KDa) was used as loading control. 
 
 
5.4.2 Expression of NF-kB2 in HCT116 cells (Western Blotting) 
HCT116 cells show an increased expression of NF-κB2 (54KDa) in cisplatin treated cells 
after 24 or 72 hours as compared to untreated and DMF treated cells (figures 5.11 and 
5.12). This pattern of increased NF-κB2 expression was similar in all the three independent 
replicates.  
 
 
Figure 5.11 
Protein expression of NF-κB2 (54KDa) in HCT116 cells after 24 hours of 5μg/ml cisplatin treatment. 
Actin (42KDa) was used as loading control. 
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Figure 5.12 
Protein expression of NF-κB2 (54KDa) in HCT116 cells after 72 hours of 5μg/ml cisplatin treatment. 
Actin (42KDa) was used as loading control. 
 
 
5.4.3 Expression of Nf-kB2 in SK-MEL-28 cells (Western Blotting) 
SK-MEL-28 cells show an increased expression of NF-κB2 (54KDa) in cisplatin treated cells 
after 72 hours as compared to untreated or DMF treated cells (figure 5.13). This pattern of 
increased NF-κB2 expression was similar in all the three independent replicates.  
                        
 
 
Figure 5.13 
Protein expression of NF-κB2 (54KDa) in SK-MEL-28 cells after 72 hours of 3μg/ml cisplatin 
treatment. Actin (42KDa) was used as loading control. 
 
 
5.4.4 Expression of PAR2 in HCT116 cells (Western Blotting) 
Another transcription factor that has been reported to regulate WWOX transcription is PAR2, 
with increased PAR2 levels causing increased WWOX expression (Suen et al., 2010). I 
therefore investigated whether there was any decrease in PAR2 activation following cisplatin 
treatment that might explain the decreased WWOX expression. Various cell lines were 
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treated with cisplatin for 24 or 72 hours, protein was extracted and the expression of PAR2 
was examined by immunoblotting. 
HCT116 cells show decreased expression of PAR2 (55KDa) in cisplatin treated cells (24 and 
72 hours) as compared to untreated or DMF (figures 5.14 and 5.15). This pattern of 
decreased PAR2 expression was similar in all the three independent replicates.    
 
  
 
Figure 5.14 
Protein expression of PAR2 (55KDa) in HCT116 cells after 24 hours of 5μg/ml cisplatin treatment. 
Actin (42KDa) was used as loading control. 
 
 
 
 
 
Figure 5.15 
Protein expression of PAR2 (55KDa) in HCT116 cells after 72 hours of 5μg/ml cisplatin treatment. 
Actin (42KDa) was used as loading control. 
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5.4.5 Expression of PAR2 in A2780 cells (Western Blotting) 
 
A2780 cells show decreased expression of PAR2 (55KDa) in cisplatin treated cells (24 and 
72 hours) as compared to untreated or DMF (figures 5.16 and 5.17). This pattern of 
decreased PAR2 expression was similar in all the three independent replicates.    
 
Figure 5.16 
Protein expression of PAR2 (55KDa) in A2780 cells after 24 hours of 4μg/ml cisplatin treatment. Actin 
(42KDa) was used as loading control. 
 
 
 
Figure 5.17 
Protein expression of PAR2 (55KDa) in A2780 cells after 72 hours of 4μg/ml cisplatin treatment. Actin 
(42KDa) was used as loading control. 
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5.5 NF-κB2 knock down by esiRNA in A2780 cells after 72 hours of cisplatin treatment 
5.5.1 esiRNA knockdown of NF-kB2 in A2780 and HCT116 cells 
The results from western blotting showed the changes in the expression of NF-κB2 in A2780 
and HCT116 cell lines following cisplatin treatment. The decrease in WWOX expression 
following cisplatin treatment may therefore be due to increased NF-κB2 levels. The next step 
was to confirm a functional link of NF-κB2 with down regulation of WWOX expression by 
cisplatin treatment. For this purpose, experiments were performed to knockdown the 
expression of NF-κB2 in A2780 and HCT116 cells. The plan was to successfully knock down 
NF-κB2 and repeat the experiments of QRT-PCR to examine the expression of WWOX to 
see if it shows different results compared with existing NF-κB2 expressing cells. The first 
step was to check if the NF-κB2 knockdown was successful. 700,000 log phase A2780 and 
HCT116 cells per well were plated in 6-well plates in serum free media (SFM) and were 
treated with NF-κB2 esiRNA (53.3pmol/well) in 12µl transfection reagent according to 
manufacturer’s instructions. As a control for off-target effects, cells were also treated with 
GFP esiRNA (53.3pmol/well) in 12µl transfection reagent. Cells treated only with 12µl 
transfection reagent (TR) were used to confirm that this did not affect their behaviour. 
Lysates were prepared and probed for NF-κB2 and actin. Initial results showed NF-κB2 was 
successfully knocked down in A2780 cells but not in HCT116 cells, as compared to controls 
(Figure 5.18).  
 
Figure 5.18 
The figure shows the expression of NF-kB2 following treatment with SFM (serum free media only i.e. 
untreated), SFM+TR (serum free media + transfection reagent), GFP (Green Fluorescent Protein, 
Mission esiRNA targeting EGFP) and NF-κB2 (Mission esiRNA for human NF-κB2) in ovarian cancer 
cells A2780. 20µg protein for A2780 and 10µg protein for HCT116 was used.  
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5.5.2 esiRNA knockdown of NF-κB2 in A2780  
Once the conditions were optimized for esiRNA knockdown in A2780 cells, three 
independent replicates were performed with the established conditions. 700,000 log phase 
A2780 cells per well 53.3pmol/well esiRNA (NF-κB2 or GFP) and 12µl transfection reagent. 
Transfected cells were then treated with cisplatin or DMF for 72 hours. Lysates were 
prepared and probed for NF-κB2 and actin. 
 As in previous experiments, cisplatin treatment resulted in increased NF-κB2 levels 
compared to untreated or DMF controls. This was observed in all of the transfected lines 
(figure 5.19). However, NF-κB2 expressions knock down by esiRNA was unsuccessful in 
A2780 cells as compared to controls (SFM, SFM+TR and GFP). All three independent 
replicates showed similar results. 
 
Figure 5.19 
The figure shows the expression of NF-κB2 following treatment with SFM (serum free media only), 
SFM+TR (serum free media + transfection reagent), GFP (Green Fluorescent Protein, Mission 
esiRNA targeting EGFP) and NF-κB2 (Mission esiRNA for human NF-κB2) in ovarian cancer cells 
A2780. 20µg protein for A2780 was used. Cis = cisplatin, DMF = dimethylformamide, UT = untreated. 
 
5.5.3 esiRNA knockdown of NF-κB2 in A2780 using different cell numbers 
Although the initial results above showed that the expression of NF-κB2 was successfully 
knocked down in A2780 cells (figure 5.18) but when the experiments were repeated using 
same conditions the NF-κB2 expressions’ knockdown was unsuccessful. So, I decided to try 
changing some conditions. Firstly, I tried varying the number of cells plated per well 
(500,000/well, 700,000/well and 900,000/well) 
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 The result (figure 5.20) show, NF-κB2 expression knock down in A2780 cells was still 
unsuccessful as compared to controls (SFM and SFM+TR). The results were similar in all 
three independent replicates. 
 
Figure 5.20 
The figure shows the expression of NF-κB2 following treatment with SFM (serum free media only), 
SFM+TR (serum free media + transfection reagent) and NF-κB2 (Mission esiRNA for human NF-kB2) 
in ovarian cancer cells A2780. 20µg protein for A2780 was used.  
 
. 
5.5.4 esiRNA knockdown of NF-κB2 in A2780 using concentration of esiRNA for 
human NF-κB2 
The experiment with different cell numbers also proved unsuccessful in knocking down 
expression of NF-κB2. Next, I tried using different concentrations of NF-κB2 esiRNA to see if 
it could knockdown successfully NF-κB2. 3µl (40pmol), 4µl (53.3pmol) and 5µl (66.62pmol) 
of (Mission esiRNA for human NF-κB2) were used for 700,000 cells per well. Lysates were 
prepared and probed for NF-κB2 and actin. The results (figure 5.21) showed the cells treated 
with 3µl of esiRNA (40pmol) had better knockdown of NF-κB2 as compared to 4µl 
(53.3pmol) and 5µl (66.62pmol) of esiRNA, although this treatment did not completely 
suppress NF-κB2 levels. 
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Figure 5.21 
The figure shows the expression of NF-κB2 following treatment with SFM (serum free media only), 
SFM+TR (serum free media + transfection reagent) and 3µl (40pmol), 4µl (53.3pmol) and 5µl 
(66.62pmol) NF-κB (Mission esiRNA for human NF-κB2) in ovarian cancer cells A2780. 20µg protein 
for A2780 was used.  
 
5.5.5 esiRNA knockdown of NF-κB2 in A2780 using low concentration of esiRNA 
The results above show that esiRNA was better knocked down when low concentration of 
esiRNA for human NF-κB2 was used as compared two high concentrations. So, in this 
experiment I repeated the transfection using 40pmol of NF-κB2 esiRNA, and then treated the 
transfected cells with cisplatin or DMF.  Lysates were prepared and probed for NF-κB2 and 
actin. Figure 5.22 show that siRNA transfection produced only a small decrease in NF-κB2 
compared to cells with siRNA (SFM and SFM-TR). This knockdown was not sufficient to 
prevent cisplatin treatment from inducing NF-κB2. This experiment was done twice, and it 
showed similar results. 
 
Figure 5.22 
The figure shows the expression of NF-κB2 following treatment with SFM (serum free media only), 
SFM+TR (serum free media + transfection reagent) and NF-κB2 (Mission esiRNA for human NF-κB2) 
expression in ovarian cancer cells A2780. 20µg protein for A2780 was used. Cis = cisplatin, DMF = 
dimethylformamide, UT = untreated. 
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5.5.6 esiRNA knockdown of NF-κB2 in A2780 using low concentration of esiRNA and 
low concentration of transfection reagent 
The above results show that the transfection conditions used were still insufficient to prevent 
cisplatin from inducing NF-κB2 expression. So, here in this experiment I decided to repeat 
the transfection using low concentration of NF-κB2 esiRNA (40pmol) and low concentration 
of transfection reagent (9μl) to see if changing concentration of transfection reagent may 
help in a successful knock down of NF-κB2.  
Figure 5.23 shows that NF-κB2 levels appear unchanged following siRNA treatment as 
compared to controls (SFM and SFM-TR). Interestingly, however, the induction of NF-κB2 
following cisplatin treatment appears to be reduced in the siRNA treated cells compared to 
the controls. 
 
 
Figure 5.23 
The figure shows the expression of NF-κB2 following treatment with SFM (serum free media only), 
SFM+TR (serum free media + transfection reagent) and NF-κB2 (Mission esiRNA for human NF-κB2) 
in ovarian cancer cells A2780. 20µg protein for A2780 was used. Cis = cisplatin, DMF = 
dimethylformamide, UT = untreated. 
 
 
5.6 SRB analysis of esiRNA transfected cells 
Cells treated with NF-κB2 showed low confluence when observed under microscope as 
compared to controls. To determine whether the siRNA treatment affected cell number 
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compared to controls the cells were stained with SRB 72 hours following transfection, and 
the SRB absorbance was measured by spectrophotometer using wavelength of 562nm.  
 The results show there was no significant difference of cell survival between NF-κB2 
treatments compared with other three treatments (figure 5.24). A preliminary analysis of cell 
cycle distribution in the transfected cells using FACS also demonstrated no differences 
between the treatments (Figures S1 and S2 in appendix).  
 
 
Figure 5.24 
Relative A2780 cell survival of NF-κB2 siRNA treated, GFP siRNA treated, and transfection reagent 
treated (SFMTR) cells compared with untreated cells in serum free media (SFM). Means of triplicate 
experiments ± SEM shown.  
 
 
Had the knockdown of NF-κB2 worked, I would then have treated these cells with cisplatin 
and DMF and analysed WWOX mRNA expression by qRT-PCR to determine whether 
cisplatin would no longer cause loss of WWOX expression in the absence of NF-κB2. 
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5.7 Discussion 
5.7.1 Does cisplatin cause disruption of common fragile sites leading to dysregulation 
of nearby genes? 
Normally CFS do not exhibit vast sequence similarities and their specific sequences do not 
seem to be accountable for their fragile nature (Huebner and Croce, 2001), but CFS-
associated genes (e.g. WWOX and FHIT) share some structural and functional similarities 
such as; both span in size more than 1Mb and exhibit fragile regions, both are tumour 
suppressor genes and show frequently reduced expression levels in various types of 
cancers (Huebner and Croce, 2001; Ludes et al., 2003). The coordination in expression of 
both genes was also showed in a study by Ishii et al. (2003), where both WWOX and FHIT 
showed loss of expression by epigenetic mechanisms in hematopoietic tumours. Another 
study of breast cancers showed that both WWOX and FHIT were inactivated concordantly 
and showed loss of expression (Guler et al., 2004). Apart from commonalities in the 
structure of WWOX and FHIT, these studies suggest together these two genes can show a 
co-ordinated change of expression during tumorigenesis in various types of cancer.  
Here in my study the results again show co-ordinated expression of these two genes, with 
greatly reduced expression of mRNA for both WWOX and FHIT in A2780 and HCT116 cells 
due to a DNA damaging chemotherapy drug cisplatin. Cisplatin’s mechanism of action is by 
forming DNA-adducts and distorting the structure of DNA. Fragile sites like FRA16D and 
FRA3B (which contain the WWOX and FHIT genes respectively) are present on the DNA 
and they are very susceptible to DNA damage. Therefore, from these data, it can be 
speculated that treatment of A2780 and HCT116 with cisplatin down regulated the 
expression of WWOX and FHIT due to DNA damage disrupting the common fragile sites 
containing these genes.  
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Other studies also support this hypothesis, showing similar responses of WWOX and FHIT 
expression following a number of different DNA damaging agents. A study by Thavathiru et 
al. (2005) used MCF-7 (breast cancer) cells which were irradiated with UV, and the results 
by northern blotting showed a dramatic decrease in the mRNA levels of WWOX and FHIT 
after 24 hours as compared to control. Similarly, in this study, treatment of MCF-7 cells with 
BPDE (Benzo[a]pyrene diol epoxide, a DNA-adduct forming chemical) also showed a 
dramatic decrease in WWOX and FHIT expression levels. Reduced mRNA expression of 
WWOX was seen after 24 hours’ exposure to these agents, but western blotting analysis 
showed there wasn’t significant decrease in protein expression of WWOX until 48 or 72 
hours. This suggests that the expression changes observed are due to transcriptional 
regulation of WWOX and FHIT.  
 BPDE is a carcinogenic agent and it forms bulky adducts with the DNA and blocks 
replication (Pietrasanta et al., 2000) which is similar to the way cisplatin form adducts with 
the DNA. Similarly, lesions in the DNA created by UV are like lesions produced by cisplatin 
and both follow NER mechanism pathway for DNA repair (Marteijn et al., 2014). NER is the 
most common mechanism of repairing DNA damage due to cisplatin or carcinogens 
(Marteijn et al., 2014; Hanawalt et al., 2002). If cells with highly damaged DNA fail to repair 
themselves by NER mechanism, mechanisms of cell cycle arrest or apoptosis are induced, 
often involving the Tumour suppressor protein P53 (Kastan et al., 1991). The nature of the 
DNA damaging agents and the cell types involved determine which genes are activated or 
which of their products participate in the DNA repair, cell cycle arrest or apoptotic pathways 
(Ko and Prives, 1996; Fans et al., 1998; Khan and Dipple, 2000). Given its importance in 
these pathways, p53 could be potentially involved in the regulation of WWOX and FHIT by 
cisplatin. In the study by Thavathiru et al. (2005) the involvement of p53 in the down 
regulation of these fragile site-associated genes was checked by using Saos-2 cells lacking 
p53. The results showed that UV still down regulated the expression of WWOX and FHIT 
suggesting it is not dependent on p53. My findings are consistent with this, showing that 
cisplatin suppressed WWOX expression equally in both HCT116 and HCT116p53null cells.  
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Despite the lack of evidence for involvement of p53 in the down-regulation of WWOX and 
FHIT, Thavathiru (2005) did provide evidence that S-phase checkpoint mechanism may be 
responsible for down regulation of WWOX and FHIT. To check the involvement of S-phase, 
caffeine was used to delay entry of cells into S-phase, and this prevented UV exposure from 
causing down regulation of WWOX and FHIT. Similar to this study, another study by Ishii et 
al. (2005) also showed that UV exposure on MEF (murine embryonic fibroblast) down 
regulated the expression of WWOX and FHIT genes in time dependent manner as 
compared to control. Again, G1-S phase was partially responsible for the down regulation of 
WWOX and FHIT. The authors also showed that the down regulation of WWOX and FHIT 
was partially dependent upon the ATR pathway. This is intriguing as there is some evidence 
to suggest that S-phase check point arrest due to UV or BPDE could be due to activation of 
ATR pathway (Guo et al., 2002), and previous studies show the key involvement of ATR in 
regulating the stability of CFS (Casper et al., 2002). Based on the results it can be 
speculated that the down regulation of WWOX and FHIT by cisplatin may be due to ATR 
pathway recognising CFS related DNA damage during an S-phase arrest. 
Concordant, down regulation of Wwox and Fhit gene expression was also shown in an in 
vivo study by Lida et al. (2005) in mice livers. The results showed that mice exposed to o-
nitrotoluene (an industrial chemical) and methyleugenol (found in oils and food products) for 
two weeks, showed loss of expression of Wwox and Fhit only in livers in a dose dependent 
manner (analysed by qRT-PCR, micro-array and western blotting). The loss of expression of 
Wwox and Fhit by these carcinogens was very prominent in livers and may represent the 
onset of early carcinogenic process. Further analysis showed significant upregulation of 
Gadd45b (growth arrest and DNA damage inducible 45β) which may be responsible for early 
onset of carcinogenic process. Mice treated with o-nitrotoluene and methyleugenol also 
showed significant upregulation of cyclin G1 (cell cycle gene) and p21 in livers. The aim of 
this study was to investigate early onset of carcinogenesis due to carcinogens but strikingly 
loss of cancer related genes (Wwox and Fhit) was observed.   
 
 
202 
 
Tobacco smoke contains carcinogens linking it strongly with lung cancer. A study of Sozzi et 
al., (1997) showed that tobacco smoke caused lesions in the DNA and molecular analysis 
showed loss of heterozygosity (LOH) of FHIT genes. Microsatellite alterations of FHIT gene 
were observed in a group of 51 lung tumours from smokers, and among them 41 (80%) 
showed LOH which affected at least one locus of the FHIT gene. In another group of 40 lung 
tumours from non-smokers, only 9 showed LOH (22%). Comparison of smokers with non-
smokers showed the difference between both groups was highly significant (p=0.0001). 
These results clearly suggest that FHIT is a molecular target of carcinogens. This study did 
not further investigate the mechanisms which may have been affected by LOH of FHIT but in 
a study by Cirombella et al., (2010) pre-neopalstic lesions adjacent to NSCLC were 
examined to see the alterations in expression of FHIT and activated check point proteins. 
Check point proteins chk1 and phosphoChk1 were examined in FHIT positive and negative 
lesions. Most of the check point proteins were visible in FHIT positive lesions but FHIT 
negative lesions did not showed any expression of Chk and phosphoChk1. This suggests 
that there is a connection between DNA damage (FHIT loss) and check point proteins, and 
loss of expression of FHIT is linked with loss of activated Chk2 in pre-neoplasia. From this 
study, it can be speculated that loss of expression of FHIT due to cisplatin in my study may 
be due to absence of check point proteins Chk1 and phoshphoChk1.  
These studies support a possible mechanism for down-regulated WWOX and FHIT 
expression that involves cisplatin induced DNA adducts promoting DNA damage disrupting 
the highly sensitive CFS regions and causing loss of nearby gene expression through an 
ATR and S-phase arrest dependent pathway. However, it remains possible that cisplatin 
instead causes alterations in specific transcription factors that directly regulate WWOX and 
FHIT expression. Recent studies have shown that PAR2 and NF-κB2 are two transcription 
factors which could possibly regulate WWOX expression.  
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5.7.2 Association of FHIT with OS in ovarian and colorectal cancer patients 
FHIT is a tumour suppressor protein and like WWOX, FHIT is also a target of deletion in 
multiple cancers and expression of FHIT was supressed in many tumour types (Mishra et al., 
2010). Apoptosis induced by FHIT has been shown in different types of cancer cells (Roz et 
al., 2002; Sevignani et al., 2003). Because of the role of FHIT in apoptosis I expect to see a 
link between higher FHIT expression and better survival rate.  
In a study by Ishii et al., (2001), immunohistochemical study of human primary tumours was 
done to observe the expression of FHIT in malignant or pre-malignant stages.  FHIT protein 
was absent or strikingly low in 60% (n=1948) of primary tumours. In pre-neoplastic lesions 
31% samples showed reduced or no FHIT (n=408). Preclinical studies showed that 
reintroduction of FHIT in 26 cancer cell lines (lung, head, neck, gastric, pancreatic etc.) 
showed inhibition of tumorigenicity in vitro and 17 cell lines out of 30 showed inhibition of in 
vivo tumorigenicity. This data shows FHIT expression is either loss or downregulated in 
cancers and its re-expression can inhibit tumorigenicity.  
Rohr et al., (2005) showed the correlation between FHIT in SCLC tumours and survival. 
Kaplan Meier analysis showed that patients with complete lack of FHIT or with less than 
25% FHIT expressing cells showed worst survival. However, survival time improved with the 
increase in percentage of FHIT expressing cells. Another study by Toledo et al., (2004) 
showed that loss of FHIT expression in NSCLC primary cells was correlated with poor 
survival of patients. Segawa et al., (2000) also showed that low expression of FHIT in 
endometrial cancer patients was associated with poor survival. Otero et al., (2004) also 
showed a multivariate analysis between FHIT and survival but showed contrary results to 
cited studies described above. They showed that tumours from advanced osopharyngeal 
squamous cell carcinoma patients with no reduction in FHIT expression levels showed 
significantly lower overall or disease-free survival suggesting no reduction in FHIT levels 
predicts poor survival outcome.  Different again, Geradts et al. (2000) showed loss of FHIT 
in NSCLC tissues by immunohistochemistry analysis but Kaplan Meier analysis showed no 
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correlation between FHIT expression and patients’ survival. Nonetheless, most of the studies 
show a correlation between low FHIT levels and poor survival.   
 My results show that cisplatin causes loss of WWOX and FHIT expression. When I looked 
for evidence of correlation between patient survival and FHIT expression in ovarian and 
colorectal cancer patients from TCGA data set, the results showed there was no correlation 
of FHIT with overall survival time (p=0.623) in ovarian cancer patients. Given that ovarian 
cancer patients would have been treated with cisplatin or carboplatin it is perhaps not 
surprising that no association of WWOX or FHIT expression with survival is seen. However, 
a possible trend towards correlation of overall survival with FHIT expression was observed 
(p=0.077) in colorectal cancer patients, who are unlikely to have received cisplatin, although 
some may have been treated with FOLFOX which includes oxaliplatin.  
 
5.7.3 Does cisplatin affect WWOX and FHIT expression via NF-κB2 regulated 
transcription?  
NF-κB2 is produced as an inactive p100 isoform which is activated by cleavage into the p52 
isoform. My results of western blotting show activation of NF-κB2 (p52) in A2780, HCT116 
and SK-MEL-28 cells after cisplatin treatment compared with untreated or DMF. This change 
in protein expression in western blotting experiments could be verified and quantified by 
pixel analysis.  The other results from qRT-PCR experiments show that this correlates with 
WWOX expression being down regulated due to cisplatin treatment, suggesting a possible 
link.  
The nuclear factor (NF-Kappa-B) is a pleotropic family of transcription factors which are 
present is almost all cell types and regulates diverse biological processes including immune 
response, cell growth and cell survival (Xiao et al., 2006). NF-κB can be activated by 
cytokines, reactive oxygen species, bacterial cell wall products, viral infection and DNA 
damage (Brasier, 2006).  NF-κB is not just a single gene but a family of transcription factors 
which are closely related to each other and are five genes which includes proteolytically 
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processed DNA binding subunits termed as   NF-κB1 (p50/p105), NF-κB2 (p52/p100) and 
transcriptional activators termed as RelA (p65), c-Rel and RelB (Siebenlist et al., 1994; 
Ghosh et al., 1998). Seven proteins arise from these five genes that share Rel Homology 
Domain (RHD) in their sequence, and their DNA binding, dimerization and interaction with 
their specific inhibitors is mediated by RHD. RelA (p65), c-Rel and RelB are synthesized in 
their mature forms and interact with the transcriptional apparatus by their transactivation 
domain. The synthesized precursor forms of NF-κB1 (p105), and NF-κB2 (p100) contain C-
terminal ankyrin repeats and the production of mature (p50 and p52 respectively) proteins 
results when proteolysis of C-terminal ankryin repeats takes place by the proteasome 
(Dolcet et al., 2005).  
 
Activation of NF-κB is important for inflammatory response and carcinogenesis and it could 
be activated by (TNF-α) canonical and (LTβR and CD40) noncanonical pathways (Figure 
5.36). Activation of NF-κB has been repeatedly shown in cancer cells and causes cancer cell 
growth, progression and metastasis. In a study of lung cancer and chronic obstructive 
pulmonary disease (COPD), proteomic analyses have revealed the involvement and linkage 
of NF-κB pathway with inflammatory signalling, oxidative stress response, and glycolysis and 
gluconeogenesis pathways (Pastor et al., 2013). Although some studies show strong 
evidence of involvement of NF-κB as a mediator of inflammation and promoter of 
carcinogenesis (Batra et al., 2011; Chen et al., 2011; Shen and Hahn, 2011) but largely it is 
unknown. A recent study in the Gprc5a gene knockout mice showed that NF-κB was 
activated in airway epithelium and it lead to lung inflammation and tumorigenesis (Deng et 
al., 2010).  Some animal models also show role of NF-κB in cancer. For example, the 
oncoprotein for reticuloendotheliosis (REV-T) retrovirus is v-REL (a viral homologue of c-Rel) 
is the transforming gene of an avian retro virus which causes leukaemia and aggressive 
lymphomas because of its oncogenic nature (Gilmore, 1999). The locus of NF-κB2 on 
chromosome 10q24 is affected by deletion or rearrangements of chromosomes, which leads 
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to the loss of ankyrin repeats of p100 and processing of active p52 protein which is linked 
with B-Cell and T-cell lymphomas and multiple myelomas (Migilazza et al., 1994; Neri et al., 
1991; Neri et al., 1995). The locus of Bcl-3 on human chromosome is 19q13 which is near 
chromosomal break point (Ohno et al., 1990). The translocation of B-Cell lymphocytic 
leukemias at (14; 19) (q32; q13) results in increased expression of Bcl-3 which is a 
transcriptional co-activator of p50 or p52 homodimers. The high expression of Bcl-3 
increases NF-κB activity (Ohno et al., 1990; Caamano et al., 1996) and up-regulates its 
transcriptional target i.e. cyclin D1 (Westerheide et al., 2001).  Another study by (Cogswell et 
al., 2000) shows that Bcl-3, p50 and p52 are selectively active in breast carcinoma as 
compared with normal breast tissue and it is linked with increased expression of cyclin D1 
(Cogswell et al., 2000). Squamous cell carcinomas of the head and neck shows activated 
NF-κB and when its activation was inhibited in these carcinomas, it inhibited cell survival and 
tumour growth (Thornburg et al., 2003). 
Fu and colleagues (2011) studied adult T-cell leukaemia (ATL) which is caused by human T-
cell leukaemia virus type I (HTLV-I), a process known to involve activation of NF-kB 
pathways (Xiao et al., 2006). For this purpose, Fu and colleagues used Jurkat cells in which 
they induced expression of the Tax oncoprotein from HTLV1. This suppressed the WWOX 
expression in a dose dependent manner. Further analysis showed suppression of WWOX 
gene due to Tax was dependent on p100/p52, as Tax expression could suppress WWOX in 
cells from p100-positive mice, but not p100-negative mice and this shows WWOX is a 
negative target of the non-canonical activation of NF-κB2. These findings were relevant with 
a previous study by Qing et al., (2007) which showed that constitutive processing of p100 
into active p52 resulted in supressed expression of WWOX.  The down regulation of WWOX 
due to HTLV-I was checked in primary ATL cells recovered from 9 ATL patients and the 
results showed that 7 out of 9 showed reduction in in WWOX expression as compared to 
normal T cells, suggesting it is a pathophysiologic event due to HTLV-I. Further analysis also 
showed that WWOX co-expression resulted in prevention of cellular transformation and 
tumorigenesis by Tax, while knockdown of WWOX increased tax mediated tumorigenesis. 
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This mechanism was shown to relate to activation of canonical NF-kB signalling by WWOX 
and could be prevented using a Y33R WWOX mutant. The principle findings of this study 
are, tumour suppressor gene WWOX is a negative target of the non-canonical NF-κB 
(p100/p52) pathway and Tax mediated tumorigenesis involves NF-κB2 suppression, WWOX 
upregulation, and subsequent activation of the canonical NF-κB pathway. 
These results from the study of Fu et al., (2011) provide a concept to analyse the results of 
qRT-PCR and western blotting from my investigations. My results of qRT-PCR showed 
cisplatin induced down regulation of WWOX tumour suppressor while western blotting 
showed cisplatin induced activation of non-canonical NF-κB2 as compared to controls. From 
the findings of Fu and colleagues, it can therefore be speculated that the down regulation of 
WWOX by cisplatin may be because of activation of non-canonical NF-κB2 because as 
shown by Fu et al., WWOX is the negative target gene for non-canonical NF-κB2. WWOX is 
a tumour suppressor gene and in cancer cells its expression is reduced which enhances 
tumorigenicity, similarly activation of NF-κB2 represents cancer cell growth, progression and 
metastasis (Pastor et al., 2013).  
This data therefore provides an alternative explanation to how cisplatin regulates WWOX 
expression. Instead of damage to CFS regions, it may be directly related to induction of a 
negative transcriptional regulator NF-κB2. I performed siRNA experiments in which I tried to 
confirm whether NF-κB2 was essential for cisplatin to alter WWOX expression. I optimized 
conditions to check first if the knock down of NF-κB2 is successful? The results suggested it 
was successful but when I performed actual experiments to test the effect of knockdown on 
WWOX expression, the knockdown was unsuccessful. I further tried to optimize by changing 
concentrations of siRNA reagents and cells numbers. Although optimization attempts 
produced some degree of NF-κB2 knockdown, this appeared to be insufficient to affect the 
suppression of WWOX by cisplatin.  
More work needs to be done to confirm the role of NF-κB2 in mediating the cisplatin induced 
suppression of WWOX. Further optimisation needs to be done to address this problem of 
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unsuccessful siRNA knockdown of NF-κB2, perhaps using different siRNA oligos. Another 
technique that could be used for silencing non-canonical NF-κB2 signalling is by inhibiting its 
nuclear translocation. This can be done by using cell permeable peptides that contain the 
nuclear localizing sequence of p52. This peptide inhibits nuclear translocation of p52-
containing dimers by binding to, and saturating, the nuclear import machinery responsible for 
the uptake of NF-κB dimers containing p52 (XU et al., 2008; ST J Nicholas; 2001; Lin et al., 
2005). Another approach that could be used would be to isolate mouse embryonic 
fibroblasts from p100+/+ and p100-/- mice (as done by Fu et al, 2011), and compare WWOX 
expression in these following cisplatin treatments. In each of these approaches a failure of 
cisplatin to suppress WWOX expression in the absence of NF-κB2 signalling would indicate 
that NF-κB2 is responsible for the WWOX down-regulation. 
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Figure 5.34: Activation of NF-κB by canonical (left) and noncanonical pathways (right) 
During resting conditions, inactive NF-κB complexes are sequestered in the cytoplasm due to binding 
of inhibitory IkB protein with NF-κB dimers. Induction of the canonical pathway takes place by NF-κB 
stimuli represented in this figure as stimulation of TNFR1 signalling followed by binding of TRADD 
which further recruits FADD and TRAF2. In next step phosphorylation of IKKα takes place in an IKKβ- 
and NEMO-dependent manner. Following phohorylation and ubiquitylation of IkBα, heterodimers 
containing p65 translocates to the nucleus. On the other side non-canonical pathway is induced by 
TNF family cytokines such as lymphotoxin-β (LT-β) by recruiting TRAF3, TRAF2 and NIK. In next step 
IKKα-mediated phosphorylation of p100-ReIB complex takes pace and after ubiquitylation leads to 
partial processing of p100 and formation of transcriptionally active p52-RelB complexes followed by 
its translocation to the nucleus (Morgan and Liu, 2011) 
Canonical Non-Canonical 
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5.7.4 Does cisplatin affect WWOX and FHIT expression via PAR2 regulated 
transcription? 
The results of my western blotting also showed decreased PAR2 expression in A2780 and 
HCT116 cells treated with cisplatin. PAR2 along with related family member proteins are 
highly expressed in vascular and extravascular tissues, pancreas, liver, prostate, ovary, 
lung, eye and uterus (Macfarlane et al., 2001; Bohm et al., 1996; D'Andrea et al., 1998). 
Also, these proteins are involved in regulation of inflammation and responses to vascular 
injury (Coughlin, 2000; Ruf et al., 2003).  
There are approximately ~900 human G protein coupled receptors (GPCRs) and this family 
of membrane spanning cell surface proteins make up about > 2% of the human genome 
(Elefsinioti et al., 2004; Schiöth and Fredriksson, 2005). Protease activated receptors 
(PARs) are exceptional GPCRs (Barry et al., 2006) with as yet no known endogenous 
extracellular ligands (Suen et al., 2010). Protease activated receptors (PARs) is a family of 
four 7-transmembrane G-protein coupled receptors which are activated by serine proteases 
(Trejo, 2003). 
Activation of PAR is a unique mechanism and takes place indirectly by proteases which 
cleave the N-terminus of four isoforms of PAR and as a result new N-terminus is exposed 
which folds back and intramolecularly self-activates PAR (Steinhoff et al., 2005).  
Research from the last few years has shown that cancer metastasis and invasion are highly 
dependent on elements of blood clotting (coagulation) cascade. Thromboplastin (TF) is a 47-
KDa transmembrane glycoprotein found on the outside of the cells and it is the main protein 
involved in initiation of the extrinsic coagulation cascade (Versteeg et al., 2004). Previous 
studies suggest TF/VIIa activates another receptor, PAR2 on cells and induces signal 
transduction pathway (Schaffner and Ruf, 2009; Hjortoe et al., 2004; Rao and Pendurthi, 
2005). Hjortoe et al., (2004) suggested that binding of FVIIa to TF on breast carcinoma cells 
results in upregulation of interleukin-8 (IL-8) via PAR2-dependent mechanism, and initiate 
cell migration and invasion. In another study of colon cancer cell line SW260, it was shown 
that PAR2 is highly expressed and PAR2-AP or TF/VIIa complex activates PAR2 and 
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regulates the expression of IL-8, TF, caspase-7 and hence promotes cell proliferation and 
migration (Zhou et al., 2008a; Zhou et al., 2010b). Activation of PAR2 causes relaxation of 
blood vessels, increases vascular permeability and leukocytes adhesion (Jacob et al., 2005). 
It was also reported that activation of PAR2 causes release of pro-inflammatory cytokines 
(e.g.IL-1b, IL-6, IL-8, TNF-a) and Intracellular Cell Adhesion Molecules -1 (ICAM-1) from 
human blood monocytes (Hjortoe et al., 2004; Johansson et al., 2005).  
Darmoul et al., (2001) showed that low concentration of trypsin mediated by PAR2 activated 
proliferation of human colon cancer cells in culture. Gastric cancer cells (MKN-1) showed 
trypsin activated an integrin α5β1-dependent adhesion to fibronectin and proliferation via 
PAR2 (Miyata et al., 2000). In a study of lung cancer, it was reported that PAR2 m-RNA 
expression was up regulated to 16-fold in pulmonary tumour alveolar walls as compared to 
normal alveolar tissues (Jin et al., 2003). Increased PAR2 expression was observed in 
proliferating stromal fibroblasts surrounding the carcinoma cells in breast cancers (D’Andrea 
et al., 2001). Proliferation of tumour cells is promoted by PAR2 in colon (Darmoul et al., 
2001; Darmoul et al., 2004), gastrium (Caruso et al., 2006; Miyata et al., 2000), pancreas 
(Tetsuoohta et al., 2003; Shimamoto et al., 2004), and glioblastoma (Okamoto et al., 2001).  
Jahan et al., (2007) showed that distribution of PAR2 was dominant in cancer cells and faint 
in stromal cells of the tumour. Both mRNA levels and PAR2 histoscores in cancer cells 
significantly increased in ovarian cancers with clinical stages (I < II < III < IV, P < 0.05) 
irrespective of histopathological type. The 36 months’ survival rate of patients with high 
PAR2 was poor as compared to patients with low PAR2. This shows PAR2 is a promoter of 
tumour growth with dissemination of ovarian cancers through angiogenesis and leads to low 
survival rates (Jahan et al., 2007). Another study in breast cancer by (Ryden et al., 2010) 
shows that clinical biopsies of breast cancer showed up regulated expression of TF and 
PAR2 in invasive cancer as compared to carcinoma in situ and the patients with newly 
diagnosed breast cancer suffered relapse due to TF phosphorylation. This study correlates 
with another study by (Schaffner et al., 2010) which also showed the evidence of cross talk 
between TF and PAR2. All these studies show the importance of PAR2 in cancer studies. 
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Suen et al. (2010) showed that PAR2 is an important transcription factor which on activation 
strongly increases the expression of WWOX. In this study, human embryonic kidney cells 
(HEK293) were used and almost 19,000 human genes were compared for intersecting up or 
down regulation by both trypsin (an endogenous protease that activates PAR2) and a 
hexapeptide (2-furoyl-LIGRLO-NH2) which activates PAR2. Both PAR1 and PAR2 activated 
many genes which are important in cancer. This study showed that activation of PAR2 
caused up-regulated expression of WWOX gene more than 8-fold in human kidney cells 
(Suen et al., 2010).  These results were interesting and provide a concept to link with my 
results of western blotting. The results of A2780 and HCT116 cells show PAR2 was highly 
expressed in untreated and DMF treated cells as compared to cisplatin treated cells. 
Therefore, another possible mechanism for down regulation of WWOX is decreased PAR2 
following cisplatin.  
To confirm whether PAR2 regulates WWOX expression or not, knock down of PAR2 by 
siRNA could be performed. Analysis of WWOX expression by QRT-PCR following cisplatin 
treatment in PAR2 knockdown and GFP knockdown control cells would determine whether 
PAR2 expression is required for suppression of WWOX. Another method to inactive PAR2 
and study its role in mediating cisplatin-induced suppression of WWOX would be to use 
commercially available PAR2 inhibitors such as; ENMD 547 (sc-207618) and GB83 (Axon 
1622). Alternatively, mouse embryonic fibroblasts could be isolated from PAR2+/+ and PAR2-
/- mice (Matej et al. 2012; de Boer et al., 2014), and used to compare WWOX expression 
following cisplatin treatment. In each of these approaches a failure of cisplatin to suppress 
WWOX expression in the absence of PAR2 signalling would indicate that PAR2 is 
responsible for the WWOX down-regulation. 
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5.8 Conclusion 
I have shown that cisplatin causes loss of WWOX and FHIT expression. This altered 
expression is due to transcriptional repression of these genes. This is likely due to cisplatin 
induced damage effecting CFS, but this response is independent of p53 regulated repair. 
Transcriptional regulators of WWOX (e.g. NF-κB2 and PAR2 are up and own regulated 
respectively by cisplatin and these may be the causes of the altered WWOX and FHIT 
expression. Cisplatin (and potentially other DNA damaging chemotherapy agents) may 
therefore cause loss of tumour suppressor gene expression which may be detrimental to the 
desired effect of the treatments and this is discussed further in chapter 6.  
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Chapter 6. Discussion 
6.1 Major findings of research  
The hypotheses behind this study were that chemotherapy drug paclitaxel induces apoptosis 
via ER-stress and WWOX may sensitize ovarian or colorectal cancer cells to paclitaxel 
induced apoptosis. Also, that the WWOX tumour suppressor would enhance cisplatin 
induced cell death, possibly through an ER-stress related mechanism.  
It has been shown by previous studies that paclitaxel induces apoptosis via ER-stress. The 
mechanism behind this activation of apoptotic pathway by paclitaxel is unfolded protein 
response and not the anti-mitotic action of taxanes. To understand the mechanism of how 
ER stress affects paclitaxel response I used inhibitors of several key ER stress proteins, but 
none of these resulted in altered paclitaxel chemo-response. To characterise the paclitaxel 
response further, I used GRP-78 and XBP-1 as markers of ER-stress, but I found no 
evidence of induction of ER-stress by paclitaxel in any of our cell line models.  
Next, I tried to determine any association of ER-stress with clinical outcome in patient 
tumour samples that might support a role of ER-stress in paclitaxel response. High 
expression of GRP-78 protein in ovarian cancer patients treated with taxol predicted longer 
overall survival, consistent with a role of ER-stress in taxane response, but no correlation 
between GRP-78 and progression free survival was observed. Furthermore, no correlation of 
GRP-78 mRNA expression was observed in terms of survival in either ovarian or colorectal 
cancer patients from the TCGA dataset. Unpublished data from Dr Paige’s group had 
suggested that WWOX regulates this ER stress pathway response to paclitaxel. However, in 
my study, WWOX expression in both IHC and RNAseq TCGA study showed no association 
with survival. There was no evidence that WWOX status could modulate the correlation of 
ER stress with survival. Overall the data therefore suggest that ER stress may have some 
relevance in paclitaxel response but WWOX did not seem to modulate that.    
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Cisplatin is another chemotherapy drug used for the treatment of tumours. Cisplatin 
damages the DNA by forming adducts with the structure of DNA. I show that treatment of 
ovarian and colorectal cancer cells with cisplatin down regulated WWOX expression. This 
demonstrated that my hypothesis that WWOX would enhance cisplatin response was wrong 
and led us to propose an alternate hypothesis that cisplatin-mediated DNA damage would 
disrupt expression of fragile site associated genes. Another fragile site associated gene 
FHIT also showed down regulation by cisplatin treatment in my experiments. This regulation 
of fragile site gene expression was independent of the p53 DNA damage response pathway 
but correlated with activation of transcription factors NF-κB2 and PAR2.  
6.2 Paclitaxel and ER-stress 
Ovarian cancer is the sixth most common cancer in the UK. Each year in UK 7400 women 
are diagnosed with ovarian cancer. The 5-year survival rate has improved in last few years 
and the current 5-year survival rate is 50% in UK (Cancer research UK, 2017). One of the 
most common problems which cancer patients face is frequent occurrence of acquired 
chemo resistance. Paclitaxel is used as first line therapy for treatment of ovarian cancers. 
Paclitaxel stabilizes the microtubules and research show that paclitaxel activates signalling 
molecules and transcription of various genes which could be responsible for apoptosis 
(Wang et al., 2000). In addition to its role in mitotic arrest, several studies suggest that 
apoptosis induced by Paclitaxel is due to endoplasmic reticulum (ER) stress also known as 
unfolded protein response (UPR) (Liao et al., 2008; Weigel et al., 2000; Pan et al., 2014).  
I looked at the involvement of apoptotic arms linked with UPR target genes such as PERK, 
JNK and caspases, but my analysis failed to find evidence of ER stress after paclitaxel 
treatment. There could be a few reasons why my in vitro studies failed to show any evidence 
of ER stress and one of them could be that paclitaxel does not cause ER stress. Based on 
the studies cited above, however, it is difficult to assume that paclitaxel does not cause ER 
stress in some cell lines at least. But despite using a range of different cell lines from 
different tumour types in my experiments I saw no evidence of this. The second reason that 
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my study could not see any evidence of ER stress due to paclitaxel could be possibly that 
GRP-78 and XBP-1 may not be the best markers to indicate ER-stress induction. However, 
published studies show that activated ER stress does result in increased GRP-78 
transcription and increased splicing of XBP-1 (Shuda et al., 2003; Thuerauf et al., 2006) 
Another possible explanation could be the paclitaxel used in experiments may be old or not 
in good quality, or its function may have been affected by the formulation of the drug. I used 
paclitaxel dissolved in DMSO and RPMI media, whereas the paclitaxel which is used in 
clinics, and was used by Dr Paige’s group to generate the preliminary data about ER-stress 
and paclitaxel response, is supplied as a non-aqueous viscous fluid containing 
polyoxyethylated castor oil and dehydrated alcohol, which was then diluted into 0.9% sodium 
chloride or 5% dextrose injection. But in my experiments, I observed cell death in paclitaxel 
treated cells which show that paclitaxel was functional and had cytotoxic effect on the cells 
but did not induce ER stress. Overall it is not clear why there was no ER stress in my 
experiments. But despite my model not working based upon published data there is likely to 
truly be a link between paclitaxel and ER stress.  
At the start of taxane therapy patients respond to paclitaxel but with time they acquire 
resistance to taxanes which is a big problem (Raguz and Yague, 2008). Taxanes show 
different levels of resistance in cancer patients with same class of drugs. For examples 
taxanes and epithilones have same mechanisms of action but mutation in β-tubulin show 
resistance to taxanes but not to epithilones (Lee et al., 2001). Similarly, patients with over 
expression of p-glycoprotein show resistance to taxanes but not ixabepilone although both 
share same mechanism of action (Mandhare et al., 2016; Hasanpourghadi et al., 2017). So, 
it depends on patients and their sensitivity to chemotherapy drugs and this makes treatment 
of cancer patients difficult because mutations vary from patient to patient and so is the 
response towards chemotherapy drugs. Although paclitaxel kill cancer cell by its anti-mitotic 
action the discovery of other pathways linked with paclitaxel response can improve the 
response of patients towards paclitaxel, for example, activation of ER stress. However, some 
cancer patients already have activated GRP-78 in their tumour cells, which means they have 
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inherently activated ER stress. This may be an advantage to the cancer cells because 
enhanced GRP-78 is cytoprotective by increasing the folding capacity of the cells to tackle 
misfolded proteins and maintenance of cellular homeostasis, but only if there is a failure in 
the ER-stress associated apoptotic response. These patients may therefore not be expected 
to respond to paclitaxel effectively because the inherently activated ER stress did not caused 
apoptosis but was limited to its cytoprotective role. In contrast, when those patients without 
inherently activated ER stress are given paclitaxel they will respond to the drug by activating 
ER stress induced apoptosis and enhancing the chemo-response to paclitaxel. Screening 
tumours for markers of activated ER-stress could therefore potentially identify patient groups 
who will respond less effectively to paclitaxel and could be used to guide treatment 
decisions. Furthermore, development of novel drugs which can change the cytoprotective 
mode of ER-stress into apoptotic response, could potentially be used to increase the efficacy 
of paclitaxel.  
The unpublished data from Dr Szymon Janczar in Dr Paige’s group suggests that WWOX 
functions in this way. Dr Janczar’s data shows that paclitaxel induces ER response in 
ovarian cancer cells which was unaltered by WWOX, but WWOX re-expression caused a 
significant shift in this response towards apoptosis. This study also showed the clinical 
relevance of these findings by using a publicly available microarray gene expression dataset 
(GEO GSE9899) of 260 ovarian cancer patents. The survival analysis showed that high 
WWOX mRNA expression predicted longer PFS in patients treated with paclitaxel but not in 
patients which did not have paclitaxel treatment. Interestingly, WWOX affected PFS only in 
patients whose tumours expressed low-GRP-78, whilst the high GRP-78 expressing group 
did not show any correlation of WWOX with PFS. It can be hypothesized from this study that 
patients with high GRP-78 expression in their tumour cells may have inherently activated ER 
stress independent of paclitaxel treatment. It is therefore speculated that WWOX status 
show no impact in high GRP-78 patients and the only mechanism of cell death is anti-mitotic 
action of paclitaxel but not ER stress. Whereas, in patients with low GRP-78 it is 
hypothesized that ER-stress is not inherently active, and therefore could be activated by 
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paclitaxel treatment. In these tumours, we speculated that WWOX status could influence the 
apoptotic outcome of ER-stress, and thus higher WWOX expression predicted longer PFS. 
The involvement of WWOX in mediating the ER-stress apoptotic response could also 
potentially be useful clinically. Tumours can be screened for WWOX expression and taxanes 
could be given only to those patients who have high WWOX expression. Another option for 
patients with low WWOX is to find a treatment that could increase WWOX expression and 
given that together with taxanes to improve outcomes.  
6.3 Cisplatin and WWOX 
My results show that cisplatin causes loss of fragile site associated tumour suppressor 
genes WWOX and FHIT. However, Salah et al., (2013) showed that WWOX can sensitize 
cancer cells to cisplatin by linking with ΔNp63. WWOX significantly enhanced the cell death 
(14 fold) in cancer cells expressing both WWOX and ΔNp63, whereas cancer cells 
expressing only ΔNp63 showed lower cell death. It was further showed WWOX does this by 
restricting the ΔNp63 to the cytoplasm which results in suppression of transcription of 
ΔNp63.  The likely reason for the difference in the two studies is that Salah et al used virally 
transduced WWOX and not endogenous WWOX which is expressed by its normal promotor. 
This was the reason cisplatin could not suppress WWOX expression in their study. However, 
this shows that WWOX can sensitize cancer cells to cisplatin induced cell death if it were not 
for the fact that cisplatin instead switched off WWOX expression.  The clinical significance of 
this finding is if WWOX is prevented from switching off, it can help cisplatin in killing cancer 
cells. Therefore, therapies designed to increase WWOX expression would be expected to 
enhance cisplatin response, as well as paclitaxel response. 
Interestingly, in ovarian cancer cisplatin is combination with paclitaxel as standard treatment. 
Based on my results, if cisplatin switches off WWOX in these tumours it means WWOX will 
be unable to sensitize the cancer cells to paclitaxel induced cell death. Thus, the one drug 
may be producing an effect that partially counteracts the other drug. The clinical significance 
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for these findings is, it will be helpful if WWOX remain expressed in cancer patients during 
the chemotherapy treatment. Potentially this might be achieved by changing the timing of the 
administration of drugs. Cisplatin down regulates WWOX, so it should not be given first, 
instead patients should be given paclitaxel first, so it can kill cancer cells by the help of 
WWOX and then later cisplatin should be given and in this way, there will be no interference. 
Another suggestion is if WWOX could be activated by some type of therapy in combination 
with cisplatin/paclitaxel which means WWOX stays active and these drugs will kill cancer 
cells more effectively. Recently, Wang et al., (2017) show that pre-treatment with kanglaite 
can sensitize colorectal cancer cells to taxol. This study further showed pre-treatment with 
kanglaite inhibited the expression of canonical pathway of NF-κB (p65) and increased the 
effect of taxol. Non-canonical pathway of NF-κB2 (p52) has not been examined in this study 
but, given my data potentially linking p52 with WWOX suppression, this raises the question 
of whether there is a possibility kanglaite may also inhibit p52 (non-canonical) as well as p65 
(canonical). Based on my findings, inhibition of non-canonical pathway by kanglaite would 
cause increased expression of WWOX which will ultimately increase the taxol response as 
they report. If this is indeed the mechanism happening in this study, then maybe combination 
of kanglaite with paclitaxel and cisplatin can give better patient outcome by helping to 
maintain high WWOX levels.  
6.4 Concluding remarks 
- My in vitro ER stress study could not see any evidence of generation of ER stress by 
paclitaxel in ovarian and colorectal cancer cells. Although in some experiments paclitaxel 
treatment did show the reduction in the number of cells compared to controls, this effect of 
paclitaxel was does not appear to be due to ER stress. 
- Clinical studies showed a correlation between GRP-78 and overall survival time but it was 
independent of action of WWOX. The data used in these analyses was from paclitaxel 
treated patients, so there is in vivo correlation between paclitaxel and ER stress marker 
GRP-78.  
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- I have shown novel data that Cisplatin down regulates the expression of fragile sites 
associated genes; WWOX and FHIT. The mechanism for this is independent of the p53 DNA 
damage response pathway but may result from transcriptional regulation by NF-kB2 and 
PAR2. 
- Further investigation into role of NF-kB2 is needed to confirm the link with regulatory 
mechanisms of WWOX, but this would suggest potential therapeutic strategies for enhancing 
cisplatin and paclitaxel response in cancer patients through upregulated expression of 
WWOX tumour suppressor.   
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Appendices 
S1.1 SRB various dilution and linearity test 
In my experiments, I am using 0.4% SRB solution to stain cells and determine the cell 
number present. There is reported to be good linearity between the amount of SRB 
absorbance measured and the number of cells present. To confirm this, spectrophotometer 
readings of various dilution of SRB were performed (ranging from 0.02% to 0.4%) to 
determine if there was a maximum SRB amount that saturated the ability of the 
spectrophotometer to measure. Absorbance was measured at a wavelength of 570nm by 
using a spectrophotometer. Figure S1.1 shows the absorbance of various percentages of 
SRB dilutions. 
 
Figure S1.1: Absorbance of various percentages of SRB dilutions 
I also performed another experiment in which cell numbers ranging from 5000/well to 
100,000 per well were plated in 96-well plates (in triplicates) and placed in incubator for 6 
hours. The plates were removed from the incubator and cells were fixed with trichloro acetic 
acid (TCA) followed by SRB staining. Figure S1.2 shows the SRB absorbance compared to 
the cell number plated and confirms the linearity relationship between number of cells and 
SRB dye.  
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Table S1.1 Representations of Dilutions % of Figure S1.1 
1 0.4% 
2 0.3% 
3 0.2% 
4 0.1% 
5 0.08% 
6 0.04% 
7 0.02% 
8 0.0% 
 
 
Figure S1.2:  Plated Cell numbers plotted against absorbance 
S 2.1 Determine the optimal concentration of Paclitaxel, tunicamycin or salubrinal to 
use in HCT116 isogenic cell lines  
Before the start of experiment, the first step was to find out the optimal drug dose 
concentrations for the ER stress inhibition experiments. For this purpose, the HCT116 
isogenic cancer cells were treated with various doses of paclitaxel, salubrinal or tunicamycin 
for 48, 72 or 96 hours and surviving cells measured by SRB staining. 
y = 0.0211x + 0.097 
R² = 0.9971 
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S 2.1.1 Determine the optimal concentration of paclitaxel to be used in HCT116 
isogenic cell lines experiments for 48, 72 or 96 hours  
Paclitaxel caused reduction of cell number in all four cell lines which was dose and time 
dependent. The different cell lines showed similar responses to paclitaxel, although the p21-
null cells exhibited a slightly greater reduction in cell number compared to the other cell 
lines. The aim of the experiment was to determine a paclitaxel dose producing approximately 
50% reduction in cell number after 72 hours in all four cell lines. Based on the results of 
these experiments (Figures S 2.1, S 2.2 and S 2.3) even a 2nM dose was slightly too high 
(producing 60-70% reduction in cell number) and therefore a 1 nM dose was selected for 
subsequent experiments in these cells. 
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Figure S2.1: Relative cell survival in HCT116 isogenic cell after treatment with paclitaxel doses for 48 hours. Experiments were repeated three times. Means 
± SEM are shown. 
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Figure S2.2: Relative cell survival in HCT116 isogenic cells after treatment with paclitaxel doses for 72 hours. Experiments were repeated three times Means 
± SEM are shown. 
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Figure S2.3: Relative cell survival in HCT116 isogenic cells after treatment with paclitaxel doses for 96 hours. Experiments were repeated three times Means 
± SEM are shown.
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S.2.1.2 Determine the optimal concentration of tunicamycin to be used in HCT116 
isogenic cell lines experiments for 48, 72 or 96 hours 
The reason for this type of result could be the increase in number of cells after 96 hours. I 
started my experiments with 6000 cells numbers/well and after 96 hours, cells increased 
their numbers and the low concentrations of drugs became ineffective on higher number of 
cells 
The aim of the experiment was to identify a tunicamycin dose producing approximately 50% 
reduction in cell number after 72 hours in all four cell lines. Based on the results, I selected 
75ng/ml tunicamycin doses for subsequent experiments. 
Figures (S 2.4, S 2.5 and S 2.6) show that tunicamycin causes a reduction in cell number in 
a dose dependent manner. Curiously the apparent effect of tunicamycin on cell number 
decreased over time.  
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Figure S2.4: Relative cell survival in HCT116 isogenic cells after treatment with tunicamycin doses for 48 hours. Experiments were repeated three times. 
Means ± SEM are shown. 
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Figure S2.5: Relative cell survival in HCT116 isogenic cells after treatment with tunicamycin doses for 72 hours. Experiments were repeated three times. 
Means ± SEM are shown.
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Figure S2.6: Relative cell survival in HCT116 isogenic cells after treatment with tunicamycin doses for 96 hours. Experiments were repeated three times. 
Means ± SEM are shown.
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S 2.2 Determine the optimal concentration of Paclitaxel, tunicamycin or salubrinal to 
use in in PEO1-H8 and PEO1-FP2 cell lines experiments 
Before the start of experiment, the first step was to find out the optimal drug dose 
concentrations for the ER stress inhibition experiments. For this purpose, ovarian cancer 
cells PEO1-H8 and PEO1-FP2 were treated with various doses of paclitaxel, salubrinal or 
tunicamycin for 48, 72 or 96 hours and surviving cells measured by SRB staining. 
S2.2.1 Determine the optimal concentration of paclitaxel to use in PEO1-H8 and PEO1-
FP2 cell lines experiments  
PEO1-H8 and PEO1-FP2 cells were treated with 2nM, 4nM, 8nM and 16nM concentrations 
of paclitaxel, and percentage surviving cells determined by SRB staining after 48 and 72 
hours. The results (S2.7) showed that paclitaxel reduced surviving cells in a dose dependent 
manner, with minimal effect seen below 8 nM. The results at 48 hours and 72 hours show 
little difference. Paclitaxel response in the PEO1-FP2 cells was slightly greater than in 
PEO1-H8 cells but this did not reach statistical significance. From these data, 16nM 
paclitaxel was chosen as an optimal dose to be used in subsequent experiments as it 
caused approximately 50% reduction in surviving cells after 72 hours. 
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Figure S2.7 shows the cell survival in PEO1-H8 and PEO1-FP2 cells after treatment with 2nM, 4nM, 8nM and 16nM paclitaxel. Cells 
were also treated with 0.18% DMSO. After 48 or 72 hours, spectrophotometric analysis was used (post SRB staining) to observe cell 
survival. Experiments were repeated twice. Means ± SEM are shown. 
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S2.2.2 Determine the optimal concentration of salubrinal to use in PEO1-H8 and PEO1-FP2 cell lines 
experiments  
PEO1-H8 and PEO1-FP2 cells were treated with 10µM, 20µM, 30µM and 60µM concentrations of salubrinal. 
After 48 or 72 hours of salubrinal treatment, surviving cells were measured with SRB staining.  Salubrinal 
alone did cause some reduction in surviving cells (20% reduction at 48 hours and 30% reduction at 72 
hours), which was not dose dependent (Figure S2.8). Therefore, doses of 30µM and 60µM were chosen for 
use with PEO1 cells, consistent with the experiments in A2780, SKOV3 and HCT116 cells above. 
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Figure S2.8 shows the cell survival in PEO1-H8 and PEO1-FP2 cells after treatment with 10µM, 20µM, 30µM and 60µM concentrations of 
salubrinal. Cells were also treated with 0.18% DMSO. After 48 or 72 hours, spectrophotometric analysis was used (post SRB staining) to 
observe cell survival. Experiments were repeated twice. Means ± SEM are shown. 
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S2.2.3 Determine the optimal concentration of tunicamycin to use in PEO1-H8 and 
PEO1-FP2 cell lines experiments  
PEO1-H8 and PEO1-FP2 cells were treated with 50ng/ml, 100ng/ml, 150ng/ml and 200ng/ml 
concentrations of tunicamycin, and surviving cells measured by SRB staining. The results 
(Figure S2.9) show that tunicamycin produced a reduction in surviving cells in a dose 
dependent manner. PEO1-FP2 cells appear to be less sensitive to tunicamycin than the 
PEO1-H8 cells. For subsequent experiments, we wanted to use the same tunicamycin dose 
in both of these lines to allow comparison. Therefore, we chose 200 ng/ml as this produced 
approximately 50% reduction in surviving cells after 72 hours in the PEO1-H8 cells and was 
consistent with doses used in other cell lines previously. 
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Figure S2.9 shows the cell survival in PEO1-H8 and PEO1-FP2 cells after treatment with 50ng/ml, 100ng/ml, 150ng/ml and 200ng/ml 
concentrations of tunicamycin (positive control for ER stress). Cells were also treated with 0.18% DMSO. After 48 or 72 hours, 
spectrophotometric analysis was used (post SRB staining) to observe cell survival. Experiments were repeated twice. Means ± SEM are 
shown. 
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S3.1 Appearance of cells following exposure to various treatments  
Pictures of cells taken after 48 hours of cisplatin treatment. S3.1 represents untreated cells, 
S3.2 represents DMF treated cells and S3.3 represent cisplatin treated cells. 
 
 
    
Figure S3.1: A2780 cells after 48 hours (Untreated) 100x 
    
Figure S3.2: A2780 cells after 48 hours of DMF treatment 100x 
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Figure S3.3: A2780 cells after 48 hours of cisplatin treatment (100x) 
S4.1 PCR product sizes 
Table S3.1: WWOX and FHIT primers used for QRT-PCR 
Primers Product size (bp) 
WWOX 100 
FHIT 166 
Β-Actin 385 
 
S5.1 Antibodies used in project 
Table S4.1 Antibodies used for western blotting and their dilutions 
Antibodies Dilutions Product codes 
Anti-PAR2 antibody 
[EPR13675] 
1:10000 ab180953 
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Anti-NF-kB p100 / p52 
antibody [0.T.173] 
1:2000 ab32859 
Goat Anti-Rabbit IgG H&L 
(HRP) 
1:1000 ab6721 
Anti-Actin antibody [ACTN05 
(C4)] 
1:1000 ab3280 
Polyclonal Goat Anti-Mouse 
Immunoglobulins HRP 
1:5000 Dako P0447 
 
 
S6.1 Preparation of cisplatin solution 
Cisplatin (C2210000-100mg) is a yellow powder which was dissolved in dimethyl formamide 
(DMF) to prepare the primary stock solution of concentration 15mg/ml. This primary stock 
solution was used to prepare secondary stock solution having concentration 1mg/ml. For 
experimental drug solution preparation, 1mg/ml cisplatin stock solution was used. The first 
step was to find out the suitable cell numbers and drug dose for the experiments. This was 
achieved by treating various cell numbers with various drug concentrations and selecting the 
one which is an IC50 dose. All the experiments were repeated three times and were 
independent of each other. 
S7.1 Analysis of DNA content by flow cytometer analysis 
The aim of this experiment was to see the different stages of cell cycle following esiRNA   
NF-kB2 knockdown along with GFP, SFM and SFM+TR treatments. This experiment was 
just to see if these different treatments disturb cell cycle at any stage during the experimental 
time period of 72-96 hours. A2780 cells were plated in 6-well plates and transfected as 
described in materials and methods. DNA content of the cell was measured by flow 
cytometer following propidium iodide (PI) staining.  
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The results of the Flow cytometer analysis show that most of the cells were at GO/G1 stage 
in all the treatments (figure S5.2 panels C-F). All treatments that included transfection 
reagent show a slightly increased number of apoptotic cells (indicated by the Sub-G0 
fraction in the Flow cytometer data, Figure S6.3 panel A, however this did not reach 
significance, and no difference in cell cycle distribution was detected between the different 
treatments (Figure S6.3 panel B). 
 
Figure S7.1 (A-B): Side scattered graphs showing single cells and doublets. Cells in the red 
dotted box in (A) are the single cells used for the analysis (Figure S7.2, C-F). (B) shows the 
alive cells in the red dotted area including single cells and doublets.  
 
A B 
 
 
284 
 
 
 
Figure S5.2 (C-F): Cell cycle analysis plot. Only single cells were used to make these plots. 
Cell cycle analysis of A2780 cells after 72 hours treatment with Nf-kB2, GFP, SFM+TR and 
SFM. A2780 cells were fixed with ethanol 
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Figure S7.3: Flow cytometer analysis of cell cycle phases. 
 
 
 
0
0.02
0.04
0.06
0.08
0.1
0.12
Sub G0
Pe
rc
en
ta
ge
s 
(%
) 
Flowcytometer  analysis 
SF_PI
SFTR_PI
GFP_PI
NF-KB_PI
A 
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
Sub G0 G0/G1 S G2/M
Pe
rc
en
ta
ge
s 
 (%
) 
Cell Cycle Phases 
SF_PI
SFTR_PI
GFP_PI
NF-KB_PI
B 
 
 
286 
 
 
S8.1 Expression of WWOX in HCT116 and HCT116-p53null cells after 24 hours of 
cisplatin treatment 
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S9.1 Paclitaxel treatment and ER stress induction in HCT116 cells 
In this experiment colorectal cancer cells HCT116 were treated with doses of paclitaxel. The 
results (Figure S9.1) show that no amplification was observed in the ‘no reverse 
transcriptase’ controls showing no genomic DNA contamination was present, except for the 
DMSO and untreated dose of GRP-78. Similar intensity of beta actin expression was seen in 
all samples showing equal loading of template (except DMSO and untreated). These results 
showed there was no increase in expression levels of GRP-78 or XBP-1(S). It shows there 
was no induction of ER-stress.  
 
 
Figure S9.1: Gel images of HCT116 after treatment with paclitaxel for 72 hours.  
Samples include NTC (no template control), UT (untreated), DM (DMSO 0.18%) and paclitaxel (16nM, 
32nM, 64nM and 128nM) treated samples. (+) represents cDNA samples from the different treatments 
and (-) indicates no reverse transcriptase controls to confirm that no genomic DNA was present.  
 
